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ABSTRACT 
 
Aptamers are single-stranded DNA or RNA molecules isolated in vitro by a selection 
and amplification method. Aptamers bind with high specificity and affinity to a wide 
range of target molecules, with dissociation constant comparable to antibodies.  
 
In this work aptamers were employed as a new kind of bio-recognition element in 
affinity biosensors for the detection of clinically relevant proteins in heterogeneous 
assay, using Piezoelectric Quartz Crystal Microbalance and Surface Plasmon Resonance  
as transducers. The work was focused on two case studies, i.e. the Thrombin-binding 
aptamer and the aptamer against C-Reactive Protein. From an analytical point of view, 
the work was devoted to the optimisation of the analytical performance of a 
piezoelectric and an optical aptasensor for Thrombin and C-Reactive Protein detection, 
respectively. Efforts towards the application of these aptasensors in complex matrices, 
such as human plasma and serum, were also undertaken, in order to demonstrate the 
wide applicability of aptamers, as an alternative to antibodies. 
  
In this work, the possibility of introducing a computationally-assisted method to study 
aptamer-protein interaction and aptamer selection was also evaluated. For this purpose, 
the Thrombin-binding aptamer was chosen as a model and a retrospective docking study 
was performed by comparing the affinity of mutated sequences for thrombin with that 
of the Thrombin-binding aptamer, on the basis of a computationally-derived binding 
score. Finally, the reliability of computational results was tested by experimental 
measurements. For this purpose, the Thrombin-binding aptamer and other mutated 
sequences, selected on the basis of their binding score, were employed for the 
development of optical biosensors and the resulting analytical performances were 
compared. Even if further studies should be carried out in order to validate the proposed 
computational approach to aptamer selection, this work can have a significant impact on 
future aptamers selection for sensors and diagnostics.  
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GENERAL INTRODUCTION 
 
 
 
 
1.1.  Aim of the thesis 
 
The aim of this work was to study a new kind of receptor for affinity biosensor 
development. Aptamers are single-stranded DNA or RNA molecules isolated in vitro by 
a selection and amplification method called SELEX (Systematic Evolution of Ligands 
by EXponential enrichment) [1,2]. The SELEX process is a powerful combinatorial 
methodology for identifying high affinity oligonucleotide ligands to any desired target, 
by screening nucleic acids libraries using iterative rounds of affinity-based enrichment 
alternating with oligonucleotide amplification using the Polymerase Chain Reaction 
(PCR). 
 
A biosensor is an analytical device in which a biological element is coupled with a 
transducer, which converts the recognition event with the target into a measurable signal 
[3]. The aim of this work was the analytical characterisation of affinity biosensors in 
which aptamers are used as novel bio-recognition elements. Nowadays, antibodies are 
the most used receptors in affinity biosensor development [4], however novel non-
natural approaches that challenge traditional methods are being discovered [5]. 
Employing the techniques of modern biotechnology, it is now possible to construct new 
receptors at will, such as aptamers [6], bio-mimetic peptides [7], molecular imprinted 
polymers [8], thus opening new paths for generation of biosensor recognition elements.  
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In this work, aptamer-based affinity biosensors (aptasensors) for the detection of 
clinically relevant proteins were developed using both mass and optical transduction 
principles, i.e. piezoelectric Quartz Crystal Microbalance (QCM) and Surface Plasmon 
Resonance (SPR) sensing. The work was focused on two case studies, i.e. Thrombin-
Binding Aptamer (TBA) and an aptamer against C-Reactive Protein (CRP). These were 
immobilised on the gold surface of a piezoelectric quartz crystal or of a Biacore chip. 
Since aptamers targeted towards any kind of compounds can be isolated by SELEX and 
can be coupled to different transduction principles; this work aims to demonstrate the 
endless range of application of aptamers in biosensors. From an analytical point of 
view, the work was devoted to the optimisation of the analytical performances of a 
piezoelectric and an optical aptasensor for thrombin and C-Reactive Protein detection, 
respectively. Efforts towards the application of these aptasensors in complex matrices, 
such as human plasma and serum, were also undertaken.    
 
The last part of the thesis describes a first attempt to introduce a computationally-
assisted method to study aptamer-protein interaction and aptamer selection. 
Computational methods allow exploration of an induced fit between protein and a 
library of ligands to be screened. As a result, molecules most likely to bind the receptor 
are ranked on the basis of a binding score [9]. On the basis of this work there is the idea 
that the validation of a computational approach could reduce the amount of 
experimental time involved in the selection technique currently used for aptamer 
development: if a computationally-assisted screen of large libraries was able to identify 
a small number of sequences potentially able to bind, only a small number of sequences 
would have to be synthesised and assayed. 
  
The aptamer-thrombin complex was chosen as a model in the computational approach. 
Starting from the oligonucleotide sequence selected by SELEX [1], a retrospective 
docking study for the selection of a thrombin aptamer was performed. For this purpose a 
modelling software was used to generate and screen libraries of oligonucleotide mutated 
sequences and to study the ligand-thrombin interaction by docking experiments. 
Docking experiments were carried out in order to verify if the sequences with the best 
score correspond to the  high-affinity binding sequences identified using SELEX.  
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1.2.    Biosensors: definition, function and applications 
 
According to the modern definition, a biosensor is a compact analytical device in which 
a biological sensing element (biochemical receptor) is integrated within, or intimately 
associated with, a physiochemical transducer, which transforms the chemical 
recognition information into an analytically useful signal (Figure 1) [3].  
 
 
 
Bioreceptor SignalTransducer
 
Figure 1: Biosensor configuration, showing bioreceptor, transducer and signal detection. 
 
 
 
Biological elements specifically coupled to transducer can be grouped into two broad 
classes: catalytic (enzymes, microorganisms, biomimetic catalysts) and affinity-based 
(antibodies, nucleic acids, receptor proteins and systematic receptors) [10,11]. The 
biological element is immobilised on the sensor surface using a variety of methods such 
as chemical or physical adsorption, physical entrapment cross-linking or covalent 
binding. The receptor immobilisation is a critical aspect, because of the stoichiometric 
nature of the analyte binding and because of the finite sensor surface area. Receptor 
durability and availability determine whether the device has potential for 
commercialisation.  
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The key point in the development of a biosensor system is to generate a measurable 
signal from the receptor-target interaction. Transduction elements can be optical, 
electrochemical, calorimetric, magnetic or mass sensitive [12]. In the two last decades 
biosensors have gained considerable success and are now employed in a wide range of 
fields, such as food, environmental and clinical analysis [13]. The success of biosensors 
is due to low costs, small sizes, fast response times, minimum sample processing and to 
very high selectivity, sensitivity and reproducibility of the measurements. The main 
properties of biosensors are specificity and sensitivity towards the target analyte and 
rapidity of the analysis. The biological elements are highly selective and sensitive 
probes, which react with the analyte yielding a specific recognition signal. The 
transducer transforms the recognition signal into an electronic, optical or similar signal, 
which may be readily quantified [14]. Thus, the biological element determines the 
selectivity, the sensitivity and the stability, whereas the transducer effects the sensitivity 
and rapidity of the analysis. 
 
These unique features make biosensors very attractive alternatives to conventional 
biological sensing devices. Compared with a conventional enzyme-linked 
immunosorbent assay (ELISA), which is characterised by one-use only, the 
immobilised biological recognition element of biosensors can often be reused or 
regenerated [15]. A wide range of biosensors have already been developed with 
numerous applications.  
 
 
 
 
1.2.1. Affinity Biosensors 
 
Biosensors are grouped into two broad classes: catalytic and affinity-based. Catalytic 
biosensors involve a catalytic event in which a substrate is converted into a product. 
Catalysis occurs at the transducer interface and depletion of the substrate or formation 
of the product is monitored by a transducer. When the biological element is an enzyme, 
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the main advantage is the very high specificity of the catalytic reaction, which helps 
avoid collateral reactions [16]. 
 
Affinity biosensors involve a reversible binding process between an immobilised 
biological receptor molecule and its target in solution. The affinity biosensor allows the 
kinetics governing the binding mechanism and detecting the reactants concentrations to 
be followed. The main advantage of affinity biosensors is the possibility of performing 
kinetic studies without requiring radioactive or fluorescent tags and recording the 
signals in real-time. The receptor-ligand interaction is detected with a high differential 
selectivity and high stability mode [17].  
 
In the construction of a bioanalytical assay, the most used bio-recognition elements are 
antibodies and nucleic acids involved in an affinity reaction leading to the formation of 
bio-complexes, such as antigen-antibody, protein-nucleic acid or complementary 
strands of ssDNA [18]. If an antibody or an antigen are the biological elements 
immobilised onto the surface transducer, the sensor is an immunosensors; if the 
bioreceptor is a nucleic acid, the sensor is an RNA or DNA biosensor and the 
biorecognition mechanism may be based on a hybridisation reaction, which relies on the 
complementarity of Cytosine-Guanine (C-G) and Adenine-Thymine (A-T) pairing of 
two single sequences of DNA. Potential applications areas for affinity-based biosensors 
techniques reported over the past decade include clinical/diagnostic, food processing, 
military/antiterrorism and environmental monitoring. 
 
Antibodies are the most widely reported biological recognition elements used in affinity 
biosensors, because of their high affinity, versatility and commercial availability [19]. 
However, the use of antibodies in multi-analyte detection methods and in very complex 
samples could encounter some limitations, mainly deriving from the nature and 
synthesis of these protein receptors. In order to circumvent some of these drawbacks, 
other recognition molecules are being explored as alternatives. In particular, recognition 
elements that do not occur naturally have been synthesised in the laboratory by 
employing modern biotechnology techniques, thus opening up new paths for affinity 
biosensor development.  
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1.3. Aptamers 
 
 
1.3.1. Introduction 
 
Aptamers are single stranded nucleic acids able to bind with high affinity and specificity 
to their target molecules and therefore they are considered to be the nucleic acid version 
of antibodies. Aptamers are generated in vitro by a selection and amplification 
technique called SELEX (Systematic Evolution of Ligands by EXponential enrichment) 
[1]. The length of aptamers is tens of nucleotides and the molecular weight is in the 
range 5-25 KDa [20]. The aptamer selection process, first reported in 1990 [2], starts 
from a large library of molecules containing randomly created sequences. This in vitro 
procedure satisfies the need to generate ligands exhibiting high affinity and specificity 
towards any defined recognition target.  
 
In contrast to DNA or RNA sequences, which bind through base-base 
complementarities, these new oligonucleotides bind the ligand as a result of three-
dimensional conformation changes [21]. Predominantly unstructured in solution, 
aptamers fold their flexible, single-stranded chains into well-defined three-dimensional 
structures upon binding to the target. In fact, the name aptamer originates from the Latin 
word “aptus”, which means “to fit” and the Greek suffix “-mer”. This folding involves 
the formation of stable stem-loop and internal loop structures, as a consequence of 
complementary Watson-Crick base-pairing [2]. In particular, RNA molecules are able 
to fold into a wide variety of conformations, while DNAs are known to fold in vitro into 
complex structures, even if less stable than the corresponding RNA structures [22]. 
 
Aptamers show a very high affinity for their targets, with dissociation constants 
typically from the micromolar to low picomolar range, which are comparable to those 
of some monoclonal antibodies, sometimes even better [23]. As a result of nearly 20 
years’ endeavour, SELEX has been applied to a variety of molecular targets, which 
includes proteins, organic and inorganic small molecules, nucleic acids, peptides, 
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antibiotics, vitamins, drugs, metal ions and even whole cells or microorganism [24]. 
Aptamers have been extensively used in many analytical applications, such as 
chromatography, electrophoresis, mass spectrometry, molecular beacons, sensors and 
biosensors. In particular, aptamers have become increasingly important molecular tools 
for diagnostic and therapeutic [25].  
 
 
 
 
1.3.2. Systematic Evolution of Ligands by EXponential enrichment 
 
The SELEX procedure (Figure 2) is a powerful tool for screening large libraries of 
randomised nucleic acids (generally 1013- 1015 different structures), generated by 
combinatorial chemistry.  
Each member in a library is a linear oligomer with a unique sequence, in which a central 
region of randomised sequence is flanked on either side by fixed regions, containing 
primer sequences for Polymerase Chain Reaction (PCR) and/or reverse transcriptase 
RT-PCR amplification, a promoter sequence for T7 RNA polymerase and perhaps 
restriction endonuclease sites for cloning. Randomisation is achieved simply by using a 
mixture (usually not equimolar) of the four standard nucleotides during solid-phase 
synthesis. In theory, a library containing a 40-nucleotide random region is represented 
by 440 (= 1.24 x 1024) individual sequences available for partitioning. Although any 
length of randomised region may be used to provide 4n theoretical random sequences, 
most libraries contain less than 1016 random sequences due to synthetic limitations. 
Therefore randomised regions of 30-60 nt are most common [26]. Generally, a library 
contains ten copies of the same random sequence. The single-stranded DNA pool is 
amplified by PCR in order to generate a double stranded DNA pool. This is then either 
transcribed (for RNA selection) or strand separated (for single-stranded DNA selection). 
As a result of Watson-Crick base-pairing and non-canonical intramolecular interactions, 
each of these sequences will adopt different three-dimensional structures, containing 
stem-loop, internal loops, etc. 
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After an incubation step with the target, the few sequences that reveal variable affinity 
towards the target are separated from the non-binding molecules by filtration through 
nitrocellulose (for protein targets) or by affinity chromatography (AC) (normally for 
small molecule targets). After elution and amplification by RT-PCR (for RNA libraries) 
or PCR (for DNA libraries), a new lower complexity pool enriched in target-binding 
species is achieved, and will be used for the next selection/amplification cycle (after in 
vitro transcription in the case of RNA libraries). Iterative rounds of selection and 
amplification are performed until the target-interacting sequences dominate the 
population: at the end of each cycle, under increasingly stringent conditions, the 
nucleotide pool is enriched in high-affinity binders, at the expense of the low-affinity 
binders.  
 
The required number of cycles depends upon the stringency imposed on each cycle and 
upon the affinity of interaction between the target and the aptamers. In general, about 8-
15 cycles of affinity selection and amplification are needed before selecting the 
‘‘winning’’ aptamers, i.e. an oligonucleotide population dominated by those sequences 
which bind the target best. After cloning and sequencing, selected aptamers can be 
chemically synthesised and their binding activity confirmed to validate their affinity and 
specificity for the target [27]. 
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Figure 2. Scheme of the in vitro selection of an RA aptamer (SELEX) (adapted from [25]). 
 
 
 
Since these experiments take from weeks to months to be completed manually, the 
SELEX process has been automated [28]. Furthermore, several SELEX techniques have 
been developed using modified randomised ssRNA or ssDNA libraries. In particular, 
photocrosslinking procedure (PhotoSELEX) uses ssDNA libraries substituted with 
fluorophore-modified nucleotides, such as 5’-iodo or 5’-bromo uridine triphosphate 
(UTP) or deoxyUTP. Upon UV irradiation with a laser, these nucleotides facilitate 
cross-linking of an aptamer to the target [29]. 
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1.3.3 Comparison of aptamers and antibodies 
 
Until recently, molecules capable of molecular recognition, and therefore useful in 
sensing, have generally been limited to antibodies. Antibodies are excellent recognition 
elements, although they present certain limitations [19]. Antibody production relies on 
induction of an animal immune system, and is therefore subject to animal to animal 
variations. Some target molecules are poorly immunogenic or toxic, making it difficult 
or impossible to raise an antibody. Due to the in vivo generation, antibodies can 
recognise their targets only under physiological conditions, limiting the extent to which 
antibodies can be functionalised and applied in, for example, organic media. The large 
size (average 150 KDa) and complexity of a typical antibody can make it difficult to 
modify the antibodies with enzyme or other labels, and sometimes such modification 
reduces the affinity of the antibody. Antibodies are sensitive to temperature, undergoing 
irreversible denaturation and have a limited shelf life. The large size of antibodies can 
also negatively impact the performances of an assay.  
 
Recently, many detection methods developed for antibodies have been successfully 
adapted to aptamer-based detections [30]. The widespread application of aptamers in 
analytical and diagnostic applications is mainly due to the advantages that they offer 
when used in place of antibodies. High specificity and affinity aptamers can, in 
principle, be selected in vitro for any target, ranging from small molecules to large 
proteins and whole cells. The in vitro generation process enables the selection of 
aptamers for non-immunogenic and even toxic compounds. Unlike antibodies, the 
aptamer selection process can be modified to produce aptamers which bind to a specific 
region of a target, with specific binding properties under different binding conditions. 
Once selected, aptamers are chemically synthesised and purified, eliminating the batch 
to batch variations encountered when using antibodies. Moreover, aptamers are usually 
highly chemically and thermally stable, but modifications can be introduced with the 
aim of enhancing the stability, affinity and specificity [22].  
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Aptamers undergo ligand-dependent conformational changes, and this aspect offers 
great flexibility in design of novel biosensors with high detection sensitivity and 
selectivity [21]. Aptamers show high selectivity and affinity toward their targets, with 
dissociation constants (KD) ranging from picomolar to nanomolar, comparable to those 
of some monoclonal antibodies, or even better [23]. Interactions between aptamers and 
their targets are usually so specific that small variations in the target molecule may 
disrupt aptamer binding. For example, the aptamers for theophylline and L-arginine can 
discriminate closely related chemical structures (caffeine and D-arginine, respectively) 
by factors as high as 4 orders of magnitude [31].  
 
Aptamer-based biosensors offer the advantage of reusability over antibody-based 
devices. Aptamer-based sensor layers can be regenerated more easily, undergo 
reversible denaturation and show a much longer shelf life [30]. Furthermore, their 
smaller size and versatility allows efficient immobilisation at high density, which is 
very important in miniaturised systems such as bioarrays and biochips. Commercial 
synthesis of aptamers by large scale manufacturing is fairly uncomplicated and cost 
effective. In addition, aptamers are more easily labelled with signal moieties, such as 
fluorophores or chemically reactive groups, even during their synthesis [19]. These 
functional groups permit aptamers to serve as conjugates of enzyme or beads. Finally, 
for in vivo applications aptamers are less likely to cause immune reaction than 
antibodies [32]. Consequently, aptamers offer a useful alternative to antibodies as 
sensing molecules, especially in the development of biosensors.  
 
Despite their advantages among antibodies, aptamers shows some drawbacks, primarily 
regarding their generation through the SELEX process and their use as recognition 
elements in bioassays. 
  
Even if to date almost all aptamers have been selected by SELEX, this process presents 
some disadvantages for aptamer generation. First of all, the starting random library 
generated by combinatorial chemistry must possess a sufficient number of different 
sequences, to ensure that the target-binding sequence exists in the pool. Random pools 
are anyway always incomplete, given the astronomical number of possible different 
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sequences that must be contained them [33]. Moreover, due to the large number of 
molecules in the initial library, selection strategies can be time consuming and 
expensive, and may not always result in the selection of the best aptamer for the desired 
application. The in vitro selection of aptamers is governed by the same principle as 
natural selection, which favours abundant targets. Rare targets, even those with high 
aptamer affinity, are often under-represented in final aptamer pools [34].  
 
SELEX is applicable mostly to amplifiable libraries, i.e. DNA/RNA molecules. Because 
of the intermediate steps of PCR amplification and strand separation, the aptamer 
generation takes a long-time and is a complex process. Hence, the efficient screening of 
large nucleotide libraries generated by combinatorial chemistry is hard to realise [35]. 
However, an automated protocol for the in vitro selection of nucleic acids was 
developed [36] and then modified to be applied to the selection of anti-proteins 
aptamers on a robotic workstation, which allowed completing approximately 12 rounds 
of selection in few days [28]. Since then, other automatic approaches have been 
proposed or improved [37], in order to reduce times and reagents in the selection 
process. 
 
A first experimental attempt at non-SELEX selection of aptamers, which avoided the 
PCR amplification step, has also been reported [38]. This method involved repetitive 
steps of partitioning by non-equilibrium capillary electrophoresis of equilibrium 
mixtures (NECEEM) and allowed the determination of the abundance of aptamers in 
the starting library up to a minimum of 5 x 10-10 sequences, limited only by currently 
available commercial instrumentation. 
 
The primary limitation on the use of aptamers as recognition elements is due to RNA 
nuclease sensitivity, which restricts in vivo and ex vivo applications [39]. An 
unmodified oligonucleotide has a half-life in serum of less than 1 minute. Therefore for 
applications requiring increased aptamer stability and ease of handling (such as 
biosensing, diagnostic and therapy) DNA aptamers are particularly useful. However, the 
chemical modification of the ribose ring at the 2’-position of pyrimidines with either an 
amino or fluoro functional group, increases the stability of RNA molecules by several 
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orders of magnitude [40]. Recently, it has been shown that nuclease-resistant aptamers 
can be generated substituting the 2’-hydroxyl position of purines with 2’-O-methyl [41].  
 
An elegant methodology for increasing aptamer stability has been through the use of 
enantiomeric (L-nucleic acid) forms known as Spiegelmers. Because naturally 
occurring nucleic acids are composed of D-nucleotides, corresponding mirror-image L-
oligonucleotides escape enzymatic recognition and subsequent degradation and 
consequently display dramatically enhanced nuclease resistance [42]. 
 
Finally, when labeled-probes are used as receptors, the labeling position has to be 
carefully selected so as not to interfere with the recognition event. To ensure the perfect 
binding of the aptamer to the analyte upon folding, the SELEX process is carried out 
using labelled oligonucleotide libraries [43].   
 
 
 
 
1.3.4 Computational approach to aptamer selection 
 
Some of the drawbacks encountered for the generation of aptamers by SELEX process 
could be tricked by the help of a computationally-assisted method: in particular, the 
introduction of a rationalized approach which makes use of a prediction model could 
overcome or minimize experimental problems currently met in SELEX process (such as 
reagent stability and separation procedures).  
 
An important goal of computationally-assisted library screening would be to maximise 
the number of sequences without synthesising all possible sequences. If a 
computationally-assisted screening of large libraries identified only a few potentially 
binding sequences, only a few sequences would have to be synthesised and assayed, 
decreasing the effort required for the development of biosensors. In contrast, after 
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selection experiments, numerous different sequences typically have to be selected, 
characterised and screened for their ability to bind a target. 
 
In silico screening of large libraries of compounds can be realised employing 
computational methods and, in the case of nucleic acids, algorithms for the prediction of 
secondary structures. Computational methods are routinely applied in the drug 
discovery process, with the purpose of predicting the binding mode of a known active 
ligand in a protein binding site, identifying new ligands using virtual screening and 
predicting the binding affinities of related compounds from a library of known active 
ligands [44]. In particular, the challenge of docking identifies the best candidate ligands, 
i.e. those compounds in a database of compounds showing the highest binding affinity 
towards the target, as a consequence of favourable steric, electrostatic, hydrophobic, van 
der Waals and hydrogen bonding interactions. The rigorous evaluation of the ∆G of 
binding, and hence the binding affinity of a ligand, is theoretically possible using 
molecular dynamics or Monte Carlo simulations. However these methods are too time-
consuming to be used for the screening of large databases [45].  
 
Scoring functions are algorithms that use simplified approximation of ∆G to calculate 
the binding affinity between a receptor and a ligand and predict the docked position of 
the ligand inside a binding pocket, through a virtual screening that allows the 
identification of high-affinity binders from low-affinity binders [46]. Docking methods 
employ scoring functions to assign a binding score to each docked compound, with the 
aim of identifying as quickly and accurately as possible the most likely candidate for the 
target. Therefore each molecule in the library must be docked into the protein to predict 
a “pose” of the ligand in the active site [47]. Scoring functions serve as an objective 
function to differentiate between diverse poses of a single ligand in the receptor binding 
site and to estimate and rank binding affinities of different ligands in a database, on the 
basis of a binding score. The best scoring pose of each molecule in the database is 
ranked to arrive at a top-ranking “hit-list”: the general assumption is that molecules that 
bind tightly to the receptor should be given a higher score. Due to their crucial role, 
several scoring functions and docking programs have been developed [48,49]. 
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The computational time required to dock and score a compound depends on the number 
of degrees of freedom as well as the complexity of the hypersurface. The degrees of 
freedom are the six degrees of translational and rotational freedom of one body relative 
to another and the conformational degrees of freedom of the ligand and the protein [44]. 
The hypersurface is generally very complex with many locally optimal values, due to 
the large number of atoms involved and the number of factors often accounted for (i.e. 
steric fitting, hydrogen bonding, electrostatics, torsional strain etc.). While the first 
docking algorithms treated both ligand and protein as rigid bodies, taking into account 
only translation and orientation, today’s docking programs treat the ligand as flexible 
and the receptor as completely rigid, thanks to improvement in computer performance. 
Therefore, the degrees of freedom are 3 rotations and 3 translations for the rigid ligand 
with respect to the protein, plus N torsional degrees of freedom for the ligands rotatable 
bonds. However, the simulations are often time-consuming and treating some protein 
side chains as flexible may be computationally prohibited [33].  
 
Algorithms for the prediction of oligonucleotide secondary structures starting from the 
nucleic acid sequence calculate the free energy of RNA or DNA secondary structures 
upon folding, predicting the base paired regions in the sequence. Examples are the 
Vienna RNA Package (Mfold) (http://www.bioinfo.φi.edu/applications/mfold/old/dna/), 
RNAfold (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi), GeneBee 
(http://www.genebee.msu.su/services/rna2_full.html), RNAsoft (www.rnasoft.ca) and 
others. These software have been used to computationally generate non-random 
libraries containing 1000 oligonucleotides of potentially active aptamers for IgG, 
transferrin and α-1-anti-trypsin protein, with the aim of reducing the complexity of the 
starting library and increasing the fraction of binders with respect to non binders [50]. 
Starting from a template sequence containing a central random region flanked between 
two fixed regions able to form a stable double stranded stem, a binding potential, i.e. a 
value generated using data from structural and thermodynamic calculations, is 
calculated for each selected oligonucleotide. Sequences showing thermodynamic 
parameters at the upper end of the free energy range for a specific secondary structure, 
i.e. the most unstable secondary structures, correlate with the sequences most likely to 
bind the target. The binding event decreases the free energy of the system; the more the 
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free energy decreases upon binding, the greater the binding strength. Thus, starting with 
a single stranded region as high in free energy as possible means that there are many 
chemical groups available for interaction with a target. This increases the likelihood of 
the oligonucleotide being a functional aptamer with high affinity. 
 
Using the Vienna RNA Package, the development of an algorithm for predicting the  
conformational change of an anti-flavin aptazyme and anti endothelial growth factor 
aptamer beacon upon binding has been shown [51]. Both the aptazyme and the aptamer 
beacon undergo small target-dependent displacement in the structure, assuming a 
different conformation referred to a “slip structure”.  Starting from a pool of sequences 
containing a central random region, for each sequence the free energy of folding was 
calculated along a series of “register” generated simply shifting a strand respect to the 
other. The changes in free energy that the sequences undergo as they slip from one 
register to another, allowing the slip structure model to be assessed and identifying the 
most stable structure. This method allows computing structures and free energies of 
millions of different sequences to be assessed in hours on a typical desktop computer. 
 
 
 
 
1.4. Aptamer-based biosensors for clinical applications  
 
 
1.4.1. Aptamers as biorecognition elements for clinical applications 
 
The detection and quantification of proteins in their native environments has always 
been a critical and challenging task and plays an essential role in basic discovery 
research as well as in clinical practice. Assays that allow rapid, simple, sensitive, 
selective and cost-effective detection of proteins are of significant importance for the 
understanding, diagnosis, treatment, and prevention of many diseases. Diagnostic 
systems able to early and accurately detect protein biomarkers, such as cytokines or 
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growth factors, have a particular emphasis in clinical and medical research. Despite 
current techniques for protein detection, such as electrophoresis, affinity 
chromatography, ELISA, the development of sensitive methods for real time protein 
analysis is still a difficult task [52]. For this purpose, a highly selective molecular 
recognition element and a novel signal transduction mechanism have to be engineered 
together for successful assay development. Among many molecular recognition 
elements, aptamers have gained increasing interest in protein sensing and the use of 
aptamers for diagnostic applications has been extensively explored [53]. Several 
strategies for transducing aptamer-protein interactions into the changes in colorimetric, 
electrochemical, mechanical, piezoelectric or fluorescent signals, and in electrophoretic 
mobility have been reported.  
 
 
 
 
1.4.2. Aptamers for Thrombin 
 
The first aptamer selected in vitro towards a protein with no known nucleic acids 
binding properties is the 15-mer thrombin binding aptamer (TBA, 5’-
GGTTGGTGTGGTTGG-3’) [54].  The 15-mer TBA binds to the fibrinogen-
recognition exosite of human α-thrombin (namely exosite I), with a KD of 26 nM . A 
29-mer thrombin binding aptamer has also been selected (5’-
CAGTCCGTGGTAGGGCAGGTTGGGGTGACTTCGTGGAA-3’), with a KD of 0.5 
nM for the protein [55].  This aptamer binds to the heparin-binding exosite of thrombin 
(namely exosite II). 
 
Two-dimensional NMR studies demonstrated that TBA folds into a unimolecular 
quadruplex structure, containing two G-quartets linked by two TT loops at one end and 
a TGT loop at the other end, usually referred to as a “chair structure” and stabilised by 
K+ ions [56]. The thymines in the TT loops are potentially base-paired across the top of 
one G-quartet. The two G-quartets are connected by two TT loops that span the narrow 
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grooves at one end and a TGT loop that spans one of the wide grooves at the other end 
of the quadruplex, as shown in Figure 3. An interesting feature of TBA is the formation 
of a T4•T13 base-pair across the G-quartet.  
 
 
Figure 3: Schematic model for TBA determined by analysis of MR spectra (from [56]). 
 
 
The 29-mer anti-thrombin aptamer was found to adopt the same G-quartets structure 
when bound to thrombin (Figure 4). 
 
 
Figure 4: Secondary structure of the 29-mer thrombin binding aptamer. The 15 nucleotides of the 
G-quartets core sequence are numbered (from [55]) 
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1.4.2.1. Thrombin 
 
The coagulation cascade is a complex series of biochemical reactions that results in the 
polymerisation of fibrin and formation of platelet/fibrin haemostatic plugs (Figure 5). In 
normal vasculature, it serves as the primary mechanism to control bleeding. However, 
with vascular pathology, activation of coagulation pathway can result in thrombosis and 
life-threatening vascular occlusion. The primary approach to the development of novel 
anticoagulant/antithrombotic drugs has been the inhibition of specific biochemical 
targets in the coagulation cascade, in which the two central target are thrombin and 
Factor Xa. Thrombin (Factor IIa) is the last enzyme protease involved in the 
coagulation cascade: it converts fibrinogen to insoluble fibrin, which forms the fibrin 
gel, either in physiological conditions or in pathological thrombus [57]. Thrombin has 
also hormone-like properties and it is involved in thrombosis and platelet activation. 
Therefore, thrombin plays a central role in inflammation and tissue repair at the vessel 
wall [58]. Currently, the most commonly used antithrombotic agent is heparin, but other 
thrombin inhibitors are clinically available, such as hirudin. 
 
 
 
Figure 5. The blood coagulation cascade. (from Website 
http://themedicalbiochemistrypage.org/blood-coagulation.html, copyright 1996 M. W. King)) 
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The concentration of thrombin in blood can vary considerably: thrombin, not present in 
blood under normal conditions, can reach low µM concentrations during the coagulation 
cascade, but low levels (low nM) of thrombin generated early in hemostasis are also 
important to the overall process [59]. Out of the hemostatic process, circulating 
thrombin has been detected at high pM range in blood of patients suffering from disease 
known to be associated with coagulation abnormalities [60]. This makes the 
determination of thrombin concentration in real time an excellent tool for obtaining 
accurate coagulability status. The measure of coagulation time forms the basis of 
clinical analysis of coagulation efficiency currently available on the diagnostic market 
[61] (Prothrombin Time (PT), activated Partial Thromboplastin Time (aPTT), Thrombin 
Time (TT) , activated Clotting Time (ACT), ThrombogramTM and inhibitors screening 
tests [62]).  
 
Thrombin is a 308-amino acids serine protease (MW 36 KDa) containing two chains. 
The A chain is composed of 36 residues and is not essential for proteolytic activities. 
The B chain is composed of 259 amino acids and contains the three active sites residues 
(Hys57, Asp102, Ser195). Thrombin has four distinct binding sites for substrates, 
inhibitors, cofactors and Na+ ions, and other three recognition sites (exosite I, exosite II 
and active site) for the molecules which take part in its different functions [63].  
 
 
 
 
1.4.2.2. The aptamer-thrombin complex 
 
The crystal structure of the complex thrombin-TBA was solved by X-Ray 
crystallography [64]. As in solution, in the crystal complex the single stranded DNA 
folds into a structure with two G-quartets, where a T7G8T9 loop is on one side of the 
quartets and the T3T4 and T12T13 loops are on the other hand.  
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Study for the identification of the binding pocket with which TBA interacts suggest that 
TBA is located in the thrombin fibrinogen-recognition exosite (the anion binding 
exosite) and overlaps the thrombin platelet receptor and thrombomodulin binding sites 
[65]. The Nuclear Magnetic Resonance (NMR) model of aptamer-thrombin complex 
(Protein Data Bank 1HAO) indicates that the dominant interactions in the fibrinogen 
exosite involve the TT loops (Figure 6), while the TGT loop interacts with the heparin-
binding site of the neighbouring thrombin [66]. In the NMR model, the major binding 
interactions in the fibrinogen-binding site appears to be hydrophobic, involving T12 
(Ile24, His71, Ile 29, Tyr117) and T3 (Tyr76, Ile82), while in the heparin exosite of a 
symmetry related thrombin molecule four residues are involved in ion pair interactions 
with the DNA [67]. The residues involved in the main aptamer-thrombin interactions 
are listed in Table 1. 
 
 
 
Figure 6: The aptamer-thrombin complex (PDB 1HAO) [67]. 
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NMR Model 
Fibrinogen-recognition exosite 
T3 Tyr76, Ile82 Hydrophobic 
T12 Ile24, His71, Ile79, Tyr117 Hydrophobic 
Heparin-binding site 
G2 O2P Arg233’ Ion pair 
G2 O2P Arg233’ Ion pair 
G5 O1P Lys236’ Ion pair 
G5 O2P Lys236’ Ion pair 
T7 O1P Lys240’ Ion pair 
T9 O1P Arg93’ Hydrogen bond, ion pair 
Table 1. Interactions between thrombin and the DA 15-mer (from [64]). 
 
 
 
 
1.4.2.3. Aptamer-based biosensors for thrombin detection 
 
TBA has been coupled with different transduction principles to demonstrate the wide 
applicability of aptamers as bioreceptors in biosensors. In particular, the majority of the 
reported aptamer-based biosensors, sensors and assays for the detection of proteins with 
a certain importance in clinical chemistry, make use of the thrombin-binding aptamer. 
Many assays, mainly biosensors, based on the thrombin-binding aptamer for the 
detection of thrombin have been developed in the last 10 years, but only few of them 
have been really used as analytical method for the detection of thrombin in real samples.  
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a) Biosensors employing labeled-thrombin 
First examples of aptasensor development for thrombin detection employed the analyte 
thrombin labeled with a fluorescein tag. In particular, a fiber-optic aptasensor for the 
measurement of thrombin was described [68]. An amino-derived TBA was immobilized 
on the surface of silica microspheres and incubated with fluorescein-labeled thrombin. 
Non-labeled thrombin was detected (DL 1 nM) using a competitive binding assay. 
Coupling the 15-mer thrombin aptamer on the sensor surface, a Love-wave biosensor 
was designed for detection of thrombin labeled with a fluorescent dye [69], with a DL 
of 72 pg/cm2. 
 
 
b) Biosensors employing functionalized anti-thrombin aptamers  
Since aptamers are easy to label with different tags (such as fluorescent or 
electrochemical dyes), generally it is desirable to employ modified receptors rather than 
modified analytes when monitoring real-time interactions. The function of proteins in 
biological system is highly dependent on their tertiary structure and therefore labeling 
proteins may cause reduction or even loss of activity, by either blocking the binding site 
or affecting the three dimensional folding of the proteins [70].   
Since one of the requirements for a biosensor is immobilisation of the receptor on the 
sensor surface, several 3’ or 5’ chemical modification of the aptamer were engineered to 
incorporate functional groups or molecules that facilitate the linkage to the surface. 
Therefore, different strategies for the development of thrombin biosensors using 
functionalized anti-thrombin aptamers were reported employing different transduction 
principles, which were mainly optical or electrochemical. 
 
An anti-thrombin fluorescein-aptamer was covalently immobilized on a microscope 
cover slip, and protein binding was detected by fluorescent anisotropy method, with a 
Detection Limit (DL) of 5 nM [71].  
 
A single-walled carbon nanotube field-effect transistor was used for the immobilisation 
of the amino-derived 15-mer thrombin aptamer. The following protein bonding caused a 
measurable decrease in conductance, and the DL was 0.1 nM [72].   
Introduction 
 
24 
 
Using methylene blue (MB) as electrochemical indicator, an electrochemical aptasensor 
for thrombin detection was developed by immobilising the biotinylated aptamer on the 
avidin-derived electrode gold surface and detecting the binding of thrombin to the  
aptamer with a DL of 10 nM [73]. A direct thrombin detection with 1 nM DL was also 
realised by immobilising the aptamer on the gold surface of a quartz crystal 
microbalance.  
 
A signaling aptamer for thrombin was created by replacing the nucleotide T7, located 
close to the protein binding site, with a fluorescent analogue, which causes an increase 
in fluorescence upon thrombin binding at nanomolar concentrations, measured by a 
fluorescence microscope imaging [74]. 
 
 
c) Aptamer beacons 
One of the more promising aptasensor approaches is aptamer beacons, optical sensors 
based on the binding-induced folding of unfolded or partially folded aptamers. In the 
absence of target, the fluorophore attached to the DNA aptamer is quenched by a 
complementary DNA fragment carrying a quencher dye. When the system is exposed to 
the target, the aptamer binds to it and the quencher-labelled DNA is released, generating 
a fluorescent signal. Because aptamer beacon couples signal generation to a binding-
specific change in the aptamers rather than to adsorption to the sensor surfaces, they are 
relatively immune to false positives arising from non-specific interactions with 
contaminants.  
 
An electronic sensor was developed by immobilising the thrombin binding aptamer 
labeled with methylene blue onto a gold electrode [75]. In the absence of the target the 
aptamer could maintain its unfolded structure and methylene blue could reach the 
electrode surface generating an electrochemical signal. Upon addition of thrombin, the 
aptamer folded its characteristic secondary structure when binding to the target, 
preventing the contact of methylene blue with the electrode. As a consequence, a 
decrease in signal was observed in the presence of thrombin. Thrombin was detected in 
the nanomolar range in buffer solutions and also in 50% diluted human serum spiked 
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with thrombin, to demonstrate the applicability of the sensor to the analysis of complex 
matrices. This “signal-off” sensor, in which the presence of the target reduces the 
signal, was further modified in a “signal-on” architecture [76] introducing a short 
methylene blue-oligonucleotide that hybridised with the immobilised aptamer. In the 
absence of target, the formation of the double strand prevented the methylene blue from 
approaching the electrode, while thrombin binding disrupted the hybrid, allowing the 
methylene-blue to reach the surface and produce a faradic current. The detection limit of 
this “signal-on” approach was 3 nM. 
 
On the basis of the same principle, the development of an electrochemical molecular 
aptamer beacon was developed [77] by immobilising a thiolated ferrocene-labelled 
thrombin aptamer on a gold electrode surface and measuring the ferrocene-enhanced 
electron transfer upon target binding, resulting in a nanomolar detection limit.  
 
 
d) Sandwich formats 
Since thrombin presents two different non-overlapping binding sites for aptamer 
interactions, aptamer-based biosensors with sandwich formats for thrombin detection 
were recently reported, in which the protein is sandwiched between two identical 
aptamers or the protein binds two different nucleotide sequences. This highlights the 
importance of identifying multiple aptamers for a single molecular target.   
 
In the first reported approach [78], the 15-mer aptamer was immobilised onto a gold 
electrode and, after thrombin bound, a sandwich assay was realised with a glucose 
dehydrogenase-labeled 29-mer aptamer. As the substrate glucose was added, an electric 
current proportional to thrombin concentration was measured, with a DL of 10 nM. 
Using a similar sandwich format, an electrochemical aptasensor for thrombin detection 
was developed by immobilising a thiolated aptamer on a gold electrode, incubating with 
thrombin and using a biotinylated 15-mer as secondary aptamer [79]. After the added of 
the streptavidin-peroxidase conjugated and further of the substrate, the enzymatic 
product was electrochemically detected. The detection limit in standard solution was 80 
nM.  
Introduction 
 
26 
 
Another strategy employed gold nanoparticles (Au-NP) to functionalise the 15-mer 
TBA, covalently immobilised on the sensor surface [80]. After the thrombin bound, the 
same Au-NP functionalised 15-mer used as secondary aptamer associated to the other 
protein binding site. Following an amplification step with HAuCl4, the absorbance 
spectra was recorded, with a detection limit of 2 nM. The same format was also realised 
using QCM measurements.  
 
An interesting approach based on the use of aptamer-functionalised Pt nanoparticles has 
been optimized [81]. In this work, the metallic nanoparticles were used not as mere 
labels for an electrochemical detection, but as catalytic molecules, with the aim of 
overcoming some of the drawbacks associated with the thermal and environmental 
instability of traditional biological redox catalytic labels such as enzymes. The assay 
was conducted by immobilising the thiolated thrombin aptamer onto a gold electrode 
and using, after the interaction with thrombin, the same aptamer fixed onto Pt 
nanoparticles as secondary ligand. The Pt nanoparticles were then used to perform the 
electrocatalytic reduction of added H2O2 detected by linear sweep voltammetry. A 
detection limit of 1 nM for thrombin was achieved with this method.  
 
The detection limit for thrombin using the specific aptamer was further improved down 
to 0.02 nM by using another sandwich assay based on gold nanoparticles and 
impedimetric detection [82]. The protein was sandwiched between the aptamer 
immobilised onto a gold substrate and the aptamer-functionalised gold nanoparticles, 
which were used to amplify the impedimetric signal. 
 
An original electrochemical sandwich-type nanoparticle-based assay was developed 
using the specific anti-thrombin antibody immobilised onto microtitre plates to capture 
thrombin [83]. The bound thrombin was then linked to aptamer-functionalised gold 
nanoparticles. The adenine nucleobases were finally released from the nanoparticles by 
acid or nuclease treatment and electrochemically detected using a pyrolytic graphite 
electrode. The method has several advantages such as the direct detection of the redox 
activity of the adenine nucleobases of the aptamer avoiding, in this label-free format, 
the time-consuming and complicated labelling of the oligonucleotides. Moreover, the 
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aptamer-modified nanoparticles served not only as a target recognition elements, but 
also as amplification tool.  
 
An aptamer-based sandwich assay based on electrochemical detection for thrombin 
analysis in complex matrices was developed by coupling the advantages of magnetic 
beads with those of aptamers [84]. The protein captured by the first aptamer, 
functionalised with magnetic beads, was detected after the addition of the second 
biotinylated aptamer and of streptavidin labelled with alkaline-phosphatase. The 
detection of the product generated by the enzymatic reaction was achieved by 
Differential Pulse Voltammetry (DPV) on screen-printed electrodes. Good sensitivity 
and selectivity were demonstrated by the sensor with a detection limit of 0.45 nM in 
buffer and negligible signal generated by negative control proteins. The system was also 
demonstrated to recognise the target analyte in protein rich media, such as thrombin 
spiked serum and plasma samples. Moreover, mimicking the physiological clogging 
event, thrombin was generated in situ by the conversion of its precursor prothrombin 
present in plasma and its concentration was measured at different incubation times. The 
results correlated well with thrombogram-mimicking software. 
 
The best sensitivity for the detection of thrombin, with a detection limit of about 8 aM, 
was reached by using an electrochemical assay coupled to a novel amplification strategy 
[85]. This ultrasensitive aptamer-based bioanalytical method was based on a sandwich 
format with the target protein captured by the first aptamer-functionalised magnetic 
nanoparticles. A second aptamer was attached to gold nanoparticles, which facilitated 
the electrochemical transduction. The innovative amplification strategy was achieved by 
forming network-like thiocyanuric acid/gold nanoparticles whose aggregation greatly 
enhanced the transduction of the aptamer-protein recognition event. 
 
A summary of the different methods with the corresponding detection limit is reported 
in Table 2. 
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Method 
Analyte 
label 
Aptamer 
label 
Secondary aptamer label 
/ amplification 
DL Ref Year 
Optical fluorescent   1 nM [68] 2000 
Optical fluorescent   
72 
pg/cm2 
[69] 2004 
Optical  fluorescent  5 nM [71] 1998 
Filed effect 
transistor 
   
0.1 
nM 
[72] 2005 
Electrochemical  MB  10 nM [73] 2005 
Acoustic    1 nM [73] 2005 
Optical  fluorescent  nM [74] 2006 
Electronic  MB  nM [75] 2005 
Electronic  MB  3 nM [76] 2005 
Electrochemical  ferrocene  nM [77] 2005 
Electrochemical   Enzyme 10 nM [78] 2005 
Electrochemical   
Biotin / streptavidin-
enzyme conjugated 
80 nM [79] 2006 
Electrochemical 
/ acoustic 
 Au NP Au NP / HAuCl4 2 nM [80] 2004 
Electrochemical   Pt NP / H2O2 1 nM [81] 2006 
Electronic   Au NP 
0.02 
nM 
[82] 2008 
Electrochemical   Au NP 3 pM [83] 2007 
Electrochemical  
Magnetic 
beads 
Biotin / streptavidin-
enzyme conjugated 
0.45 
nM 
[84] 2007 
Electrochemical  
Magnetic 
beads 
Au NP 8 aM [85] 2007 
Table 2. Overview of different aptamer-based biosensors developed for the detection of thrombin. 
Limit of detection of the assay is reported with the relative amplification strategies. 
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e) Aptamer-based biosensor arrays 
Since the value of any single marker is significantly enhanced by combination with 
other markers, the most relevant application of proteomics to disease is the analysis of 
multiple protein targets simultaneously, a task that has proved challenging in recent 
years. The main characteristic of a large multiplexed protein array is its ability to retain 
the specificity and sensitivity of detection without compromising the quality of 
individual reagents. The rapid detection and profiling of multiple protein biomarkers in 
blood and serum samples are a potentially powerful method for the diagnosis of 
diseases and the monitoring of subsequent therapeutic treatments. Microarrays of RNA 
aptamers are emerging as an attractive alternative to antibody arrays for the multiplexed 
bioaffinity detection and identification of protein biomarkers. 
 
The development of an aptamer chip-based biosensor with fluorescence detection that is 
capable of specifically quantifying levels of several proteins with relevance to cancer, in 
particular thrombin, inosine monophosphate dehydrogenase (IMPDH), vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), has been 
described [86]. 5’ biotinylated aptamers attached to a 12-carbon linker were 
immobilised on a streptavidin-derivatised glass substrate. The protein targets were 
spiked in complex biological solution, such as bacterial cell lysate diluted 1:10, and the 
target binding event was monitored using fluorescence polarisation anisotropy 
technique.  
 
Another technique recently employed for the detection of protein on aptamer 
microarrays is Surface Plasmon Resonance Imaging (SPRI) [87]. Enzymatically 
amplified SPRI measurements of RNA aptamer microarrays were used to detect protein 
biomarkers (VEGF and Thrombin) down to subpicomolar concentrations. A surface-
immobilised aptamer is used to capture the proteins onto the RNA microarray, and then 
the antibody conjugated with Horse Radish Peroxidase (HRP) is bound to the array 
element via the formation of an RNA aptamer/protein/antibody-HRP sandwich 
structure. On the addition of the substrate TMB (3,3’,5,5’-tetramethylbenzidine), HRP 
catalyses localised formation of a dark blue precipitate, that is detected using SPRI 
measurements.  
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1.4.3. Aptamer for C-Reactive Protein 
 
An RNA aptamer against C-Reactive Protein (CRP) was selected by SELEX [88] 
starting from a oligonucleotide library in which each sequence contained a central 43-
mer random region flanked by constant regions. The constant regions included targets 
for PCR primers and cloning sites and a T7 promoter. After 10 rounds of SELEX, the 
resulting aptamer sequence was a 44-mer showing a KD of 125 nM: 
(5’-GCCUGUAAGGUGGUCGGUGUGGCGAGUGUGUUAGGAGAGAUUGC-3’). 
 
 
 
1.4.3.1. C- Reactive Protein 
 
C-Reactive Protein, so named for its capacity to precipitate the somatic C-
polysaccharide of Streptococcus pneumonia, is a critical component of the immune 
system discovered nearly 70 years ago by scientists exploring the human inflammatory 
response. CRP is one of the cytokine-induced “acute-phase” proteins whose blood 
levels rise during a general, unspecific response to infections and non-infections 
inflammatory processes. Because of its lack of specificity, for about 30 years CRP has 
been considered not to provide clinically useful information [89].  
CRP is a serum soluble protein synthesised in the liver by hepatocytes and its 
production is stimulated by proinflammatory cytokines, particularly interleukin (IL)-6 
and tumor necrosis factor-α (TNF)- α [90].  Several recent studies have shown that CRP 
can be produced by non-hepatic tissues, such as epithelial cells of the respiratory tract, 
renal epithelium and neuronal cells [91]. 
 
 
a) CRP structure  
CRP (MW 115.135) belongs to the pentraxin family of calcium-dependent ligand-
binding plasma proteins having five identical, non-covalently associate subunits that 
form a symmetrical ring. Each nonglycosylated polypeptide subunit (MW 23 kDa) 
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contains 206 aminoacid residues and has the characteristic “lectin fold”, composed of a 
two antiparallel β sheet, with an α  helix on the other protein face [92].  The ligand 
binding site for phosphocholine is composed of loops with two calcium ions next to a 
hydrophobic pocket (Figure 7). Phosphocholine binds to CRP in a calcium dependent 
manner, which then begins the complement pathway [89].  
 
 
 
 
 
Figure 7. Molecular structure of human CRP. (a) Ribbon diagram of the crystal structure, showing 
the lectin fold and the two calcium ions in the ligand-binding site of each protomer. (b) Space-filling 
model of the CRP molecule, showing a single phosphocoline molecule located in the ligand-binding 
site of each subunit. (from [89]) 
 
 
In vitro studies [93,94,95] have shown that after binding to plasma membrane or in 
denaturing or oxidative environment, native CRP loses its pentameric symmetry 
(pCRP), resulting in a modified or monomeric CRP (mCRP), which may be the major 
CRP promoter of the proinflammatory response in the coronary arteries. Khreiss et al. 
[94] suggested that the bioactivity of CRP is expressed when the pentameric structure 
dissociates and undergoes a conformational rearrangement, resulting in formation of 
mCRP; in fact, mCRP was able to induce endothelial activation within 4 hours, whereas 
native CRP showed a proinflammatory effect in 24 hours.  
 
a b 
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Even though it is currently not known how mCRP is generated in vivo, acid-EDTA or 
urea-EDTA treatment of CRP, as well as surface adsorption and immobilisation on 
plastic surface, might cause the native CRP to irreversibly dissociate in monomers [93]. 
It has also been demonstrated [95,96] that in the absence of calcium ions, in neutral or 
mildly acid environments, the pentameric CRP slowly but continuously dissociated. The 
dissociation rate increased with the storage time. For this reason commercial high-purity 
(> 99%) human native CRP is stored in NaN3-free buffer containing CaCl2 to prevent 
spontaneous formation of mCRP from the pentamer.  
 
 
b) CRP levels 
CRP is normally present in healthy adults at concentrations < 10 ppm. In healthy young 
people the average concentration of CRP is 0.8 ppm, but serum levels increase in 
response to a variety of inflammatory stimuli, such as trauma, tissue necrosis, infection, 
surgery or myocardial infarction. Following an acute phase stimulus, values may rapidly 
increase over 1000 fold, from less than 50 ppb to more than 500 ppm, resulting in the 
release of elevated quantities into the circulation. When the stimulus for increased 
production completely ceases, the circulating CRP concentration falls rapidly [89]. The 
amount of CRP depends however on a variety of factors, including genetics and 
lifestyle habits. On average, smoking, high blood pressure, being overweight, sleep 
disturbances, depression, chronic fatigue, aging and physical inactivity are associated 
with high levels of CRP [97].  
 
The recent attention focused on CRP reflects the discovery of its role in the prediction 
of future cardiovascular diseases (CVD) in apparently healthy people. It has been shown 
that an increased CRP production can be associated with a risk of atherothrombotic 
events, including coronary events, ischemic stroke, myocardial infarction [98,99]. 
Furthermore, CRP is detectable in the early stages of atherosclerotic plaque evolution, 
and can be used to predict the development of type 2 diabetes mellitus [100].   
 
Although other inflammation markers show predictive associations with coronary 
events, the interest in CRP arises from its high stability in serum or plasma and the 
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availability of robust, well standardised and reproducible CRP immunoassays [89]. 
Furthermore CRP has a long half-life in serum, its levels remain stable over time 
without exhibiting circadian variability and fasting blood sample are not required [101]. 
 
 
c) CRP commercial assays 
Different methods for CRP detection are commercially available. Conventional CRP 
assays include qualitative, semi-quantitative and quantitative assays (for example latex 
agglutination), used for evaluation of infections, tissue injury and inflammatory 
disorders [90]. These assays provide information for the diagnosis, therapy and 
monitoring of inflammatory diseases. For conventional CRP assays, test values are 
considered to be clinically significant at levels above 10 mg/L [102]. 
 
A lower limit of quantitation (LOQ), intended as the lowest concentration at which bias 
and precision are within acceptance criteria (i.e.% Coefficient of Variation ≤ 20% 
[102]) is achieved with high sensitivity CRP assays (hsCRP), which comprise 
immunonephelometric, immunoturbidimetric, immunoluminometric, microparticle 
enzyme immunoassay and sandwich immunoassay (such as ELISA) technologies [103]. 
These assays are used to evaluate conditions thought to be associated with inflammation 
in otherwise healthy people. Manufacturers of different hsCRP tests based on 
immunoturbidimetry or immunonephelometry claims detection limits between 0.005 
and 0.08 ppm, intended as the minimum detectable concentration of the assay as 
measured by 2SD (standard deviation) from the mean of a zero standard [90]. The 
detection limit for commercial hsCRP assays based on ELISA tests is 0.1 ppm or even 
less. hsCRP assays are referred to as cardiac CRP assays (cCRP) when they are used for 
prediction of future cardiovascular diseases in conjunction with traditional clinical 
laboratory evaluation of acute coronary syndromes. Therefore, hsCRP represents the 
inflammatory marker to assess cardiovascular risk; its clinical cut-off points have been 
set in low (< 1.0 ppm), moderate (1.0 – 3.0 ppm) and high risk (3.0 – 10 ppm) [104] 
(Figure 8).  
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Figure 8: CRP cut-off points to assess cardiovascular risk (adapted from[97]). 
 
 
Despite the commercial availability of automated hsCRP assays, there is still a need for 
a high sensitive CRP assay showing high precision at levels between 0.15 and 10 ppm 
to evaluate primary CVD prevention for patients at intermediate risk. Therefore, new 
generations of CRP assays are under development.  
 
 
 
 
1.4.3.2. Immuno- Sensors and Biosensors for C-Reactive Protein detection  
 
Immunochemical approaches for CRP detection as an alternative to commercially 
available immunoassays have been reported. Among these, a liposome-based 
immunosorbent assay (LISA) to detect human CRP in standard solution was described 
[105]. Liposomes containing Ru(bpy)3
2+ (bpy = 2,2’-bipyridine) were prepared as an 
electrogenerated chemiluminescent (ECL) tag and polyclonal antiCRP antibodies were 
introduced onto liposomes via a streptavidin/biotin linkage. A sandwich assay was 
realised by using magnetic beads modified with polyclonal antiCRP antibodies, in order 
to magnetically separate the antigen-antibody conjugates from unreacted species. The 
addition of NaCl and TritonX caused liberation of Ru(bpy)3
2+ from reacted liposomes 
and its detection was performed by luminescence and electrochemical techniques, with 
an experimental Detection Limit of 0.1 ppm, intended as the lowest concentration 
reliably detected.  
 
Alternative new approaches for CRP detection in complex matrices such as whole 
blood, serum and plasma have been studied. In particular, a magnetic permeability 
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detection based immunoassay to detect CRP in venous and capillary whole blood 
samples was developed [106]. Monoclonal anti-CRP antibodies were immobilised on 
the dextran polymer shell of superparamagnetic nanoparticles and polyclonal anti-CRP 
antibodies were immobilised on silica microparticles. After the addition of CRP, the 
sandwich silica-microparticles/CRP/superparamagnetic nanoparticles formed and 
precipitated. The enrichment of superparamagnetic nanoparticles in the pellet was 
measured with a Detection Limit (LOD) of 0.2 ppm, intended as the lowest CRP 
concentration giving a signal higher than the signal of the zero standard plus 3 standard 
deviations. 
 
A high-throughput multi-antigen microfluidic fluorescence immunoassay to detect 
simultaneously CRP, prostate specific antigen PSA, ferritin and vascular endothelial 
growth factor (VEGF) in spiked blood sample was also described [107]. After 
immobilisation of monoclonal antibodies on epoxide microchambers, ELISA tests were 
performed using biotinylated antibodies and fluorescently-labelled streptavidin, with an 
experimental Detection Limit of 1 ppb for CRP.   
 
A few immune-biosensors for CRP detection in buffer solution or real matrices have 
been described, using transduction principles such as optical. In particular, an 
immunological optical biosensor capable to detect and recognise pCRP and mCRP in 
buffer solution was developed [108]. Since pCRP and mCRP exhibit different 
bioactivities for antibodies, three different monoclonal antibodies were immobilised on 
a gold sensor surface covered with a protein G layer and the analyte binding was 
monitored using surface plasmon resonance, yielding an experimental detection limit of 
1 ppm. Other SPR-based biosensors for CRP detection have been recently reported, in 
which the covalent immobilisation of the analyte CRP on the gold sensor surface is 
achieved by using amide-linked N-hydroxysuccinimmide (NHS) – dextran [109], or the 
covalent immobilisation of an anti-CRP antibody is realised by forming a self-
assembled monolayer (SAM) of poly(thiophene) containing NHS ester groups [110].  
 
A label-free dual-polarisation interferometric biosensor for CRP was also developed by 
immobilising a monoclonal antibody, anti-CRP, on a glutaraldehyde-functionalised 
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sensor chip. Changes in the refractive index were monitored upon injection of 0.01 ppm 
CRP [111].  
 
Electrochemical impedance was employed for the development of a label-free 
immunosensor for CRP, using a three-dimensional ordered macroporous gold film-
modified electrode [112].  After antibody anti-CRP immobilisation on the electrode, the 
increase of impedance upon CRP binding was measured, yielding an experimental 
detection limit of 0.1 ppm.   
 
The detection of CRP  in blood, serum and urine-spiked samples was performed using a 
magnetic biosensor exploiting the frequency-mixing technique [113]. A two-frequency 
magnetic field excitation was used and the magnetic response was detected at a third 
frequency, which was a linear combination of the applied frequencies. Commercial 
columns containing polyethylene were modified by immobilisation of monoclonal anti-
CRP antibody. After the CRP binding, a different biotinylated monoclonal anti-CRP 
antibody linked to magnetic-beads modified by streptavidin was added, giving an 
experimental detection limit of 25 ppb.  
 
An acoustic biosensor for label-free CRP detection in diluted spiked serum was 
developed [114] by immobilising an anti-CRP chip on a piezoelectric quartz crystal and 
recording the oscillation frequency shifts upon the analyte binding and the consequent 
binding of the secondary anti-CRP antibody, to realise a sandwich assay. The detection 
of the lower spiked CRP concentration (0.1 ppm) in serum correlated well with a 
commercial hsCRP ELISA. 
 
Finally, two different assay types, binding inhibition and sandwich assay, were used to 
measure CRP in human spiked serum, using fluorescence as transduction principle 
[115]. For the sandwich assay, an anti-CRP capture antibody was immobilised on the 
aminodextran-modified sensor surface, followed by diluted serum sample and further 
secondary fluorescent-labelled antibody injections. For the binding inhibition assay, the 
analyte CRP was covalently bound to the surface, then a mixture of diluted spiked 
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serum and fluorescent-labelled anti-CRP antibody was injected. The experimental limits 
of detection were respectively 0.13 ppm and 0.055 ppm.  
 
 
 
 
1.5. Transduction Systems: Theory 
 
Piezoelectric and Surface Plasmon Resonance (SPR) transduction methods have been 
widely used in biosensor development, mainly because they allow the detection of 
label-free targets and the kinetic measurement of molecular interactions in real-time. 
Moreover, piezoelectric crystals and SPR chips can be regenerated, allowing a multi-use 
of the sensor. 
 
 
 
1.5.1. Piezoelectric Biosensors: theory and applications of piezoelectric 
effect 
 
Piezoelectric crystals are acoustic transducers generally utilised as microbalance or 
microviscosimeters. In particular, piezoelectric quartz crystals are the basic elements of 
quartz crystal microbalance (QCM) device. The term “piezoelectric” is derived from the 
Greek word piezen meaning “to press”. The first investigation on the piezoelectricity 
was performed in 1880 by Jacques and Pierre Curie [116], who observed that a 
mechanical stress applied to the surfaces of various kinds of crystal caused a 
corresponding electrical potential across the crystal, whose magnitude was proportional 
to the applied stress. The charges generated in a piezoelectric crystal are due to the 
formation of dipoles that result from the displacement of atoms in an acentric crystalline 
material. The Curies also verified the converse piezoelectric effect, in which application 
of a voltage across these crystals caused a corresponding mechanical strain. This causes 
a vibrational, or oscillatory, motion in the crystal, resulting in the generation of acoustic 
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standing waves at a characteristic resonant frequency. The wave is called bulk acoustic 
wave (BAW) or surface acoustic wave (SAW) in the case of propagation through the 
substrate or on the surface, respectively.  
 
A few naturally abundant crystals (i.e. quartz, tourmaline and Rochelle salt) are 
piezoelectric, but many other materials exhibit this effect, including quartz analogue 
crystals, such as berlinite (AlPO4), gallium orthophosphate (GaPO4), ceramics with 
perovskite or tungsten-bronze structures (BaTiO3, KNbO3, LiNbO3, LiTaO3, BiFeO3, 
NaxWO3, Ba2NaNb5O5, Pb2KNb5O15). However, only quartz provides the unique 
combination of mechanical, electrical, chemical and thermal properties, which allowed 
its commercial success.  
 
Direct and converse piezoelectricity has a wide range of applications. Piezoelectric 
quartz crystals are used in quartz watches, computers and in many high-performance 
devices (such as Atomic Force Microscopy) to apply tiny mechanical displacements on 
the scale of nanometers. Furthermore, such crystals are employed as quartz crystal 
microbalance for thickness monitoring. 
 
The quartz crystal microbalance is a bulk acoustic wave device based on the converse 
piezoelectric effect, in which a quartz crystal is sandwiched between two electrodes. 
The resonant frequency of the quartz crystal depends on several parameters, such as 
size, density and cut [117]. The most used devices employ AT-cut quartz crystals, sliced 
with an angle of 35°10’ with respect to the optical z-axis (Figure 9). AT-cut quartz 
crystals show a high frequency stability and a temperature coefficient close to zero 
between 0 and 50 °C [118]. AT-cut crystals oscillate in the thickness shear mode (TSM) 
[119]. 
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Figure 9. AT-cut quartz crystals with a cut angle of 35° 10' with respect to the optical z-axis 
perform shear displacements perpendicular to the resonator surface (from Website 
http://www.tau.ac.il/~phchlab/experiments/QCM/QCM.html). 
 
 
The application of a voltage between the two electrodes causes a shear deformation of 
the crystal, which is maximised at the crystal faces, making the device sensitive to 
surface interactions. The resonant condition with the acoustic wave is satisfied by 
including the crystal into an oscillation circuit, where the frequency of the alternating 
potential difference applied to the electrodes matches the fundamental frequency of the 
crystal. The fundamental frequency depends upon the thickness of the wafer, its 
chemical structure, its shape and its mass [120].  
 
Since the oscillation frequency depends on the crystal mass, deposition of thin films on 
the crystal surface increases the resonator thickness and decreases the frequency in 
proportion to the film mass.  Measurements of the crystal frequency allow the detection 
of the film mass, therefore the device operates like a ‘microbalance’. 
 
The first quantitative investigation of the piezoelectric effect was performed by 
Sauerbrey [121], who derived the relationship for the change in frequency ∆F (in Hz) 
caused by the added mass ∆m (in g) in vacuum or in air: 
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where F0 is the fundamental resonant frequency of unloaded quartz, µQ is the shear 
modulus of AT-cut quartz (2.947 x 1011 gcm-1s-2), ρQ is the density of the quartz (2.648 
gcm-3) and A is the surface area in cm2. The Sauerbrey equation assumes a uniform 
distribution of mass on the entire electrode portion of an AT-cut quartz crystal. Mass 
sensitivity decreases monotonically with the radius, in a Gaussian manner becoming 
negligible at and beyond the electrode boundary [122]. Another assumption of this 
equation is that the mass added or lost at the crystal surface does not experience any 
deformation during the oscillation; this is true for thin, rigid layers in vacuum or in air. 
For thicker, less rigid layers as happens for quartz crystals operating in liquid, a more 
complex theory is necessary. Many factors such as density, viscosity, conductivity and 
dielectric constant of the liquid may influence the oscillating behaviour. When a quartz 
crystal oscillates in contact with a liquid, a shear motion on the surface generates 
motion in the liquid near the interface. The resonant frequency change of a quartz 
crystal having one face in contact with liquid is described by the Kanazawa and Gordon 
equation [123] : 
 
 ( ) 21230 QQLLFF ρµπηρ−=∆                                      (equation 1.2) 
 
where Lρ  is the density of the liquid and Lη  is the viscosity of the liquid. 
 
Piezoelectric crystals have been used as microbalances and as a microviscometer owing 
to their small size, high sensitivity, simplicity of construction and operation, low cost, 
light weight and the low power required [124].  
 
The quartz-crystal microbalance has traditionally been used in many applications such 
as thin film deposition control, etching studies, aerosol mass measurements and space 
system contamination studies [120]. Recently however, the interest in the application of 
piezoelectric devices in the field of analysis has increased, since it was realised that 
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many opportunities for molecular sensing can be opened up once a suitable recognition 
layer or molecule is coated on the crystal [125]. Therefore by immobilising an affinity 
ligand on the surface of a quartz crystal covered with gold or silver, an affinity mass 
sensor is realised. When the affinity reaction with the target in solution take place, the 
binding ligates can be determined at nanogram levels from the piezoelectric frequency 
shift. Such piezoelectric biosensors have found a wide range of applications in food 
[126,127], environmental and clinical [128,129] analysis. 
 
 
 
 
1.5.2. Optical Biosensors: theory of Surface Plasmon Resonance 
phenomenon 
 
Surface Plasmon Resonance (SPR) is an optical technique that uses evanescent waves 
as a valuable tool to investigate chemical and biological interactions occurring at the 
surface of a thin sensing layer. Surface Plasmons (SPs) are electromagnetic waves that 
propagate along the boundary between a dielectric and a metal (gold or silver), because 
of their interaction with the free electrons of the conductor. In this interaction, the free 
electrons respond collectively by oscillating in resonance with the light wave. The most 
common method to excite surface plasmons is the Krestchmann prism configuration, 
which operates under condition of total internal reflection [130].  
 
In general, total internal reflection occurs at a boundary interface between two media of 
different refractive indices when incoming light entering from the side having higher 
refractive index is partly reflected and partly refracted. Above a certain angle of 
incidence no light is refracted across the interface and total internal reflection is 
observed. As a consequence, an electromagnetic field called “evanescent wave” is 
generated and penetrates into the medium having a lower refractive index. In the 
Kretschmann prism configuration one face of the prism is coated with a thin metal film 
acting as the sensor surface and the incident light beam is totally reflected at the prism-
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metal interface, generating an evanescent wave that penetrates into the metal layer 
(Figure 10). At the resonant angle, the propagation constant of the evanescent wave 
matches that of surface plasmons. The evanescent field exponentially decays from the 
sensor surface into the bulk solution, with a characteristic decay length of a few tens to 
a few hundreds of nanometers. Therefore, the system is sensitive to refractive index 
changes within the decay length [131]. 
 
 
Figure 10. Surface plasmon excitation in the Kretschmann configuration: the incoming light is 
reflected at the glass/gold interface. Changes of the refractive index in the dielectric medium are 
sensed up to 100 nm from the interface (adapted from [132] and [130]).  
 
 
Only p-polarized light, with its electric field vector oscillating perpendicular to the 
plane of the thin film, can be coupled into the plasmon mode. The s-polarised light, with 
its electric field vector oriented parallel to the metal film, cannot excite palsmons but 
can be used as a reference beam, since it is reflected at the metal surface.  
The surface plasmon wave is affected by changes in refractive index near the metal 
surface and the coupling efficiency of the incident light into the plasmon mode can be 
monitored by scanning the incident beam angle throughout a range of values. The 
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incident beam angle giving maximum surface plasmon coupling (θsp) is reached when a 
minimum in reflectivity is observed. At this particular angle of incidence, light is most 
efficiently coupled into the plasmon mode, therefore the reflection from the metal film 
is most attenuated as well as the intensity of the reflected light measured by a detector 
(Figure 11). 
 
(a)
Sample
θsp
Metal film
Incidentp-polarized
light
Reflected light 
to photodetector
Θsp =  Surface Plasmon coupling angle                                        
 
 
  
 
Figure 11. (a) Surface Plasmon coupling angle, θsp (adapted from [130]); (b) The position of the 
strong minimum that occurs at the SPR resonance condition depends sensitively on the refractive 
index of the material above and near the gold surface, as it is sampled by the evanescent light 
intensity, which decays exponentially with distance above the gold surface (adapted from [133]). 
 
(b) 
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The SPR principle is used to develop biosensors which rely on the refractive index 
change induced by molecular interactions occurring at the sensor surface and related to 
the sample concentration or surface density. After the biorecognition molecule is 
immobilised on the metal sensor surface, the affinity reaction with the target is realised, 
resulting in a refractive index change near the sensor surface, which can be detect 
optically as the sensing transduction signal. Sensing is performed by relating θsp to small 
changes in the refractive index at the external surface of the metal film (Figure 12). 
 
 
 
Figure 12.  The θ shift when the refractive index of the surface layer is changed, for example 
through the binding of biomolecules to the surface (adapted from [134]).       
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The most used metals for plasmon generation are gold and silver, because of their 
optical qualities and the ease with which they can be deposited onto a substrate with 
accurate thickness. The optimal metal thickness lie in the range 40 - 60 nm.  
 
The Biacore was the first commercial SPR biosensor, launched by Pharmacia Biosensor 
in 1990. The Biacore instrument is based on SPR technology using a modified 
Kretschmann prism arrangement, in which a multiwavelengh excitation and a 
cylindrical glass prism are employed with the aim of eliminating moving components 
and beam spreading on the gold sensor surface. The surface plasmon resonance angle is 
followed in real time to monitor biointeractions and is expressed in arbitrary units, 
called resonance units (RU).  A detactable refractive index change is produced by 
analytes having MW > 1500.  
 
Different types of chip consisting of glass coated with a bare or modified gold layer are 
available from Biacore. The most commonly used chips are CM5, where 
carboxymethylated dextran is covalently attached to the gold surface. Ligands 
immobilisation on CM5 can be performed via amine coupling, thiol-sulphide exchange 
or aldehyde coupling. The commercial success of Biacore is due to the sensor chip 
technology, which allows simple inter-exchanging at the sensor surface, and the use of 
microfluidic handling systems, which facilitate working with small sample volumes to 
be transported to the chip in a continuous flow, while ensuring a constant analyte 
concentration on the sensor surface all along the injection. Because of its high 
sensitivity, Biacore SPR has been applied in biosensors development for the detection 
of proteins, with a detection limit ranging from picomolecule to nanomolecule 
concentrations, but also for detection of DNA molecules, cancer biomarkers and 
bacterial cells [135].  
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MATERIALS AND METHODS 
 
 
 
This chapter describes the methods and protocols used to perform the experiments, and 
the materials and reagents purchased for this purpose. All reagents used were obtained 
from Merck (Darmstadt, Germany) unless otherwise specified.  
 
 
 
 
2.1. Transduction systems: experimental apparatus 
 
 
2.1.1. Piezoelectric biosensor for Thrombin detection 
 
A piezoelectric system was employed for the development of an aptasensor for 
thrombin detection. The resonators used in this work were AT-cut quartz crystals 
having a circular shape, with a diameter of 14 mm and thickness 165 µm (International 
Crystal Manufacturing, USA). Gold electrodes (42.6 mm2, Ø 7.4 mm) were evaporated 
on both sides (Figure 13): a 90 nm layer of gold (999.99 % pure) was deposited under 
vacuum evaporation on a 10 nm layer of Ni-Cr alloy, which assured good adhesion of 
the gold to the crystal surface. The fundamental resonant frequency of the resonators 
was 9.5 MHz and, according to the Sauerbrey equation (Equation 1.1), a frequency shift 
of 1 Hz is equivalent to 2.2 ng/cm2 increase of the crystal mass (452 Hz/µg). Steel 
contacts allowed the resonator to be housed in a measurement cell for measurements in 
liquids. 
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Figure 13. Piezoelectric quartz crystal. 
 
 
The quartz crystal was housed inside the measurement cell, such that only one side of 
the resonator was in contact with the solution in the cell well; in this way, two 
measurements could be performed with the same resonator, one on each side.  
 
The cell was made of methacrylate (Figure 14a), which is resistant and inert to the 
chemicals used in the experiments. In addition, this material is transparent, so that it is 
possible to observe any anomalies (e.g. air bubbles) that could be present in the well. 
The cell consisted of two blocks of methacrylate, which were held together by two 
screws. The crystal was housed between these two blocks, sandwiched between two 
Viton® o-rings, which assured that the crystal was held in the cell and prevented the 
wetting of the electrical contacts by the solution - both prerequisites for proper 
functioning of the system. 
 
This kind of cell was used for batch measurements and the solution of the reagents was 
inserted into the cell by pipetting it directly in the upper cell well. The volume of the 
well was about 1 ml, but the typical volumes for the measurements were 100 or 200 µl.  
 
The resonator frequency shifts were continuously recorded using a quartz crystal 
analyzer (QCMagic, Elbatech, Marciana, LI, Italy), configured as a multi-array system 
(Figure 14b).  
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Figure 14. (a) QCM measurement cell; (b) QCMagic (Elbatech, Marciana, LI, Italy). 
 
 
The QCMagic was interfaced to the driving computer by means of a digital counter 
board, which could drive up to 4 oscillator units, thus allowing operation with up to 4 
independent quartz crystals (or with two pairs of working/reference crystals). The 
QCMagic can be equipped with low-volume static or flow-through reaction chambers, 
where the oscillating crystal is housed.  
 
QCMagic makes use of a precision internal reference crystal, used as a timebase 
comparator. Depending on the frequency of this internal timebase, each unit can be 
tuned to work with a specific working crystal, chosen between 1 and 10 MHz. A 
computer connected to the QCMagic system interface reads directly the data, displayed 
as resonance frequency vs. acquisition number, by means of the specific software, 
running under MS-Windows™. The resonant frequency can be measured with an 
accuracy of 0.1 Hz. 
 
 
 
 
 
 
 (b) (a) 
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2.1.2.  Optical biosensor: experimental set-up for Biacore 
 
For the SPR experiments, the Biacore™ X analytical device (Biacore; Uppsala, 
Sweden) was used (Figure 15). The monitoring and analysis of the data was performed 
using the manufacturer’s software Biaevaluation Version 3.1. The bare Biacore sensor 
chip (Biacore; Uppsala, Sweden) consists of a glass slide (1 cm2) coated with gold (50 
nm) on one side and embedded in a plastic support platform. The gold layer is often 
covered with a linking layer to facilitate binding of biomolecules, in particular 
carboxylated dextran-coated chips CM5 (Biacore; Uppsala, Sweden) were employed for 
the immobilisation of biotinylated aptamers. A shift of 1000 RU represents an increase 
in surface protein concentration of approximately 1 ng/mm2. The Biacore resolution is 
approximately 1.0 RU. 
 
 
Figure 15. Biacore X device.  
 
 
 
 
2.1.2.1. Special precautions for C-Reactive Protein detection  
 
In the case of CRP detection with the specific anti-CRP RNA aptamer, special 
precautions had to be adopted with the aim of preventing aptamer degradation by 
RNase. Since the Biacore instrument provides a closed environment, SPR experiments 
were performed under virtually nuclease-free conditions. Before use, the 
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instrumentation (the fluidic cartridge and the tubing) was treated with cleaning solutions 
by running a specific Biacore cleaning procedures (Biacore Desorb and Sanitaze 
methods). Moreover, all the external instrumental components (the needle and the 
tubing) were treated with a specific RNase inhibiting solution (RNaseZap™; Sigma, 
Milan, Italy). Before chip docking, the RNase inhibiting solution was injected (20 µl at 
20 µl/min) followed by ten subsequent injections of diethylpyrocarbonate (DEPC; 
Sigma, Milan, Italy) treated water, with which all solutions and buffers were also 
prepared. DEPC-treated water was prepared adding 1 ml of DEPC to 1 liter of MilliQ 
water and stirred overnight. The solution was then autoclaved at 1 atm for 20 min and 
filtered with 0.22 µm pore size filters (Nalgene; Milan, Italy). RNase free tips (Sarstedt, 
Numbrecht, Germany) and vials (Abgene; UK) were used for all the experiments.  
 
These precautions were not necessary when using the anti-CRP RNA aptamer modified 
with 2’-fluoropyrimidines, since it is resistant to RNase degradation for up to 15 hours 
in biological fluids.  
 
 
 
 
2.2. Linking a biological recognition element with the 
transduction system: immobilisation procedures 
 
A key step in biosensor development is the immobilisation of the biological recognition 
element onto the transducer. In this thesis two immobilisation procedures were used to 
link aptamers to gold surfaces: 
- Covalent immobilisation on gold surface of thiol-modified aptamers by creation 
of a self assembled monolayer (SAM) 
- Immobilisation of biotin-modified aptamers by affinity reaction with 
streptavidin-gold modified surface. 
 
Materials and Methods 
 
52 
 
With the aim of studying these two different immobilisation procedures, aptamers were 
purchased carrying different functionalisations (biotin or thiol dye). In addition, 
different spacers were tested, with the aim of conferring some flexibility to the 
immobilised molecule, without interfering with the binding to protein. In particular, a 
polyT tail formed by 20 thymines and a TEG (triethylene glycol) tail (C2H14O4) were 
tested as spacer arms.  
 
The 15-mer thrombin aptamers (MWG Biotech; Milan, Italy) had the following 
sequences: 
- Biotinylated 15-mer aptamer: 5’-biotin-GGT TGG TGT GGT TGG-3’ 
(Molecular Weight 5175 g/mol)  
- Biotinylated 15-mer aptamer with polyT (20) tail: 5’-biotin-TT TTT TTT TTT 
TTT TTT TTT GGT TGG TGT GGT TGG-3’ (Molecular Weight 11258 g/mol) 
- Thiolated 15-mer aptamer: HS-(CH2)6-GGT TGG TGT GGT TGG-3’ 
(Molecular Weight 4921 g/mol) 
- BiotinTEG 15-mer aptamer: 5’-BiotinTEG-GGT TGG TGT GGT TGG-3’ 
(Molecular Weight 5296 g/mol) 
- BiotinTEG 15-mer sequence mutated in positions 5 and 14: 5’-BiotinTEG-GGT 
TTG TGT GGT TAG-3’ (Molecular Weight 5255 g/mol)  
- BiotinTEG 15-mer sequence mutated in positions 4 and 15: 5’-BiotinTEG-GGT 
AGG TGT GGT TGC-3’ (Molecular Weight 5265 g/mol) 
- BiotinTEG 15-mer sequence mutated in positions 3 and 11: 5’-BiotinTEG-GGC 
TGG TGT GAT TGG-3’ (Molecular Weight 5265 g/mol) 
The aptamers were received lyophilised and then diluted in MilliQ water and stored at   
-20 °C. 
 
The 44-mer CRP aptamers (IBA Gmbh; Göttingen, Germany) had the following 
sequences: 
- Biotinylated aptamer with polyT (20) tail: 5’-TT TTT TTT TTT TTT TTT TTT 
GCC UGU AAG GUG GUC GGU GUG GCG AGU GUG UUA GGA GAG 
AUU GC-3’ (Molecular Weight 20132 g/mol) 
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- BiotinTEG aptamer: 5’-biotinTEG GCC UGU AAG GUG GUC GGU GUG 
GCG AGU GUG UUA GGA GAG AUU GC-3’ (Molecular Weight 14110 
g/mol). The same aptamer sequence biotinylated in 5’ was also purchased 
modified with 2’-fluoropirymidines (Molecular Weight 13643 g/mol).  
The aptamers were received lyophilized and then diluted in MilliQ water and stored at   
-20 °C. 
 
 
 
 
2.2.1. Immobilisation of  biotinylated aptamers on piezoelectric and optical 
devices 
 
The procedure for the immobilisation of a biotinylated probe on a gold sensor surface 
was developed by Löfas [136] for surface plasmon resonance and further adapted to 
piezoelectric sensing [137]. According to this procedure, a gold sensor surface was 
modified with a carboxylated dextran layer on a self assembled monolayer (SAM) of 
alkanethiols; after the covalently linkage of streptavidin on the dextran layer, the 
biotinylated probe immobilisation was realised exploiting the high affinity and 
selectivity of the streptavidin-biotin interaction.  
 
A detailed explanation of the multi-step immobilisation protocol followed for the 
piezoelectric measurements is described below. For the SPR measurements, since 
dextran modified chips (Biacore CM5) were employed, only the final steps of the 
procedure were employed.  
 
 
a) QCM device 
Before the immobilisation step, the quartz crystal surface was cleaned with a boiling 
solution of H2O2, NH3 (30%) and MilliQ water in a ratio 1:1:5. The crystal was dipped 
in this solution for 10 minutes, then washed with MilliQ water and air dried. The 
Materials and Methods 
 
54 
 
formation of the SAM was realised by coating the crystal with an unstirred 1 mM 
ethanolic solution of 11-mercapto-1-undecanol, HS(CH2)11OH (Sigma; Milan, Italy), at 
room temperature for 48 hours, in the dark. The solution of 11-mercapto-1-undecanol 
was freshly prepared before use (2 mg of the thiol in 10 ml of ethanol). After washing 
with ethanol and MilliQ water, the crystal was sonicated in ethanol (10 minutes) to 
remove excess thiols, then rinsed with ethanol and MilliQ water. The hydroxylic surface 
was then treated with a 600 mM solution of epichlorohydrine in a 1:1 mixture of 400 
mM NaOH and bis-2-methoxyethyl ether (diglyme) for 4 hours. This step allowed the 
introduction of epoxy groups on the surface, as electrophilic coupling sites for further 
binding of dextran. After washing with water, the crystal was immersed for 20 hours in 
a basic dextran solution (3 g of Dextran 500 (Amersham Biosciences, UK) in 10 ml of 
NaOH 100 mM). Due to the high concentration of hydroxyl groups in the dextran 
molecule, chemical modifications of this polymer was possible without significantly 
affecting its hydrophilicity. Therefore, the surface was further functionalised with 
carboxymethyl groups using 1M bromoacetic acid (Sigma, Milan, Italy) in 2 M NaOH 
for 16 hours. All the reactions were performed at room temperature out of the 
piezoelectric cell. Finally, the crystal was washed with MilliQ water and stored at 4 °C 
for several days.  
 
For the surface activation of the carboxylic groups on the dextran for amino-coupling, 
the crystal was housed in the cell. The negatively charged crystal surface was activated 
with 200 µl of a solution of 50 mM N-Hydroxysuccinimide (NHS; Sigma, Milan, Italy) 
and 200 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC; Sigma, Milan, 
Italy) in water. This reaction converted a fraction of carboxylic groups into active esters. 
The NHS/EDAC solution was prepared immediately before use to avoid loss of activity. 
After 5 minutes, the activating solution was replaced by a 200 µg/ml streptavidin 
(Sigma; Milan, Italy) solution in acetate buffer 10 mM, pH 5. Due to its neutral pI, at 
this pH streptavidin is positively charged and the electrostatic attraction of the protein 
molecules to the activated and partially negatively charged dextran considerably 
enhances the coupling yield. A much higher local concentration of the protein in the still 
partly negatively charged dextran layer compared to the bulk concentration is thus 
obtained and favours the reaction of the nucleophilic groups in the protein over 
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hydrolysis of the esters. After 20 minutes, the free residual reacting sites were blocked 
with 200 µl of a solution of ethanolamine hydrochloride (pH 8.6, 1 M water solution). 
This step was performed for 20 minutes. The quartz crystal modified surface was then 
washed with the immobilisation buffer (150 mM NaCl, 20 mM Na2HPO4, 0.1 mM 
EDTA, pH 7.4). Finally, the biotinylated aptamer was added (200 µl of a solution 1.0 
µM in immobilisation buffer) and the reaction was allowed to proceed for 20 minutes, 
via streptavidin-biotin interaction. At this final stage the crystal was ready for the first 
cycle of binding, performed in binding buffer. The immobilisation protocol is shown 
schematically in Figure 16. 
 
 
Figure 16. Immobilisation of biotinylated probes on quartz crystal microbalance. The scheme also 
shows the functional groups involved.  
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b) SPR device 
For the SPR measurements, the biotinylated aptamer immobilisation was realised on 
dextran-modified CM5 Biacore chips, according to the final part of the protocol and 
using the following times of reaction: 
- Activation step with 50 mM NHS, 200 mM EDAC in water: 7 min. 
- Covalent immobilisation of 200 ppm streptavidin in 10 mM acetate buffer, pH 
5.0: 7 min. 
- Saturation of free carboxylic groups with 1M ethanolamine hydrochloride, pH 
8.6: 7 min. 
- Aptamer immobilisation after a thermal treatment (95 °C 1 min, 0 °C 10 min) 
[138,139]: 20 min. The thermal treatment can unfold the aptamer strand making 
the biotin label at 5’ end available for the interaction with streptavidin on the 
chip surface. Therefore, before the immobilisation, the biotinylated aptamer was 
heated at 90 °C for 1 min to unfold the DNA strand and then cooled in ice for 10 
min in order to block the DNA in its unfolded structure.  
 
After the aptamer immobilisation, the surface was blocked with 500 ppm biotin (Sigma; 
Milan, Italy) solution in immobilisation buffer (20 min), to saturate the free streptavidin 
sites. The immobilisation procedure was performed at a constant flow rate of 5 µl/min at 
25 °C, using as running buffer the same solution as binding buffer, degassed daily prior 
to use.  
 
 
 
 
2.2.2. Immobilisation of thiolated aptamer  
 
The gold sensor surface was modified with a thiolated aptamer and a blocking thiol by 
chemisorption via SH-Au interaction [140, 141]. The use of a blocking thiol such as 6-
mercapto-1-hexanol (MCH; Sigma, Milan, Italy) improved the immobilisation 
efficiency; the thiolated probe alone could lie flat onto the surface because of non-
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specific interactions between the oligonucleotide bases and the gold surface, while 
MCH attached to the unoccupied gold regions replacing non-specifically adsorbed 
probes. In this way, a better orientation of the probe could be achieved. The 
immobilisation methodology based on thiolated probes is illustrated in Figure 17.  
 
 
 
Figure 17. Immobilisation of thiolated probes. 
 
 
For thiolated aptamer immobilisation on QCM device, the resonator was washed with a 
boiling solution of H2O2, NH3 (30%) and MilliQ water in a ratio 1:1:5. The crystal was 
dipped in this solution for 10 minutes, then washed with MilliQ water and air dried. 
Then the crystal was housed in the cell and treated with a 1 µM solution of thiolated 
probe in immobilisation solution (1 M KH2PO4, pH 3.8) for two hours, then washed 
with immobilisation solution and MilliQ water. Afterwards, 200 µl of blocking thiol 
solution (MCH) was injected into the cell and the reaction was allowed to proceed for 1 
h, before the final washing with MilliQ water. As a final step, MilliQ water was 
replaced by 100 µl of binding buffer and the frequency was allowed to stabilise.  
 
 
 
 
2.3 Binding measurement procedures   
 
After the aptamer immobilisation on the piezoelectric crystal or on the Biacore chip, the 
binding between the immobilised receptor and the target protein was monitored. The 
measurement cycle consisted of recording the baseline, followed by target injection, 
washing with buffer and surface regeneration. The regeneration step consisted of an 
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acid, basic or highly saline treatment, which released the sensor-bound analyte from the 
aptamer without affecting its capacity to further bind the protein and allowing a multiple 
use of the sensor. 
 
 
 
 
2.3.1. Binding protocol for Thrombin detection with piezoelectric device 
 
During the piezoelectric aptasensor development for thrombin detection, 50 mM Tris-
HCl, pH 7.4, 140 mM NaCl, 1 mM MgCl2 was used as binding buffer. Human α-
Thrombin was purchased by Sigma (Milan, Italy). Thrombin is shipped as lyophilised 
powder containing 417 NIH Units of protein (3093 NIH Units/mg). Thrombin stock 
solution (3.6 µM in 20 µl binding buffer) was stored at -20 °C and further dilutions in 
binding buffer were stored in ice during measurements. Human serum albumin (HSA; 
Sigma, Milan, Italy; Product Number A9511) was used as negative control. Albumin 
was shipped lyophilised and stored at 4 °C. Further dilutions were prepared in the same 
binding buffer and used after preparation. 
 
A generic example of an interaction between the immobilised thrombin aptamer and its 
protein target in solution is reported in Figure 17. A stable baseline was initially 
recorded when the crystal together with the immobilised probe was in contact with 100 
µl of binding buffer. The aptamer-protein interaction was performed by replacing the 
binding buffer with an equal volume (100 µl) of a solution containing the target 
molecule (in the concentration range 50 - 200 nM), prepared using the same buffer. At 
the end of the time necessary for the interaction to occur, the surface was washed with 
binding buffer to remove the unbounded molecules or the molecules that could non-
specifically absorb on the crystal surface. When the frequency had reached a stable 
value, the frequency value was recorded. The frequency shifts reported in this work are 
always the difference between two stable frequency values (± 1 Hz) recorded in binding 
buffer: in particular, the frequency shift is reported as the difference between the final 
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value (D) and the value displayed before the binding reaction (A). Since both frequency 
values are taken when the crystal is in contact with the same buffer solution (binding 
buffer), the shift is only due to compounds fixed on the gold surface during the reaction 
[18]. A signal generated by the aptamer-protein interaction is considered significant 
when the difference between the frequency values corresponding to the buffers is higher 
than 3 Hz. Different concentrations of the protein were used to build a calibration plot. 
 
After each cycle of binding, the aptamer-thrombin interaction was regenerated (E) by 1 
min treatment with 2M NaCl. With this treatment the sensor-bound analyte was released  
from the surface, and the baseline was reached again, allowing multiuse of the sensor 
(F). All the experiments were performed at room temperature.  
 
Analyte addition
Washing
 
Figure 18. Schematic diagram of a piezoelectric measurement. Typical sensorgram recorded during 
a binding reaction. A) The probe is immobilised on the sensor surface. Recording of the baseline in 
binding buffer. B) Injection of the protein solution. The aptamer-protein interaction was monitored 
in real time. C) Removing the DA solution and washing with binding buffer. D) Baseline in 
binding buffer. The analytical signal due to the complex formation is given by KF(Hz)=F(D)−F(A). 
E) Regeneration and washing with binding buffer. F) Baseline in binding buffer after regeneration. 
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With the same procedure, HSA was used as negative control, to test the specificity of 
the interaction and the presence of non-specific adsorption on the surface.   
 
 
 
 
2.3.2. Binding protocol with optical device 
 
For SPR measurements, after aptamer immobilisation the binding between the 
immobilised receptor and proteins was monitored with an interaction time of 15 
minutes, followed by washing with running buffer and surface regeneration. Binding 
interactions were monitored at a constant flow rate of 2 µl/min at 25°C. A schematic 
representation of a sensorgram is reported in Figure 19, where the SPR signal is 
expressed in Resonant Units (RU). 
 
 
Figure 19. Schematic representation of a SPR sensorgram (from http://www.biacore.com).  
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a) Thrombin 
For the optimisation of the binding procedure between the immobilised aptamer and 
thrombin by SPR experiments, different binding buffers and regeneration solutions were 
tested. 4-(2-hydroxyethyl)piperazine-1-ethanesulonic acid (HEPES), tris-
(hydroxymethyl)aminomethane (Tris-HCl), polyoxyethylene-sorbitan monolaurate 
(Tween 20) and all the other reagents for the buffers and the regenerating solutions were 
purchased from Sigma (Milan, Itlay). The following buffers were tested both as running 
solutions and protein dilution to 20 nM: 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% 
Tween 20; 50 mM Tris-HCl pH 7.4, 140 mM NaCl, 5 mM KCl, 1 mM MgCl2; 50 mM 
Tris-HCl pH 7.4, 140 mM NaCl, 1 mM MgCl2; 10 mM HEPES pH 8. The following 
solutions were tested to release the protein from the surface: SDS (0.025%); 12 mM 
NaOH with 1.2% EtOH;  50 mM HCl; 2 M NaCl.  
 
 
b) C-Reactive Protein 
For the optical aptasensor development for CRP detection, purified human C-Reactive 
Protein was purchased by Biodesign (Milan, Italy) in concentration 2000 ppm in buffer 
0.1 M Tris, 0.2 M NaCl, 2 mM CaCl2, pH 7.5 containing 0.1 % NaN3 as preservative. 
The protein solution was stored at 4°C. Further dilutions were performed and kept in ice 
during the experiments to prevent denaturation.  
 
Concentration of CRP solutions was expressed as mg/l (ppm), in order to allow a direct 
comparison of the results obtained in this work with other results reported in literature, 
where clinically-relevant proteins are usually measured as mg/l. In contrast, thrombin 
solutions were reported as molarities, according to other papers cited in this work.   
 
2-(N-morpholino)ethanesulfonic acid (MES) and all the other reagents for the buffers 
were purchased from Sigma (Milan, Itlay). The following binding buffers were tested 
both as running buffer and for protein dilutions, in order to find the one granting the 
highest sensitivity for CRP: 10 mM MES pH 6.0; 10 mM HEPES pH 6.0; 10 mM Tris-
HCl pH 6.0; 10 mM MES pH 6.5; 10 mM HEPES pH 6.5; 10 mM Tris-HCl pH 6.5; 10 
mM HEPES pH 7.0; 10 mM Tris-HCl pH 7.0; 10 mM HEPES pH 7.5; 10 mM Tris-HCl 
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pH 7.5. The selected binding buffer was further added with 0.005% (v/v) of Tween 20 
and 2 mM CaCl2.  
 
HSA and human immunoglobulin G (IgG; Sigma, Milan, Italy) were used as negative 
controls. The aptamer-CRP binding was dissociated with 1 min injection of HCl at 
different concentrations (1, 10 or 25 mM), depending upon the entity of the binding 
shift to be regenerated. With this treatment the sensor-bound analyte was released from 
the immobilised aptamer. 
 
 
 
 
2.4. Experiments in complex matrices  
 
 
2.4.1. Treatment of human serum and plasma for Thrombin detection 
 
Human serum from clotted male whole blood (Product Number H1388) and Human 
citrated plasma (Product Number P9523), provided by Sigma (Milan, Italy), were 
divided into aliquots and stored at -20 °C. Standard solutions of thrombin were added to 
serum or plasma to test the performance of the piezoelectric aptasensor in complex 
matrices. Since serum does not contain coagulation factors, the addition of thrombin did 
not affect the samples. On the contrary, the addition of thrombin to plasma, which 
contains all the proteins involved in the coagulation cascade including fibrinogen, leads 
to the formation of fibrin and to rapid sample clotting. To avoid this phenomenon, 
fibrinogen was precipitated from plasma before the addition of thrombin in the 
preparation of spiked samples. Such selective precipitation is based on the use of 
ammonium sulfate as precipitant: 250 µL of plasma was treated with 1250 µL of 2 M 
ammonium sulfate and 1000 µL of 0.1 M sodium chloride. The solution was mixed for 
3-4 min, then centrifuged for 2 min at 15000 rounds per minutes (RPM), and the 
supernatant was collected and eluted with binding buffer using NAP™ 10 columns for 
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rapid desalting and buffer exchange (Amersham Biosciences; Milan, Italy). The amount 
of protein in the raw plasma and the eluted solution was evaluated by 
spectrophotometric measurements at λ = 280 nm, and a loss of protein content (~40%) 
was detected after precipitation of fibrinogen. 
 
 
 
 
2.4.2. Treatment of human serum for C-Reactive Protein detection 
 
For the complex matrix treatment, different approaches were tested:  
- Magnetic beads coupled with protein G with diameter 2.8 ± 0.2 µm were purchased 
from Dynal Biotech (Milan, Italy). Standard solutions of CRP (0.01 ppm), HSA 
(500 ppm), hIgG (240 ppm) or a mixture of them with and without addition of CRP 
were incubated with 200 µL of magnetic beads suspension for 20 minutes; then the 
magnetic separation between the beads and the solution was performed by the use of 
a magnetic bar. The solutions were further diluted (1:2) in order to reach the relative 
concentrations corresponding to a 1:100 serum dilution. The quantity of protein 
recovered after the treatment was roughly estimated by spectrophotometric 
measurements at λ = 280 nm. The treated solutions were then tested using the 
optical aptasensor. 
 
- Affinity columns removing both hIgG and HSA (IgG Removal Kit) were purchased 
by GE Healthcare and used for the treatment of undiluted human serum. The serum 
eluted from the column resulted diluted 30 times and was further diluted 3 times to 
reach a final dilution 1:90. This solution was then added with a commercial product 
able to further reduce the matrix effect: in particular, a non specific binding reducer 
(NSB-Reducer™; Biacore, Sweden) containing carboxymethyl dextran sodium salt 
(10 mg/ml) in 0.15 M NaCl, 0.02% NaN3 was employed. Standard solutions of CRP 
in the concentration range 0.1– 0.4 ppm were spiked in the treated matrix.   
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2.5. Computational approach to the study of aptamer-thrombin 
interaction using Openeye Scientific Software 
 
With the aim of calculating through simulations the interaction energy between 
thrombin and DNA sequences, a library of oligonucleotides was created and screened 
by computational methods in order to identify potentially binding sequences.  
 
For this purpose, 15-mer DNA sequences were virtually created using the software 
package Hyperchem 7.5, which performs molecular modeling and simulations. All the 
other modeling steps were then performed using Openeye Scientific Software Inc. This 
free software resource offers large-scale modeling applications and toolkits. All the 
experiments were performed on a Acer Veriton T661, RAM 3 GBytes, supported by 
platform Microsoft Windows XP.  
 
The Openeye application VIDA was used to visualise images of the molecule structures 
and to handle very large data sets. The other Openeye applications (with the exception 
of Fred-Receptor) are command line driven programs. Once the library of 15-mer 
mutated sequences was generated starting from the TBA sequence, the proposed general 
procedure consisted of several steps: 
 
a. Creation of the binding box where each sequence will be docked, using the 
Openeye application Fred-Receptor 
b. Energy minimisation of each sequence structure in the library, using the 
Openeye application Szybki-1.2.2 
c. Generation of conformers for each minimised sequence, using the Openeye 
application Omega2-2.2.1 
d. Docking of each sequence in the receptor site and scoring, using FRED2.2.3 
(Fast Rigid Exhaustive Scoring), which is the Openeye protein-ligand docking 
program.  
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2.5.1. Creation of the library 
 
The 15-mer TBA aptamer (5’-GGTTGGTGTGGTTGG-3’) was drawn as a single 
strand in helix conformation by means of HyperChem 7.5 and used as a reference 
structure where mutations have to be introduced. HyperChem allows the substitution of 
nucleotide residues with others present in the database.  
 
The automatic creation of mutated sequences as single strands in helix conformation in 
HyperChem 7.5 was realised by using a special script equipped with a modifiable input 
file. The program had been written and kindly provided by Mr. Leonid Sislo, a student 
in Computer Science at Kanaus University of Technology (Lithuania) during his visit to 
our laboratory. This special script performed the generation of combinations with the 
aid of AutoIt v3 framework, which is a freeware BASIC-like automation language used 
to script simple Windows-based tasks. The special script was equipped with an input 
file which stored modifiable rules for limiting the number of sequences to be generated, 
in order to complete the library generation in a working day. In particular, the number 
of mutations to be performed, i.e. the number of mutated nucleotides with respect to the 
TBA sequence, can be varied at will, with the aim of reducing the search space with 
respect to the number of possible mutated DNA sequences. In this way the generation of 
a library of 990 different sequences each containing a maximum of two mutations with 
respect to the TBA sequence was performed. The script output file consisted of a set of 
oligonucleotide structures saved in format .pdb, which is compatible with both the 
HyperChem 7.5 and Openeye software packages. In order to briefly indicate the 
mutations performed, the following procedure was adopted: the central number 
indicating the position in the sequence was squeezed between the symbol indicating the 
nucleotide in the TBA sequence for that position (on the left) and the symbol indicating 
the mutated nucleotide (on the right).  
 
The library was added with three virtually generated sequences, which in literature have 
been experimentally tested for weakly binding to thrombin: 
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- 5’-GGT GGT GGT TGT GGT-3’, having 6 mutations (Mutations T4G, G6T, 
T7G, G10T, T13G, G15T) with respect to the TBA sequence and referred to as 
sequence “a” [54] 
- 5’-GGT AGG GTC GGA TGG-3’ (Mutations T4A, T7G, G8T, T9C, T12A) 
referred to as sequence “b” [55] 
- 5’-GGT AGG GCA GGT TGG-3’ (Mutations T4A, T7G, G8C, T9A), referred 
to as sequence “c” [55] 
As a consequence, the library contained 994 different sequences as single strands in 
helix conformation. 
 
 
 
 
2.5.2. Creation of the binding box 
 
The binding box is defined as the area comprising the ligand and the site of the protein 
interacting with the ligand. For binding box design, the ligand-protein complex structure 
was downloaded from the Protein Data Bank and the Openeye Scientific Software 
toolkit Fred-Receptor was used. Fred-Receptor is a wizard like graphics utility that 
designs the box for subsequent docking with FRED, the Openeye docking program. To 
design the box, the ligand structure was selected as reference (reference ligand) and a 
3D rectangular box was automatically generated. The binding box describes the general 
area of the protein where ligands are expected to bind. Any molecule that FRED will 
dock, must fit within the binding box, although this is only one of several criterion 
required for docking. Since box size indirectly influences docking speed, the receptor 
site contours can be varied. Typical box sizes range from 1000 to 8000 cubic 
Ångstroms.  
 
Thrombin shows two different binding sites for aptamers, but only the aptamer-
thrombin complex, where the 15-mer TBA interacts with the fibrinogen-binding 
exosite, has been solved by NMR [67] and it is present in Protein Data Bank (code 
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1HAO). Therefore, the TBA aptamer-thrombin complex structure 1HAO was 
downloaded from Protein Data Bank in order to define by using Fred-Receptor the 
binding box, around the aptamer, in the Fibrinogen-binding exosite. With the aim of 
studying the aptamer-thrombin interaction also in the heparin-binding exosite, the 
heparin-thrombin complex (code 1TB6) was downloaded from Protein Data Bank and a 
box was automatically created around heparin by Fred-Receptor. The binding box 
contours were then modified, in order to define a binding box of dimensions similar to 
that in the fibrinogen-binding exosite, so that the aptamer should fit in.  
 
Fred-Receptor docks the reference ligand (in this case the 15-mer TBA) to the protein 
and scores the resulting interaction on the basis of a scoring function. The scoring 
function used in this work was ShapeGauss [45], that is a shape-based fitting scoring 
function proprietary of Openeye. This attempts to quantitate how well a pair of atoms 
interact using a Gaussian representation of atomic volumes. The score is best (more 
negative) when atomic surfaces touch, but do not interpenetrate. The two receptor site 
boxes and the Shapegauss scoring function were also employed by FRED to dock each 
sequence in the library, after the minimisation step and the generation of conformers. 
 
 
 
 
2.5.3. Energy minimisation and conformational search 
 
The library of nucleotide sequences (in format .pdb) was visualized in VIDA and saved 
as a multi-file of structures in format .oeb, which is the molecular file format that 
Openeye toolkits Szybki-1.2.2. and Omega2-1.2.2 support. The energy of the molecules 
contained in this multi-file was then minimized by Szybki-1.2.2, which uses the Merck 
Molecular Force Field (MMFF) [142] for energy optimisation. The MMFF potential 
expression is given by the sum of seven terms: bond stretching, angle bending, stretch-
bending, out-of-plane bending, torsion, Van der Waals and electrostatic interactions. 
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For Szybki-1.2.2 running, default settings were kept with the exception of max_iter = 
4000.   
 
Once each structure was minimised, conformers of each molecule were discovered 
using Omega2-2.2.1. Omega is designed to be used with the large libraries of 
compounds required by computer-aided drug design, and it is able to rapidly generate 
multi-conformer structure databases. This toolkit splits a molecule into parts and then 
adopts the use of advanced algorithms to link the structures together in order to produce 
a stable conformer. Molecular modeling results generally depend on the quality of the 
conformers generated, upon which results are rationalised and predictions are made. For 
running Omega2-2.2.1, default settings were retained.  
 
 
 
 
2.5.4. Docking and Scoring 
 
Using the multi-conformer library and the binding box file as input, the docking 
program FRED-2.2.3 outputs the molecules of the database most likely to bind to the 
receptor. Typical docking time for FRED is a few seconds per ligand. For each multi-
conformer ligand, FRED generates candidate poses and exhaustively examines all 
possible poses within the binding box, translating and rotating each molecule of the 
multi-conformer library within the box by specified angular and translational step (by 
default, 1.5 Å and 1 Å respectively). Poses that do not fit within the active box or do not 
match the defined constraints are rejected. All remaining poses are ranked on the basis 
of a scoring function. As explained above, in this work ShapeGauss was used as scoring 
function. A systematic solid body optimisation of the top-ranked poses is then 
performed against ShapeGauss, by rigidly rotating and translating the molecule at half 
the step-size used in the exhaustive docking. As an output file, FRED returns a hit-list 
of scored docked structures. 
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RESULTS  
 
 
 
 
3.1. Development of a piezoelectric aptasensor to detect 
Thrombin 
 
A piezoelectric aptamer-based affinity biosensor to detect label-free Thrombin was 
developed. The best conditions for the assay had to be found, in order to critically 
evaluate the aptasensor’s analytical performance, in terms of selectivity, linearity (R2), 
reproducibility (coefficient of variation CV%) and stability (number of cycles).  
 
 
 
 
3.1.1. Optimisation of experimental conditions with Biacore 
 
As a first optimisation step, SPR measurements were performed in order to determine 
the optimal aptamer-analyte binding protocol. For this purpose, the 5’ biotinylated 15-
mer thrombin aptamer with polyT tail was immobilised onto the SPR chip at a 
concentration of 1µM. Different binding buffers (in terms of ionic strength, pH, Mg2+ 
content) were tested for the dilution of thrombin to 20 nM and the binding with the 
immobilised aptamer was then monitored, in order to valuate which buffer promoted the 
binding step. The best performance in terms of sensitivity and reproducibility were 
observed with Tris-HCl pH 7.4, independently by the presence of KCl (Figure 20). 
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However Tris-HCl pH 7.4 not containing KCl was chosen as the binding buffer to be 
used for further experiments.  
 
Different regeneration solutions were also tested, such as 0.025 % SDS, 0.1 M NaOH, 2 
M NaCl, 50 mM HCl, with the aim of releasing the bound analyte from the sensor 
without affecting the aptamer’s capacity to bind thrombin. A complete surface 
regeneration was achieved by a treatment with NaCl 2M (1 min). These optimised 
binding conditions (binding buffer and regeneration solution) were then transferred to 
the piezoelectric system. 
 
 
Figure 20. Comparison between different binding buffers (Biacore CM5 chip with biotinylated 15-
mer aptamer with PolyT tail). Each error bar represents standard deviation of three replicates 
(n=3).  
 
 
 
3.1.2. Analytical performance of Thrombin detection with the piezoelectric 
device 
 
For the development of the piezoelectric aptasensor, the 15-mer TBA was immobilised 
on the gold surface of 9.5 MHz piezoelectric crystals and the analyte (Thrombin) in 
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solution was added. The analytical signal (Frequency vs. Time) was recorded in real-
time without the use of any label. 
 
In the development of aptasensors, it is important to select a proper immobilisation 
protocol to ensure good analytical performances. For this reason, two immobilisation 
protocols were compared, in order to choose which aptamer design assured higher 
sensitivity and reproducibility: 1µM aptamer modified at its 5’ with a biotin group and a 
polyT (20-mer) tail was immobilised onto the gold surface of a quartz crystal previously 
modified with streptavidin amino-coupled to a carboxylated dextran layer, according to 
the procedure described in paragraph 2.2.1. (Figure 21); 1 µM aptamer modified at its 5’ 
end with a thiol group was directly attached to bare gold crystal surface, according to 
the procedure described in paragraph 2.2.2 (Figure 22).  
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Figure 21. Typical frequency variation (vs. Time) recorded during the functionalisation of the 
crystal and the biotinylated aptamer immobilisation. The entity of the immobilisation can be 
evaluated by the difference between the frequency shift of the two steps Buffer (B) – Buffer (A).  
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Figure 22. Typical frequency variation (vs. Time) recorded during the immobilisation of the 
thiolated aptamer on the crystal surface. The entity of the immobilisation can be evaluated by the 
difference between the frequency shift of the two steps Buffer (B) – Buffer (A).  
 
 
 
From the shifts resulting from the immobilisation of the two different aptamers, a 
similar density of immobilised molecules was estimated considering 1 Hz = 2 ng/cm2, 
according to the Sauerbrey equation (Equation 1.1). This density similarity allowed a 
correct comparison between the different aptamers when evaluating their sensitivity for 
the detection of thrombin. For this purpose, the binding between the immobilised 
aptamer and 100 and 200 nM thrombin was studied with an interaction time of 20 min 
and the sensor surface was then regenerated with 1 minute treatment with NaCl 2M 
(Figure 23). The regeneration was considered successful if the frequency value 
registered with buffer returned to the frequency value corresponding to the same buffer 
before the analyte binding.  
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Figure 23. Typical frequency variations (vs. time) recorded during the binding of thrombin (100 
nM) to the immobilised aptamer. The reported analytical datum is the difference in frequency 
between Buffer (B) and Buffer (A) which represent the baseline. 
 
 
The immobilisation results for the biotinylated and the thiolated aptamer are reported in 
Table 3. The aptamers tested were compared in terms of signal amplitude and 
reproducibility: the results indicated that the best performances were obtained when 
immobilising the biotinylated aptamer rather than the thiolated one.  
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Immobilised 
aptamer  
Immobilisation 
shift  
(Hz) 
Density 
(molecules/cm2) 
Thrombin 
100 nM 
(Hz) 
Thrombin 
200 nM 
(Hz) 
Biotinylated 
aptamer (with tail) 
-225 ± 36 2.4 x 1013 -16 ± 9 -48 ± 10 
Thiolated aptamer -138 ± 30 3.4 x 1013 -12 ± 13 -23 ± 13 
Table 3. Comparison between the results obtained with the aptasensor when immobilizing the 
Biotinylated or the Thiolated Aptamer (aptamer concentration: 1 µM; interaction time with 
thrombin: 20 min). Sample size of n = 3. Density was calculated from the immobilisation shift by 
applying Sauerbrey equation [equation 1.1] and it was reported as molecules/cm2 considering the 
molecular weight of each sequence and the Avogadro number. 
 
 
As a second optimisation step, the influence of a spacer in the aptamer-binding 
behaviour was studied. In a heterogeneous-phase assay, the probe has to be fixed on the 
sensor surface in order to obtain an ordered and oriented layer, so that the flexibility of 
the bioreceptor is assured without altering the affinity for the target molecule [25]. For 
this reason, the influence of a spacer was investigated, by testing the 5’ biotinylated 15-
mer aptamer in presence or absence of a tail of 20 thymins. Since the 15-mer aptamer 
sequence contained only thymine and guanine bases, the presence of a spacer consisting 
only of thymine avoids A:T base pairing, therefore the aptamer secondary structure was 
probably not affected. The best analytical performances were observed with the aptamer 
carrying the polyT tail (Figure 24), which showed a good sensitivity and reproducibility 
(CV for the two concentrations, 13%). The higher sensitivity obtained with this aptamer 
was probably due to the presence of the spacer, which maintains the aptamer far from 
the sensor surface, avoiding steric hindrance and allowing the proper conformation for 
molecular recognition. On the contrary, when the biotinylated aptamer without polyT 
tail was immobilised, very low sensitivity was found (∆F for 200 nM Thrombin < 20 
Hz), even if comparable surface density occurred (2.1 x 1013 molecules/cm2).  
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Figure 24. Comparison between the results obtained with the aptasensor when 100 and 200 nM 
Thrombin was bound to the immobilised Biotinylated Aptamer with polyT tail or without the polyT 
tail. Each error bar represents standard deviation of three replicates (n=3). (aptamer 
concentration: 1 µM; interaction time with thrombin: 20 min). 
 
 
Further investigation were then conducted with the biotinylated aptamer carrying the 
polyT tail, in order to study the different parameters influencing the aptamer 
immobilisation and consequently its binding to the protein. In particular, the influences 
of a thermal treatment of the aptamer (heating at 95 °C for 1 min and then cooling in ice 
for 10 min) and its concentration (varied from 0.1 to 1 µM) were investigated. 
Moreover, during the optimisation of the binding conditions, the interaction time was 
increased from 20 to 30 min. The results are reported in Table 4, which shows the 
improvements in terms of sensitivity, linearity, reproducibility and reusability, by 
varying these parameters. Three repetitions were carried out for each standard solution 
in order to evaluate the reproducibility. Thrombin calibration curves obtained in the 
different experimental conditions are reported in Appendix. Despite the importance of 
these simple key steps for aptasensor analytical performance, the minimum detectable 
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amount using the assay, defined as the lowest concentration of analyte giving a 
measurable signal, remained 50 nM in all cases.  
 
 
Immobilised aptamer 
concentration 
Density 
(molecules/cm2) 
Binding 
Time 
Linear Regression R2 Cycles 
1 µM 2.4 x 1013 20 min y = -0.22x + 1.94 0.933 14 
1 µM 
thermal treatment 
2.5 x 1013 20 min y = -0.23x + 0.42 0.977 18 
0.5 µM 
thermal treatment 
2.0 x 1013 
20 min y = -0.23x + 0.68 0.988 18 
0.5 µM 
thermal treatment 
30 min y = -0.22x 0.998 22 
Table 4. Comparison between the analytical characteristics of the sensor obtained when 
immobilising the biotinylated aptamer with a polyT tail. Density was calculated from 
immobilisation shift by applying Sauerbrey equation [equation 1.1] and it was reported as 
molecules/cm2 considering the molecular weight of the immobilised sequence and the Avogadro 
number. 
 
 
 
The thermal treatment unfolds the aptamer DNA strand making the 5’-end of the biotin 
label available for interaction with streptavidin on the crystal surface. Even if the 
thermal treatment has no effect on the aptamer surface density (2.5 x 1013 
molecules/cm2), the linearity in the thrombin range 0-200 nM (R2 = 0.977) significantly 
improved, probably because the thermal treatment ensures correct intramolecular 
folding.  
 
The aptamer concentration was reduced in order to decrease the steric hindrance on the 
sensor surface and to allow the correct aptamer folding upon thrombin binding. The 
results indicated that the surface capacity was not affected by the dilution from 1 to 0.5 
µM of the aptamer (2.0 x 1013 molecules/cm2), but the sensor analytical performances 
further improved in terms of linearity (R2 = 0.988). On the contrary, a further dilution to 
0.1 µM dramatically reduced the sensor sensitivity (Table 5). 
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Immobilised aptamer 
concentration 
Density 
(molecules/cm2) 
100 nM Thrombin Binding 
(Hz) 
0.5 µM thermal treatment 2.0 x 1013 -20 ± 2 
0.1 µM thermal treatment 6.0 x 1012 -13 ± 6 
Table 5. Comparison between the analytical characteristics of the sensor obtained when 
immobilising the biotinylated aptamer with a polyT tail in concentration 0.5 or 0.1 µM after 
thermal treatment (binding time 20 min, sample size of n = 3). Density was calculated from 
immobilisation shift by applying Sauerbrey equation [equation 1.1] and it was reported as 
molecules/cm2 considering the molecular weight of the immobilised sequence and the Avogadro 
number. 
 
 
Finally, the increase in the interaction time from 20 to 30 min, which allowed the 
binding curve to reach a plateau, resulted in further improved linearity (R2 = 0.998). 
Using the crystal modified with 0.5 µM aptamer with polyT tail after thermal treatment, 
a calibration curve for thrombin was constructed in the concentration range 0-200 nM, 
allowing the binding reaction to proceed for 30 minutes (Figure 25).  
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Figure 25. Calibration curve for thrombin in the range 0 – 200 nM in binding buffer. Each error 
bar represents standard deviation of three replicates (n=3). (Binding time 30 min; concentration of 
15-mer biotinylated aptamer with polyT tail 0.5 µM). 
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Negative controls were tested to demonstrate the specificity of the interaction. Human 
serum albumin is present in plasma and serum at high concentration (~ 50000 mg/l, i.e. 
770 µM). The absence of non-specific adsorption was tested using HSA as negative 
control, at a concentration of 77 µM in binding buffer, in a 1400-fold excess with 
respect to thrombin. The interaction did not result in a measurable frequency decrease 
(∆F < 3 Hz), demonstrating the high specificity of the sensor (Figure 26). 
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Figure 26. Typical curve obtained with 77 µM Human Serum Albumin interacting with the 
immobilised aptamer (Interaction time 30 min). The reported analytical datum will be the 
difference in frequency between Buffer (B) and Buffer (A) which represents the baseline. 
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3.1.3. Detection of Thrombin in complex matrix 
 
The ability of the aptasensor to detect the analyte in complex matrices was tested. 
Thrombin is the last enzyme protease involved in the coagulation cascade and it 
converts fibrinogen to insoluble fibrin that forms the fibrin gel [57]. Since the detection 
of thrombin in plasma or blood is clinically relevant, an aptamer-based sensor as an 
alternative diagnostic tool for thrombin analysis or blood coagulation investigation 
could be of considerable interest in the clinical diagnostics. Standard solutions of 
thrombin were added to serum and plasma to test the performance of the aptasensor in 
these complex matrices.  
 
Since serum does not contain coagulation factors, the addition of thrombin does not 
affect the samples. Thrombin was detected in serum diluted 1:100 spiked with thrombin 
in a concentration range 0-200 nM, with a blank value of -32 ± 8 Hz. The recorded 
signals increased with the concentration of added thrombin, demonstrating that the 
aptasensor was able to operate in this complex matrix (Figure 27). 
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Figure 27. Frequency shifts obtained with different concentrations of thrombin (0-200 nM) 
interacting with the immobilised aptamer. Thrombin was added to serum (1:100 in binding buffer). 
Each error bar represents standard deviation of three replicates (n=3). Interaction time 30 min. 
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Since serum does not contain the proteins involved in coagulation, further experiments 
were carried out with plasma, which is the matrix where normally thrombin is detected. 
The addition of thrombin to plasma, which contains all the proteins involved in the 
coagulation cascade including fibrinogen, leads to the formation of fibrin and to rapid 
sample clotting. To avoid this phenomenon, fibrinogen was selectively precipitated 
from plasma before the addition of thrombin in the preparation of spiked samples, using 
ammonium sulphate as precipitant. A loss of protein content (~ 40%) was detected after 
precipitation of fibrinogen by spectrophotometric measurements at 280 nm. Figure 28 
shows the signals obtained in spiked plasma without fibrinogen (final dilution 1:100). 
Reproducibility was good (CV% = 13%), and the response was linear in the tested 
concentration range, 0-200 nM (R2 = 0.990). In this range, no saturation of the surface 
was observed. The matrix effect with a blank signal of -21 Hz is present, but despite the 
high complexity of the matrix, the increase in thrombin concentration could be detected.  
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Figure 28. Calibration plot obtained with different concentrations of thrombin in buffer and 
plasma. Each error bar represents standard deviation of three replicates (n=3). 
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3.2. Development of an optical aptasensor to detect C-Reactive 
Protein 
 
The development of an RNA aptamer-based optical biosensor was realized by 
immobilising the 44-mer aptamer specific for CRP on the gold surface of Biacore CM5 
chips and monitoring the interaction with the label-free target analyte. Also in this case 
study, the optimal conditions for the binding in the heterogeneous phase were to be 
found by optimisation of some simple but critical parameters, in order to reach 
acceptable analytical performances of the aptasensor.  
 
 
 
 
3.2.1. Analytical performance of C-Reactive Protein detection with the 
optical device 
 
In aptasensor development, good analytical performance can be ensured by selecting a 
proper immobilisation protocol. Studies with thrombin reported above had shown that 
improved sensor performance could be obtained by the addition of a spacer to the 
aptamer sequence, in order to facilitate a correct aptamer-protein binding. For this 
reason, also in the case of CRP a polyT tail consisting of 20 thymins was linked to the 
5’ end of the aptamer, together with a biotin group to ensure that it was anchored 
correctly to the streptavidin-modified surface. Because of the presence of the four kinds 
of nucleotides in the CRP aptamer sequence, an oligonucleotides tail could cause the 
formation of intra-molecular folding in the aptamer structure. To avoid this problem, a 
non-oligonucleotide tail could be necessary. For this reason a TEG tail at the 5’ end of 
the aptamer was also considered, consisting of a 16-atom mixed polarity spacer arm, 
which gives flexibility and optimal capture by streptavidin. In both cases, before 
immobilization, the aptamer solution was subjected to a thermal treatment (95 °C for 1 
min, 0 °C for 10 min), which unfolded the aptamer, making the biotin label at the 5′ end 
available for interaction with streptavidin on the surface. Finally, the surface was 
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saturated with biotin. In Figure 29, the immobilisation of the aptamer with the BioTEG 
tail on the dextran-streptavidin-modified chip is reported versus the SPR signal.  
 
 
 
Figure 29. Immobilisation of the CRP aptamer with the BioTEG tail on CM5 chip modified with 
streptavidin. After the activation with HS/EDAC, streptavidin (200 ppm) was covalently bound to 
the carboxylic groups present on the dextran and finally saturated with ethanolamine. The RA 
aptamer (1 µM in immobilisation buffer), thermally treated, was anchored to the surface via biotin-
streptavidin binding, with a resulting shift in the resonance signal of 1988 RU. Finally biotin (500 
ppm) was added to saturate the free sites of streptavidin.  
 
 
 
 
3.2.1.1. Optimisation of the binding conditions 
 
When developing an aptasensor, the first step is to optimise the buffer to be employed 
in the assay. After the immobilisation of the aptamer with the polyT tail, the interaction 
between the immobilised receptor and 1 ppm CRP was monitored with an association 
time of 15 min followed by washing with running buffer. The experiments were 
conducted at 25 °C. The analyte CRP was dissolved in several buffers differing in salts 
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composition and pH. The effect of the pH in the range 6-7.5 was studied. During the 
experiments the same buffer was used as a solvent to dissolve the analyte (binding 
buffer) and as running buffer, flowing on the chip surface before and after CRP 
injection. The following buffers were tested: MES 10 mM pH 6.0, HEPES 10 mM pH 
6.0, Tris/HCl 10 mM pH 6.0, MES 10 mM pH 6.5, HEPES 10 mM pH 6.5, Tris/HCl 10 
mM pH 6.5,  HEPES 10 mM pH 7.0, Tris/HCl 10 mM pH 7.0, HEPES 10 mM pH 7.5, 
Tris/HCl 10 mM pH 7.5. Tris/HCl buffer was tested since a similar buffer was used for 
the aptamer selection in the SELEX process [88]. The results are shown in Figure 30, 
where the frequency shifts recorded for the interaction of the immobilized aptamer with 
1 ppm CRP as well as with 100 ppm HSA are reported.  
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Figure 30. Binding buffer optimisation using 1 ppm CRP and 100 fold-excess concentration of 
human serum albumin (100 ppm HSA) as negative control. The same buffer used in the binding 
assay was also employed as running buffer. Each error bar represents standard deviation of three 
replicates (n=3). 
 
 
HSA was chosen as negative control since it is the most abundant protein in serum. 
HEPES 10 mM at pH 6.5 was chosen as binding and running buffer, since in this buffer 
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the best ratio between the specific signal (in presence of CRP) and the unspecific signal 
(in presence of HSA) was found. For the following experiments, the optimised buffer 
(Hepes 10 mM pH 6.5) was added with 0.005% Tween 20 in order to remove the slight 
baseline drift, as suggested in Biacore X™ manual. 
 
After each binding cycle, the surface was regenerated by 1 min treatment with HCl (1, 
10 or 25 mM depending upon the entity of the binding shift to be regenerated) or with 1 
mM NaOH.  
 
 
 
 
3.2.1.2. Effect of calcium ions 
 
It is reported that in the absence of calcium ions CRP in neutral or mildly acid 
environment self-dissociates, slowly but persistently [95]. Therefore the pentameric 
CRP (pCRP) is stored in buffer containing CaCl2 to prevent spontaneous formation of 
monomeric CRP (mCRP) [94]. In fact, the purified CRP purchased for this study was 
stored in buffer containing 2 mM CaCl2. Despite the important role that calcium ions 
play in the CRP pentameric structure maintenance, it should be considered that the 
selection process for generating the CRP aptamer was conducted in absence of calcium 
ions [88]. For this reason the influence of calcium ions on the binding was also 
investigated, in the case of both polyT and TEG modified aptamers.  
 
The binding curve for 0.05 ppm CRP prepared in the optimised buffer (Hepes 10 mM 
pH 6.5, 0.005% Tween 20), i.e. in the absence of calcium ions, is reported in Figure 31. 
The aptamer-CRP interaction time was set to 15 minutes, but it was observed that as 
soon as the injection ended, CRP slowly dissociated. For this reason the binding shift 
was recorded 15 min from the end of the injection.  
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Figure 31. CRP binding curve in the absence of calcium ions in the binding buffer. Immobilised 
aptamer: CRP aptamer with polyT tail. CRP concentration: 0.5 ppm. Binding time: 15 min. 
Binding and running buffer: Hepes 10 mM, pH 6.5, 0.005% Tween 20. Flowrate 2 µl/min, T 25 °C. 
Binding shift recorded 15 min after the end of injection: 784 RU. Regeneration: HCl 1 mM (3 
injections).  
 
 
 
a) Optimisation of the aptamer concentration 
The aptamer concentration is one of the critical parameters that influence the analytical 
performances of the assay; for this reason it was decreased from 1 µM to 0.1 µM in 
order to reduce the steric hindrance on the surface. 
 
The analytical performance of the CRP aptamer with the TEG tail were studied in the 
absence of calcium ions using as running and binding buffer the one resulted from the 
optimisation step (Hepes 10 mM pH 6.5) and added with 0.005% Tween 20 for the 
baseline stabilisation. Calibration curves were obtained using the CRP aptamer with the 
TEG tail immobilised at two different concentrations (1 and 0.1 µM) and they are 
compared in Figure 32. The reported measurements (in RU) were referred to three 
repetitions (n=3) of each protein concentration and were registered 15 min after the end 
Results 
 
86 
 
of injection because of the dissociation. A sensitivity increase (10 times) was found 
when 0.1 µM aptamer was used for immobilisation, probably as a consequence of the 
decreased steric hindrance on the surface. The analytical characteristics of the assay for 
the two different concentrations of the aptamer with the TEG tail are compared in Table 
6. 
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Figure 32. Calibration curves obtained by immobilising CRP aptamer with the TEG tail at two 
different concentrations (1 µM and 0.1 µM) in Hepes 10 mM, pH 6.5, 0.005% Tween 20 on CM5 
Biacore chip. Each error bar represents standard deviation of three replicates (n=3). Flowrate 2 
µl/min, 25 °C. Binding shifts were recorded 15 min after the end of injection. 
 
 
Aptamer concentration 
(µM) 
1 0.1 
Linear range (ppm) 0 – 1 0 – 0.5 
Experimental DL (ppm) 0.1 0.015 
R2 0.990 0.999 
Linear Regression y = 293.0x – 17.9 y = 703.8x + 2.3 
Table 6. Analytical characteristics of the assay using the aptamer with the TEG tail immobilised on 
the chip at two different concentrations (1 and 0.1 µM). Binding Buffer Hepes 10 mM, pH 6.5, 
0.005% Tween 20. Interaction time 15 min.  
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b) Comparison between the two different tails 
The surfaces carrying the aptamers modified with the two different tails were tested for 
their ability to bind the target analyte in the absence of calcium ions.  The most suitable 
tail was identified by investigating the effect of the two different spacers on the 
aptasensor performance, following the same identical procedure for the immobilisation 
of the two aptamers and using the optimised running and binding buffer (Hepes 10 mM 
pH 6.5, 0.005% Tween 20). Since the best analytical results in the case of the CRP 
aptamer with the TEG tail were obtained by using a concentration of 0.1 µM for the 
immobilisation, the same concentration was used also for the immobilisation of the CRP 
aptamer with the polyT tail. A comparison of the analytical characteristics of the assays 
is reported in Table 7. From the comparison, a slightly superior analytical behaviour for 
the TEG tail aptamer was found in terms of linearity (R2) and the minimum detectable 
amount of the analyte, defined as the lowest concentration giving a measurable signal.  
 
 
 
 
 
 
 
 
 
 
Table 7. Analytical characteristics of the assay using the 0.1 µM aptamer with TEG tail or with 
polyT tail immobilised on the chip. Data recorded in the absence of calcium ions. 
 
 
 
 
c)  Calibration in presence of calcium ions  
The influence of the calcium ions on the analytical performances of the assay was 
studied. Physiological calcium concentration is 2 mM as total calcium and 1.3 mM as 
Ca2+ free ion. To mimic the physiological conditions, 2 mM Ca2+ was added to the 
Aptamer modification TEG PolyT 
Aptamer concentration (µM) 0.1 0.1 
Linear Range (ppm) 0 – 0.5 0 – 0.5 
Experimental DL (ppm) 0.015 0.05 
R2 0.999 0.997 
Binding Buffer Hepes 10 mM pH 6.5, 0.005% Tween 20 
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binding and running buffer. As can be observed from the sensorgram recorded during 
the binding of 0.025 ppm CRP to the immobilised TEG aptamer (Figure 33), the 
complex aptamer–CRP curve did not dissociate at the end of the injection, indicating a 
higher stability of the complex in the presence of Ca2+. 
 
22400
22420
22440
22460
22480
22500
22520
22540
22560
22580
22600
20800 21000 21200 21400 21600 21800 22000 22200 22400
S
ig
n
a
l (
R
U
)
Time (sec)
HCl
NaOH
 
Figure 33. CRP binding curve in the presence of calcium ions. CRP aptamer with the TEG tail, 
CRP  concentration 0.025 ppm, binding and running buffer: Hepes 10 mM, pH 6.5, 0.005 %, 
Tween 20, CaCl2 2 mM. Binding shift at the end of injection: 115 RU. Regeneration injections in 
order to return  to the baseline: 1 mM HCl, 1 mM aOH. 
 
 
As a consequence of the CRP-aptamer complex stability, higher RU signals were 
recorded after 15 min of interaction. As can be observed from the calibration curves 
reported in Figure 34, an increase of sensitivity was registered using chips modified 
with either the TEG aptamer or the polyT aptamer: in both cases, the minimum 
detectable amount of the analyte was reduced to 0.005 ppm. Nevertheless, the sensor 
carrying the aptamer with the TEG tail showed a higher sensitivity, expressed as the 
slope of the regression line, while the reproducibility obtained using the aptamer 
modified by both tails was similar (Table 8). The binding constant, using the 
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BIAevaluation 3.1 program, was estimated to be 0.5 nM (expressed as KD). This value, 
calculated with the TEG modified aptamer, was lower than the one reported in literature 
(125 nM), calculated in solution, but in absence of calcium [88]. 
 
-50
50
150
250
350
450
550
650
0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.1
S
h
if
t 
(R
U
)
Conc (ppm)
BioTEG 0.1uM
PolyT 0.1uM
 
Figure 34. Calibration curves obtained by immobilizing CRP aptamer 0.1 µM with the polyT tail or 
the TEG tail . Each error bar represents standard deviation of three replicates (n=3). Flowrate 2 
µl/min, 25°C. Binding shifts were recorded at the end of injection. 
 
 
Aptamer modification PolyT TEG 
Binding Buffer Hepes 10 mM, pH 6.5, 0.005% Tween 20, CaCl2 2mM 
Linear Range (ppm) 0 – 0.1 0 – 0.1 
Experimental DL (ppm) 0.005  0.005 
R2 0.975 0.982 
Linear Regression y = 2827.3x -12.3 y = 6297.9 x -27.7 
Cycles 50 50 
Table 8. Analytical characteristics of the assay using chips modified with the polyT-tail or the TEG-
tail aptamer (concentration 0.1 µM), in presence of calcium ions in the binding buffer. 
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Using the TEG aptamer, the sensor was also tested by decreasing the calcium 
concentration down to 1 mM. Similar results as to those obtained for 2 mM Ca2+ were 
found. In particular, when a low (0.025 ppm) CRP concentration was tested, 358 RU 
and 327 RU were recorded, respectively in presence of 1 mM and 2 mM Ca2+. Similar 
findings were obtained with 0.1 ppm CRP: 78 RU and 95 RU were found, respectively 
for 1 mM and 2mM Ca2+. 
 
 
 
d) Specificity 
The specificity of the aptasensor was tested using 500 ppm HSA under the optimised 
binding conditions (binding buffer Hepes 10 mM, pH 6.5, 2 mM CaCl2, 0.005% Tween 
20). When the aptamer with TEG tail was used as immobilised probe, the recorded 
response was 10% of the CRP signal at the same dilution factor (10 ± 4 RU vs 58 ± 5 
RU). Furthermore, the TEG tail assured a better specificity towards HSA than the PolyT 
tail (Figure 35).  
 
 
Figure 35. Specificity test with negative control: comparison between the two spacers. HSA and 
CRP diluted 1:100 respect to the physiological conditions. Each error bar represents standard 
deviation of three replicates (n=3). Binding and running buffer: Hepes 10 mM, pH 6.5, 0.005 %, 
Tween 20,  CaCl2 2 mM. Binding shifts recorded at the end of injection. 
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3.2.2. Detection of C-Reactive Protein in complex matrix 
The possibility to detect C-Reactive Protein directly in a complex matrix such as serum 
samples was evaluated. For this purpose, serum samples were diluted 1:100 and filtered 
(0.2 µm filter) in order to remove the particulate matter and avoid clogging of the 
Biacore microfluidic system. The SPR sensor, modified by immobilisation of the CRP 
aptamer with the TEG tail, was directly exposed to the serum solutions and the response 
recorded. Unfortunately, a very high RU signal (>17000 RU) was measured. 
Furthermore, after the exposure to diluted serum the sensor surface could not be 
completely regenerated and following further injection of CRP standard solution, the 
aptamer was unable to bind the analyte anymore.  
 
Simulated serum solutions were produced in RNase-free environment in order to 
estimate the matrix effect. Since one important protein class in serum is represented by 
immunoglobulins (IgG), the aptasensor was exposed to an IgG solution, prepared in 
RNase-free binding buffer. The concentration of IgG injected into the chip was 120 
ppm, because it is the concentration present in a 1:100 diluted serum. The relative 
results indicated a very important RU shift (>17000 RU) induced by IgG, demonstrating 
a clear interfering effect in the assay. However, the surface was completely regenerated 
and the ability of the aptamer to bind its target was preserved. From this preliminary 
study, it was evident that a sample clean up had to be conducted to minimise such 
matrix effects.  
 
 
 
 
3.2.2.1. Pre-treatment of simulated serum samples with magnetic beads 
 
An additional sample pre-treatment was applied, in order to remove IgG from simulated 
serum solutions by using magnetic beads coupled with protein G, able to bind the Fc 
portion of IgG. Different standard solutions containing CRP or HSA or IgG or a mixture 
of them with and without addition of CRP, were tested at a concentration corresponding 
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to a 1:100 serum dilution. The recovery of the proteins after such sample pre-treatment 
was evaluated by spectrophotometric measurements at λ=280 nm. The results are shown 
in Table 9. The recovery data and the RU signals indicated that CRP and HSA were not 
retained by the beads; whereas IgG was partially removed from the sample and a 
recovery of 16% was observed, resulting in a significant RU shift. In the case of the 
mixtures containing HSA and IgG or HSA, IgG and CRP, the recorded RU signals were 
always lower than those related to each single component. This could be due to an 
interaction effect between IgG and the other proteins.  
 
 
Solution 
Recovery of proteins 
after treatment 
Shift 
(RU) 
CRP 0.01 ppm 99 % 38 
IgG 120 ppm 16 % 158 
HSA 500 ppm 100 % 22 
HSA 500 ppm + IgG 120 ppm 58 % 70 
HSA 500 ppm + IgG 120 ppm + CRP 0.01 ppm 51 % 83 
Table 9. Summary of the standard solutions that were pre-treated by magnetic beads coupled to 
protein G and then tested with the aptasensor. The proteins recovery after this pre-treatment were 
estimated by spectrophotometric measurements. 
 
 
 
 
3.2.2.2. Pretreatment of human serum with purification columns  
 
An affinity column was used to treat human serum in order to remove IgG and HSA 
from the matrix and consequently minimise the non-specific signal. The treated serum 
eluted from the column resulted diluted 1:27 and it was further diluted 1:3 with 
binding buffer. The resulting solution was then added with a commercial non-specific 
binding reducer (NSB Reducer), to further reduce the matrix effect. As a first step, the 
concentration of NSB reducer to be added and the incubation time was optimised. For 
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this purpose, serum treated using an affinity column and further diluted 1:3 was added 
with different concentrations of NSB reducer (1000, 2000 and 4000 ppm), using 
various incubation times prior of the injection (0, 5, 10, 20 min). As it can be 
observed in Figure 36, the addition of 1000 ppm NSB reducer to pre-treated serum, 
with 5 min incubation time, caused a significant decrease in the non-specific signal, 
from thousands of RU to 513 RU.  
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Figure 36. Decrease of the non-specific signal of pre-treated serum by incubation with SB 
Reducer. Sample size of n = 1. 
 
 
However, when a standard solution of CRP was spiked to the treated solution (serum 
eluted from the affinity column, further diluted 1:3 and added with 1000 ppm NSB 
Reducer, incubation time 5 min), a significant signal variation was not observed, even at 
high CRP concentrations. In fact, after the addition of 0.2 or 0.3 ppm of CRP signals 
corresponding to 531 and 549 RU, respectively, were recorded, in comparison with 513 
RU caused by non-specific signal.   
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3.2.2.3. Comparison between modified and non-modified aptamer for C-
Reactive Protein 
 
The RNA aptamer is sensitive to degradation by RNase, which are present in any 
biological sample. Consequently the possibility that the CRP aptamer was destroyed 
when dealing with serum solutions exists. For this reason the CRP aptamer was 
purchased modified with 2’ F-pyrimidines to increase its stability, with the aim of 
directly detecting CRP in serum samples.  
 
In order to understand if the modification altered the affinity of the aptamer towards 
CRP, the analytical characteristics of the modified aptamer were compared with those 
obtained with the non-modified aptamer under the same experimental conditions. For 
this purpose, 0.1 µM of modified CRP aptamer with the BioTEG tail was immobilised 
on a SPR chip and standard solutions of the analyte at different concentrations were 
made up in binding buffer containing calcium ions (Hepes 10 mM, pH 6.5, 2 mM 
CaCl2, 0.005% Tween 20) prepared in MilliQ water not treated with DEPC. Surface 
regeneration after CRP binding was realised with 1 minute treatment of 1 mM NaOH. 
The CRP calibration plot obtained with the modified aptamer is reported in Figure 37. 
The aptasensor realised with the modified aptamer showed a good linearity in the range 
0 – 0.2 ppm (R2 = 0.997) and good reproducibility (CV av % = 16 %). The aptasensor 
specificity was also tested using 5000 ppm HSA as negative control (1:10 dilution with 
respect to physiological concentration) and a shift of 557 ± 29 RU was recorded.  
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Figure 37. Calibration plot for the CRP aptamer modified with 2’-F-pyrimidines. Each error bar 
represents standard deviation of three replicates (n=3). Interaction time 15 min. Flowrate 2 µl/min, 
25 °C. Binding shifts recorded at the end of injection.  
 
 
The difference between the modified and non-modified RNA aptamer is compared in 
Table 10. The sensitivity (expressed by the slope of the curve) and the minimum 
detectable amount of the analyte for the modified aptamer were worse than for the un-
modified one, but sufficient to detect normal levels of CRP in diluted serum.  
 
 Biotin-TEG CRP aptamer 
 modified Non-modified 
Binding Buffer Hepes 10 mM, pH 6.5, 0.005% Tween 20, CaCl2 2mM 
Linear Range (ppm) 0 – 0.2 0 – 0.1 
Experimental DL (ppm) 0.015 0.005 
R2 0.997 0.982 
Linear Regression y = 1126.0 x + 6.5 y = 6297.9 x -27.7 
Table 10. Comparison of analytical parameters of the aptasensor realised by immobilising RA 
aptamer non-modified and modified with 2’-F-pyrimidines.  
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The immobilised aptamer modified with 2’-F-pyrimidines was exposed to human serum 
diluted 1:100 and again a very high non-specific signal corresponding to thousands of 
RU was recorded. However, the surface was completely regenerated and the capacity of 
the aptamer to bind CRP was not affected.  
 
 
 
 
3.2.2.4. Sandwich assay 
The possibility to realise a sandwich assay using the CRP aptamer as secondary ligand 
was evaluated. For this purpose, 2’-F-pyrimidine modified CRP aptamer immobilised 
onto CM5 Biacore chip was exposed to a standard solution of 0.2 ppm CRP and then to 
a standard solution of 0.1 µM CRP aptamer, prepared in binding buffer (interaction time 
15 minutes). As a result, a shift of 284 ± 5 RU was recorded for 0.2 ppm CRP and the 
SPR signal was further enhanced by 48 ± 2 RU by the secondary aptamer (Figure 38). 
This result suggests that CRP aptamer was able to bind the aptamer-protein complex 
formed at the chip surface. Since the shift of 1000 RU corresponds to 0.8 ng/mm2 
(Biacore User Manual), the density of bound molecules was calculated from the binding 
shifts relative to CRP and to the secondary aptamer, taking into account the molecular 
weight of each molecule and the Avogadro number. As a result, 1.2 x 1011 
molecules/cm2 of CRP were bound to the primary aptamer and 1.7 x 1011 
molecules/cm2 of secondary aptamer were bound to CRP, suggesting a 1:1 
stechiometry. 
 
This result could be exploited to develop an indirect sandwich assay for CRP detection 
in real samples, in order to reduce the matrix effect observed in the direct assay.  
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Figure 38. Sandwich assay: 0.2 ppm CRP was bound to the immobilised CRP aptamer (Interaction 
time 15 min, binding shift 221 RU), then the secondary aptamer at a concentration of 0.1 µM was 
added (Interaction time 15 min, binding shift 50 RU). Immobilised aptamer: 0.1 µM CRP aptamer 
modified with 2’-F-pyrimidines. Flowrate 2 µl/min, 25 °C.  
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3.3. Selection of  Thrombin-binding aptamers by a 
computational approach 
 
The aptamer-thrombin complex NMR structure (1HAO), in which the 15-mer TBA in 
its typical chair-conformation interacts with the fibrinogen-binding exosite, was 
downloaded from Protein Data Bank. By means of Fred-Receptor, a 25803 Å3 binding 
box was defined (Figure 39a) and the 15-mer TBA in the chair-shaped conformation 
was docked to the protein as a reference ligand. Using Shapegauss as scoring function, 
100 possible binding poses were ranked for the chair-shaped aptamer, with binding 
scores comprised in the range -1762 ÷ -1549 (Figure 39b). Binding scores were 
expressed as arbitrary units describing the affinity between aptamer and protein. 
 
 
 
Figure 39. Creation of the binding box. a) A 25803 Å3 rectangular box was created for the 15-mer 
TBA aptamer, in the aptamer-thrombin complex (1HAO) downloaded from Protein Data Bank. b) 
The 15-mer TBA in the chair-shaped conformation was docked to the protein and the relative poses 
were scored; the top-ranked pose received a binding score of -1762. 
 
 
With the aim of studying the aptamer-thrombin interaction also in the heparin-binding 
exosite, the heparin-thrombin complex (code 1TB6) was downloaded from Protein Data 
Bank and a binding box was automatically created for heparin. The binding box 
b 
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contours were then modified, in order to define a 28427 Å3 protein receptor site, in 
which the aptamer should fit (Figure 40a). Using Shapegauss as scoring function, 100 
possible binding poses were ranked for the chair-shaped aptamer, with binding scores 
comprise in the range -1373 ÷ -1141 (Figure 40b).  
 
 
   
Figure 40. a) A 28427 Å3 rectangular box was created in the heparin-binding exosite using the 
heparin-thrombin complex (1TB6) downloaded from Protein Data Bank. b) The 15-mer TBA in the 
chair-shaped conformation was docked to the protein receptor site and the relative poses were 
scored; the top-ranked pose received a binding score of -1373. 
 
 
The library of sequences created in Hyperchem by the use of the special algorithm 
contained the TBA sequence, 990 different sequences having one or two mutations 
respect to the TBA and the three low-binding sequences reported in literature (named 
sequences “a”, “b” and “c”). As a result, the library contained 994 sequences, which 
were minimised (computing time 1 day, 2 h, 29 min). To take into account the 
flexibility of the oligonucleotides, overcoming the serious limitation of considering 
nucleotides as rigid, conformers were generated for each sequence: the Openeye 
software OMEGA generated an average of 53 conformers for each sequence, in 5 days, 
5 h, 1 min. Consequently, the database was represented by the conformers of the 994 
oligonucleotide, around 53000 units. In order to give an idea of the minimisation energy 
a b 
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and number of conformers obtained, the results for the sequences selected for the 
following experimental part and for the three low binding sequences were quantitatively 
reported in Table 11. 
 
 
Code Sequence Mutations 
Minimisation Energy 
(Kcal/mol) 
Conformers 
TBA 
5’-GGT TGG TGT 
GGT TGG-3’ 
- -1030 44 
Best 
5’-GGT TTG TGT 
GGT TAG-3’ 
G5T, G14A -993 91 
Medium 
5’-GGC TGG TGT 
GAT TGG-3’ 
T3C, G11A -959 112 
Worst 
5’-GGT AGG TGT 
GGT TGC-3’ 
T4A, G15C -996 61 
“a” 
5’-GGT GGT GGT 
TGT GGT-3’ 
T4G, G6T, 
T7G, G10T, 
T13G, G15T 
-1050 45 
“b” 
5’-GGT AGG GTC 
GGA TGG 
T4A, T7G, 
G8T, T9C, 
T12A 
-833 39 
“c” 
5’-GGT AGG 
GCA GGT TGG-3’ 
T4A, T7G, 
G8C, T9A 
-834 80 
Table 11. Computational summary results for the oligonucleotide sequences selected for 
experimental screening. The oligonucleotide sequences, the mutations with respect to the TBA 
sequence, the minimisation energy and the number of conformers generated are reported.  
 
 
After these preliminary steps for the binding box and preparing conformers, FRED (the 
protein-ligand docking program by Openeye) was run with Shapegauss as scoring 
function. The run completed in 1 day, 12 hours, 33 minutes when docking was 
performed in the Fibrinogen-binding exosite and in 1 day, 10 hours, 31 minutes when 
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docking was performed in the Heparin-binding exosite. Therefore, the binding score 
together with a molecule file containing the docked structures of the top scored 
conformer for each sequence was generated. The binding score obtained was given only 
by one component, i.e. the shape score, while the hydrogen atoms were ignored.  
 
 
 
 
3.3.1. Analysis of the binding scores 
 
From the docking simulation in the Fibrinogen binding exosite, 174 sequences were not 
scored since no valid pose was found. The best conformer in terms of binding score was 
that coming from the mutated sequence G5T,G14A, with a total score of −1748. 
Considering the full ligand library, the total score ranged from −1748 to −667, but only  
98 elements reached a score between −1748 and −1500, while the majority of 
oligonucleotides ( 657 elements) had total score between −1500 and −1000 and 65 
sequences had a total score higher than -1000 (Figure 41).  
 
The docking step in the Heparin binding exosite failed for 194 sequences, which was 
not scored since no valid pose was found. The best conformer in term of binding score 
was that coming from the mutated sequence G6T, with a total score of -1486. 
Considering the full ligand library, the total score was comprised between -1486 and -
404, therefore lower binding scores were in general found in the heparin binding exosite 
with respect to the fibrinogen binding exosite (Figure 42). Only 90 elements reached a 
score between −1486 and −1200, while the majority of oligonucleotides (672 elements) 
had total score between −1200 and −700 and 38 sequences had a total score higher than 
-700. 
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Figure 41. Binding score for each sequence in the database docked to the Fibrinogen-binding 
exosite.  
 
 
 
Figure 42. Binding score for each sequence in the database docked to the Heparin-binding exosite. 
Results 
 
103 
 
The binding scores obtained for library docking in each exosite were divided in three 
parts, in order to classify high-binding sequences from low-binding sequences. 
Calculations were carried out in order to quantitate how many times a mutation 
appeared in each position and results are reported in Table 12. Among the 98 sequences 
having the most favourable binding score in the fibrinogen binding site (Binding score < 
-1500), positions G1, G2 and G6 were the most mutated, while positions T9, G10, T12 
and G15 were the less mutated. Up to 12 mutated sequences among 19 showed mutation 
G1T, but in general a trend towards a particular mutation was not observed. Among 93 
sequences having the most favourable binding score in the heparin binding site (Binding 
score < -1200), positions most mutated were G1, T7, T13 and G14, while G10 was the 
less mutated position. Also in this case, a bias was observed for mutation G1T (10 
sequences among 16), but in general there was not a clear prevalence of a mutation with 
respect to the others. However, for both the binding sites mutations in cytosine were 
unfavoured in comparison to mutations in adenine, in all the positions. In contrast with 
results reported by Tasset et al. [55], mutation of position 4 with an adenine (T4A) did 
not seem to promote the oligonucleotide binding to the heparin-binding site. In fact, 
only one sequence having mutation T4A achieved a highly favourable binding score.  
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Binding Score 
TBA G G T T G G T G T G G T T G G 
Mutation Fibrinogen-Binding Site 
< -1500 
A 
4 9 6 4 4 6 6 6 3 3 3 1 7 7 2 
-1500 <BS< -1000 26 26 29 28 30 29 28 33 32 34 33 25 23 26 30 
> -1000 4 5 3 3 2 3 1 2 0 2 2 11 3 4 4 
< -1500 
C 
3 6 6 0 3 6 3 5 2 2 4 2 4 2 2 
-1500 <BS< -1000 34 31 29 23 24 30 33 24 29 25 35 34 28 29 35 
> -1000 0 1 5 6 2 1 2 5 1 3 2 2 2 4 3 
< -1500 
G 
- - 1 8 - - 5 - 3 - - 3 3 - - 
-1500 <BS< -1000 - - 34 23 - - 31 - 32 - - 25 30 - - 
< -1000 - - 0 2 - - 1 - 4 - - 8 3 - - 
< -1500 
T 
12 6 - - 3 10 - 3 - 1 5 - - 7 4 
-1500 <BS< -1000 27 23 - - 28 23 - 22 - 17 26 - - 27 32 
> -1000 1 0 - - 2 1 - 6 - 5 2 - - 1 2 
Binding Score Mutation Heparin-Binding Site 
< -1200 
A 
4 5 5 1 4 3 6 6 4 4 5 0 6 5 4 
-1200 <BS< -700 26 33 32 32 31 33 28 33 31 31 30 25 26 30 29 
> -700 2 0 1 2 0 1 1 2 0 4 2 1 2 3 2 
< -1200 
C 
2 2 3 0 1 3 5 2 1 0 4 4 2 6 5 
-1200 <BS< -700 36 36 34 23 26 34 32 29 26 32 31 27 28 23 32 
> -700 1 1 2 7 2 2 0 3 4 0 1 3 1 3 1 
< -1200 
G 
- - 2 8 - - 6 - 5 - - 7 7 - - 
-1200 <BS< -700 - - 34 22 - - 31 - 33 - - 21 27 - - 
> -700 - - 1 2 - - 0 - 1 - - 0 1 - - 
< -1200 
T 
10 3 - - 4 7 - 2 - 2 2 - - 5 4 
-1200 <BS< -700 29 25 - - 26 28 - 22 - 18 30 - - 30 32 
> -700 1 1 - - 6 0 - 3 - 2 1 - - 1 1 
Table 12. Tabulation of the data resulting from the analysis of binding scores for docking the 
oligonucleotides library in both the thrombin binding sites. Binding scores were divided in three 
classes for each exosite in order to distinguish sequences having the highest affinity from those 
having the lowest affinity.  Quantification of how many times a mutation appeared in each position 
was reported.                                
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Taking into consideration the two binding exosites, the mutated sequence G5T,G14A 
(named “Best”) was the top scored in the Fibrinogen-binding exosite and the tenth 
scored in the Heparin-binding exosite; the TBA sequence was ranked 192th and 490th in 
the two exosites respectively, the mutated sequence T3C,G11A (named “Medium”) was 
ranked  564th and 60th respectively and the mutated sequence T4A,G15C (named 
“Worst”) was bottom ranked in both the binding sites. These binding scores were taken 
into consideration in the choice of the ligands for the experimental test, in order to have 
a variety of candidates:  the best and worst ranked, for which a huge difference in term 
of binding scores was highlighted, plus a sequence for which an intermediate behavior 
had to be expected. A binding score % was calculated by assigning value 100 to the 
mutated sequence G5T,G14 (“Best”) for the Fibrinogen-binding site and to the mutated 
sequence G6T for the Heparin-binding site.  
 
Regarding the three sequences experimentally tested in literature for low-binding, 
docking of sequence “c” failed in both the exosites, while sequences “a” and “b” were 
ranked bottom in both the exosites (Binding Score sequence “a”: -907 and -713 
respectively; Binding Score sequence “b”: -1023 and -811 respectively).  
The simulation results for the most interesting sequences are summarized in Table 13.  
 
Code 
Fibrinogen Binding Exosite 
 820 docked sequences 
Heparin Binding Exosite 
 800 docked sequences 
Binding 
Score 
Hit-list 
position  
Binding 
Score % 
Binding 
Score 
Hit-list 
position 
Binding 
Score % 
Best -1748 1 100 -1364 10 91.8 
TBA -1422 192 81.3 -982 490 66.1 
Medium -1209 564 69.2 -1256 60 83.3 
Worst -667 820 38.2 -404 800 27.2 
“a” -907 799 51.9 -713 761 48.0 
“b” -1023 746 58.5 -811  707 54.6 
Table 13. Binding Scores and relative hit list position for the oligonucleotide sequences chosen for 
the experimental test and for the docked sequences reported in literature for low-binding to 
Thrombin. 
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Binding scores obtained by docking the database in the fibrinogen-binding exosite were 
graphically correlated with the binding scores obtained by docking the library in the 
heparin-binding exosite (Figure 43). This aimed to immediately represent the behaviour 
of each docked sequence in both the binding sites. As can be observed, most of the 
sequences tended to bind the fibrinogen binding site rather than the heparin site, and the 
mutated sequence named “Medium” obtained the same binding scores for both the 
exosites.  
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Figure 43. Scatter plot of the binding scores obtained by docking the database in the Fibrinogen-
binding site versus the binding scores obtained by docking the database in the Heparin-binding site. 
The line represents the graph diagonal.  
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3.3.2. Experimental tests 
 
Experimental tests were conducted in order to verify if the binding scores agreed with 
the analytical behaviour of the sequences. For this purpose, the 15-mer Thrombin-
binding aptamer as well as the best sequence, the worst sequence and the sequence with 
intermediate behaviour resulting from the simulation experiments were immobilised on 
CM5 Biacore chips, in concentration 0.5 µM, following the procedure described in 
paragraph 2.2.1. To assure each immobilised sequence a certain flexibility, a no 
oligonucleotide spacer (BioTEG tail) was chosen in order to avoid base-pairing, which 
affects the aptamer’s secondary structure. Two chips were employed for each sequence 
and, from the resulting immobilisation shifts, a similar density of immobilised 
molecules was estimated considering 1000 RU = 0.8 ng/mm2 (Biacore User Manual). 
This density similarity allowed a direct comparison among the different sequences when 
testing their sensitivity for the detection of thrombin. The results for the immobilisation 
step are reported in Table 14. 
 
Sequence 
Code 
Chip 1 Chip 2 
 Immobilisation 
Shift (RU) 
Density 
(molecules/cm2) 
Immobilisation 
Shift (RU) 
Density 
(molecules/cm2) 
TBA 1116 1.0 x 1013 1194 1.1 x 1013 
Best 931 8.5 x 1012 918 8.4 x 1012 
Medium 1126 1.0 x 1013 1080 9.9 x 1012 
Worst 957 8.8 x 1012 911 8.3 x 1012 
Table 14. Comparison between different immobilised BiotinTEG sequences onto Biacore CM5 
Chips. Concentration of each sequence: 0.5 µM. Density was calculated from immobilisation shifts 
(1000 RU = 0.8 ng/mm2, according to the Biacore User Manual) and it was reported as 
molecules/cm2 considering the molecular weight of each immobilised sequence and the Avogadro 
number. 
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3.3.2.1. Binding Buffer optimisation  
 
Binding experiments were performed with the target thrombin solution prepared in the 
previously optimised buffer (50 mM Tris-HCl pH 7.4, 140 mM NaCl, 1 mM MgCl2, 
0.005% Tween 20), as reported in paragraph 3.1.1. The same buffer was used also as 
running solution. The thrombin-aptamer interaction time was 15 minutes and the 
surface was regenerated after each binding cycle by a treatment with 1 mM or 5 mM 
NaOH.  
 
When testing the TBA sequence, a binding shift was recorded in the thrombin 
concentration range 0-10 nM, with a minimum detectable amount of the analyte of 0.5 
nM (Figure 44). On the contrary, when testing the mutated sequences, a change in 
refractive index was observed during the protein injection, but no binding shift was 
recorded, even at very high thrombin concentration (Figure 45) 
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Figure 44. Binding shifts recorded for different concentrations of thrombin when the TBA sequence 
was immobilised on a CM5 chip. Each error bar represents standard deviation of three replicates 
(n=3). The thrombin solution was prepared in buffer 50 mM Tris-HCl pH 7.4, 140 mM aCl, 1 mM 
MgCl2, 0.005% Tween 20. 
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Figure 45. Interaction between 400 nM Thrombin and the immobilised mutated sequence 
G5T,G14A (named “Best”). o binding shift was recorded after 15 min interaction. Running and 
Binding buffer: 50 mM Tris-HCl, pH 7.4, 140 mM aCl, 1 mM MgCl2, 0.005% Tween 20. 
 
 
It should be noticed that in the computational experiments, phenomena occurring in 
solution such as ionic strength, pH and in trace compounds interferences could not be 
taken into account. In fact, Openeye Scientific Software performs modelling 
experiments in vacuum or in solution, by introducing an implicit solvation model that 
simulate an aqueous solution.  For this reason, in the experimental test the ionic strength 
of the binding buffer was drastically reduced, in order to reproduce the binding 
conditions of the simulation: for this purpose, a 400 nM thrombin solution was prepared 
by diluting the 4000 nM stock solution (in 50 mM Tris-HCl, pH 7.4, 140 mM NaCl, 1 
mM MgCl2) in MilliQ water and the binding curve was registered, using the binding 
buffer as running solution. Under these conditions, a binding curve was registered, but a 
complete dissociation was observed at the end of injection (Figure 46). 
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Figure 46. Binding curves for 400 nM thrombin interacting with the immobilised mutated sequence 
G5T,G14A (“Best”) and the TBA sequence. The thrombin solution was prepared by diluting 1:10 
the thrombin stock solution with MilliQ water. The previously optimised binding buffer was used 
as running solution (50 mM Tris-HCl, pH 7.4, 140 mM aCl, 1 mM MgCl2, 0.005% Tween 20). A 
dissociation curve was observed as soon as the injection ended. 
 
 
On the contrary, when MilliQ water was used as running buffer as well as for the 
preparation of 400 nM thrombin, the binding curve did not dissociate at the end of the 
injection and the measurement of a binding shift was possible (Figure 47).  
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Figure 47. Binding curve for 100 nM thrombin interacting with the immobilised mutated sequence 
G5T,G14A (“Best”) and the TBA sequence. MilliQ water was used as running buffer. The 
thrombin solution was prepared by diluting 1:10 the thrombin stock solution with MilliQ water. 
Binding shifts of 2455 RU and 1013 RU were registered when the immobilised sequence was 
G5T,G14A or TBA, respectively.  
 
 
It seemed that the binding curve shape as well as the binding shift depended upon the 
ionic strength of the binding and running buffer, which had to be minimised to 
reproduce the conditions used in the computational experiments. Curve shape suggested 
that a successful rapid binding to a stable plateau was not achieved when experiments 
were performed in water; on the contrary, a slow binding was observed, without 
reaching a plateau during the ligand pulse. This could cause a irreproducible binding, 
probably due to the binding buffer conditions (Biacore User Manual). In addition, 
several problems were encountered when using MilliQ water as running and binding 
buffer: since the 4 µM thrombin stock solution was prepared in 50 mM Tris-HCl, pH 
7.4, 140 mM NaCl, 1 mM MgCl2, different dilutions of this buffer were made up when 
preparing different concentrations of thrombin; secondly, the protein structure could be 
affected in a highly diluted environment; finally, a baseline drift was observed when 
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working in MilliQ water. To overcome these problems, further experiments were 
performed in order to find the lowest ionic strength which supported a binding curve 
without departing from the computational conditions. For this purpose, the optimised 
binding buffer was diluted 1:10 or 1:50 with MilliQ water and the resulting solutions 
were used as running and binding buffer. Using the buffer diluted 1:10, a slight 
dissociation was observed when 100 nM thrombin was bound to the mutated sequence 
G5T,G14A (“Best”) (Figure 48). On the contrary, using the buffer diluted 1:50 the 
binding curve did not dissociate at the end of the injection. Therefore, this solution (1 
mM Tris-HCl, pH 7.4, 2.8 mM NaCl, 0.02 mM MgCl2) was chosen for the following 
experiments, aimed to verify if the experimental and computational analysis agreed.  
 
 
 
Figure 48. Binding curves for 100 nM thrombin interacting with the immobilised mutated sequence 
G5T,G14A (“Best”) and the TBA sequence, when binding buffer diluted 1:10 or 1:50 was used as 
running solution as well as for the dilution of the stock thrombin solution. In the case of binding 
buffer diluted 1:50, binding shifts of  1296 RU and  824 RU were recorded when the immobilised 
sequence was G5T,G14A or TBA, respectively.  
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3.3.2.2. Comparison between the experimentally tested sequences 
 
Using the binding buffer diluted 1:50, the analytical performances of the four 
oligonucleotide sequences were compared in terms of signal amplitude, sensitivity 
(slope), linearity (R2) and reproducibility. The results indicated that a slightly better 
performance was obtained with the mutated sequence G5T,G14A (“Best”), while a 
slightly worse performance was obtained with the mutated sequence T4A,G15C 
(“Worst”), in agreement with the simulation findings (Table 15). The behaviours of the 
TBA and the mutated sequence T3C,G11A (“Medium”) were very similar and 
intermediate between the other two sequences (Figure 49). 
 
Sequence Code Linear Regression R2 
TBA y = 5.35x – 10.7 R² = 0.992 
Best y = 7.86x - 18.8 R² = 0.994 
Medium y = 5.05x – 8.2 R² = 0.997 
Worst y = 3.33x – 7.5 R² = 0.985 
Table 15. Analytical behaviour of the four experimentally tested immobilised sequences in the 
optimised binding conditions (Binding buffer diluted 1:50) 
 
 
As a consequence of the reduction in ionic strength, thrombin was detected in the 
concentration range 0-50 nM with a minimum detectable amount of the analyte of 5 
nM, with all the four sequences tested. In contrast, a thrombin concentration range of 0-
10 nM was achieved with the immobilised TBA sequence, using the optimised buffer as 
binding and running buffer, with a minimum detectable amount of analyte of 0.5 nM. 
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Figure 49. Thrombin calibration plots obtained with the four experimentally tested immobilised 
sequences in the optimised binding conditions (Binding buffer diluted 1:50). Each error bar 
represents standard deviation of three replicates (n=3). 
 
 
 
The specificity of each sequence was tested in the optimised binding conditions using 
human serum albumin as negative control. Using binding buffer diluted 1:50, HSA 
solutions were prepared in concentration 77 µM, corresponding to a dilution 1:100 with 
respect to physiological concentrations. Very similar results were recorded when HSA 
was exposed to each of the immobilised sequence, with a slightly higher unspecific 
signal observed in the case of sequence “Medium” (Figure 50). However it is worthy to 
note that in silico experiments only evaluated the affinity of each ligand to thrombin, 
independently by their specificity towards other proteins. 
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Figure 50. Specificity test with HSA 77 µM for the four experimentally tested immobilised sequence 
in the optimised binding conditions (Binding buffer diluted 1:50). Each error bar represents 
standard deviation of three replicates (n = 3). 
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DISCUSSION 
 
 
 
4.1. Optimisation of critical parameters influencing the aptamer-
protein affinity reaction 
 
Aptamers represent a very interesting affinity reagent with potential application in 
diagnostics, rivalling antibodies due to several advantages, mainly deriving from their 
chemical synthesis. In this thesis the suitability of aptamers as receptor molecules on 
solid surfaces for protein detection was investigated. For this purpose a well described 
and studied DNA aptamer specific for thrombin was chosen as a model system for 
biosensor development and coupled to label-free piezoelectric transduction. 
Furthermore, optical transduction was also used for another case study, where an RNA 
aptamer specific for C-Reactive Protein was employed. This latter aptamer was coupled 
to an optical chip and the principle of Surface Plasmon Resonance was used to study the 
interaction. So far, no application of CRP aptamer nor any studies on its employment 
have been described. Only its selection using the SELEX process has been reported in 
the literature [88]. 
 
Both QCM and SPR techniques have their own strengths and weaknesses for the 
development of aptamer-based biosensors. QCM is rather more likely to be used for the 
development of a new commercial aptasensor than SPR with the Biacore device, due to 
its simple and cheap costruction. However, because of RNA sensitivity to nucleases, 
SPR was used for the optimisation process of the CRP-binding aptamer, since the 
Biacore facilitated a relatively controlled environment. In addition, since both 
transduction methods involve direct affinity sensing on a gold surface, many parallels 
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exist between the two approaches. The advantage of QCM and SPR-based biosensing 
over other technologies is their fast and reliable analysis in real-time, without the use of 
labels, together with the possibility of repeated use of the sensor surface. Thus, direct 
aptamer-based assays were developed for thrombin and CRP detection without the use 
of any label and the experimental conditions for binding in heterogeneous phase were 
found. The optimisation step was of paramount importance since the behaviour of 
aptamers fixed onto solid supports (i.e. in heterogeneous phase) can vary considerably 
with respect to their performances in solution. It has been demonstrated [143] that some 
of the conditions optimised for an aptamer (such as kind of binding buffer, pH, ionic 
strength, regeneration solution) are not universal for all aptamers; on the contrary, these 
assay conditions have to be optimised on an individual aptamer basis since each 
aptamer possess a unique structure for target binding that must be considered. For this 
reason, the working conditions from one optimised system cannot be directly 
transferred to another one. However, despite the individual characteristics of each 
aptamer, other critical parameters for optimal aptamer performance are of general 
applicability in aptasensing development (for example, the presence of a spacer in the 
aptamer sequence), when other transduction principles are employed.  
 
Therefore a critical evaluation of important simple key steps in development of both 
aptasensors studied was conducted, because of their significant implications for 
analytical performance in terms of selectivity, linearity (R2), reproducibility and 
stability (cycles). In particular, the influence of the aptamer immobilisation procedure 
(chemistry, length, concentration and pre-treatment of the aptamer) as well as the 
binding conditions employed in the assays was studied.  
 
 
 
4.1.1. Optimisation of the immobilisation step  
 
To date, a rational evaluation of different important key steps in aptasensor 
development has been reported only for an enzyme linked oligonucleotide assay 
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(ELONA) assay [143]. In this thesis work the TBA and CRP aptamers were 
immobilised onto the gold surfaces of a quartz crystal or of a SPR chip through the 
biotin- or thiol- derived 5’ end. For this purpose, two standardized procedures for 
coupling of oligonucleotide sequences onto gold surfaces were applied [144]. In 
particular, immobilisation of biotinylated probe was realised on a layer of streptavidin 
linked to carboxylated dextran, fixed onto the gold surface on a self-assembled 
monolayer of 11-mercaptoundecanol; self assembly of the thiol-labelled probe was 
achieved on the gold surface via direct chemisorption. The two immobilisation methods 
were used for the modification of the piezoelectric crystal with the TBA probe and 
compared in terms of sensitivity and reproducibility: despite the long-time required for 
crystal preparation, the best procedure turned out to be the one based on dextran and 
streptavidin, in accordance with other reports  [145]. For this reason this procedure was 
also used in the case of CRP detection, by immobilising the biotinylated CRP aptamer 
onto CM5 Biacore chips, already modified with a dextran layer. 
 
As reported in paragraph 1.4.2.3. of this thesis, the TBA aptamer immobilisation 
through the 5’ [79; 68; 78; 80; 75] or 3’ [72; 73] modified end has been successfully 
demonstrated in numerous works. Studies of TBA aptamer showed that chemical 
modification of the 5’ or 3’ termini minimally perturbed thrombin-binding [71], since 
the interaction with thrombin is thought to occur adjacent to the T3T4 and T12T13 
loops. However, other authors reported that an increased binding efficiency was 
observed when TBA was immobilised through its 3’-termini instead of 5’ [143]. 
 
Since aptamers require the adoption of a particular structure to facilitate protein binding, 
the presence of a spacer arm in the aptamer sequence was studied in the case of both 
thrombin and CRP, in order to evaluate whether this spacer allowed increased flexibility 
of the aptamers to form the binding conformation. The results with TBA aptamer 
showed that coupling the receptors to the gold surface via a linker molecule (a polyT or 
a TEG tail) was advantageous to sterically assist the analyte binding. Improved target 
binding was observed in presence of a spacer, presumably due to the decreased steric 
hindrance, with consequent improved folding and analyte recognition. These findings 
correlated well with others previously reported. In particular, when developing an 
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aptamer-based quartz crystal biosensor to detect IgE, Liss et al. [146] demonstrated that 
the folded aptamer structure was stabilised by extending the sequence with the addition 
of other bases, in order to allow the formation of a longer stem and consequently a more 
stable tertiary structure. Other authors showed that the addition of a linker consisting of 
six carbon atoms correlated with improved thrombin binding [143].  
 
In the case of CRP, the analytical characteristics of the assay using the aptamer 
modified with a polyT or a TEG tail were compared and an improved performance was 
observed in the case of TEG, probably because this non-oligonucleotide spacer avoids 
intra-molecular folding in the aptamer structure. Intra-molecular folding in presence of 
the polyT tail was not observed in the case of the TBA, since this aptamer was formed 
only by guanines and thymines and consequently A·T base pairing was avoided. This 
problem was, however, taken into account in the choice of the spacer for the mutated 
TBA sequences, which contained all of the four nucleotides. Thereby, it has been shown 
the necessity to identify the most suitable tail to be used as a spacer when immobilising 
the aptamer of interest on a solid surface. 
 
From the immobilisation shifts, the density of immobilised aptamer on the solid surface 
was evaluated in terms of molecules/cm2. In the case of the SPR device, a density of 
about 1013 molecules/cm2 was calculated for different 15-mer oligonucleotide 
sequences, assuming that a shift of 1000 RU corresponds to 0.8 ng/mm2, as reported in 
the Biacore User Manual. In the case of the QCM device, a density of about 1013 
molecules/cm2 was also calculated assuming 1 Hz = 2 ng/cm2, according to the 
Sauerbrey equation (Equation 1.1). However, it should be noted that the Sauerbrey 
equation is valid only for a dry crystal operating in air. When working in solution, 
additional viscoelastic contributions to frequency changes should be taken into account 
at the level of the layer absorbed at the crystal and the surrounding electrolyte. 
Furthermore, water molecules entrapped into the layer could also give a contribution to 
the mass increase at the sensor surface. In order to correct changes of frequency 
connected with viscoelesticity, some authors have suggested the introduction of a 
correction factor of approximately 2 to the calculated number of molecules/cm2 [73; 
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147; 148]. However, even if this correction had been taken into account, similar surface 
densities would have been calculated for all the analysed oligonucleotide sequences.  
 
Both in the cases of thrombin and CRP, improved analytical performances of the assays 
were observed on decreasing the aptamer concentration from 1 µM to 0.5 or 0.1 µM, 
respectively, even if the dilution did not affect the surface capacity. In addition, the 
influence of a thermal treatment on the aptamer was studied. Prior to the immobilisation 
step, the aptamers were denatured by incubation for 10 minutes at 95 °C, followed by 
rapid cooling on ice. This methodology is routinely executed with DNA or RNA probes 
with the aim of unfolding any pre-existing 3-D structures that may interfere with target 
binding [147; 146; 139]. Results for thrombin detection showed that aptamer 
denaturation improved the efficiency of the assay in terms of linearity and 
reproducibility and for this reason the thermal treatment was adopted also for C-
Reactive Protein detection. However, Baldrich et al. [143] reported that TBA 
denaturation was not needed for the assay’s optimal performance, but this result might 
be due to the presence of KCl, which promoted the folding of the quadruplex structure.  
 
 
 
 
4.1.2. Optimisation of the binding conditions  
 
The first critical parameter to be taken into account in the optimisation of the binding 
event was the binding buffer. The buffer system applied during the SELEX process is of 
critical importance for subsequent aptamer-ligand binding experiments [149]. Even 
though the binding buffer used in the SELEX process for the aptamer identification 
should ensure the optimum protein-aptamer interaction in solution, the effect of factors 
such as pH, ionic strength and presence of particular ions could affect or promote the 
binding in the heterogeneous phase. For this reason, the binding buffer to be used in the 
assay had to be optimised both in the case of thrombin and CRP detection.  
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In the case of thrombin, 20 mM Tris-acetate, pH 7.4, 140 mM NaCl, 5 mM KCl, 1 mM 
CaCl2, 1 mM MgCl2 was employed by Bock et al. [54] for the selection of the 15-mer 
thrombin aptamer, while the use of 50 mM Tris HCl, pH 7.5, 100 mM NaCl, 1 mM 
MgCl2 resulted in the selection of the 29-mer aptamer [55]. In this work, different 
binding buffers were tested in order to find the best interaction conditions with thrombin 
and improved performances in terms of sensitivity and reproducibility were obtained 
with a buffer very similar to that employed by Tasset et al. (50 mM Tris-HCl, pH 7.4, 
140 mM NaCl, 1 mM MgCl2), not containing potassium ions. Several authors 
demonstrated that K+ had a stabilising effect on the thrombin-aptamer interaction in 
aqueous solution, because K+ is believed to shift the equilibrium toward the TBA 
quadruplex conformation [54; 56; 64; 150; 151]. The various aptasensors for thrombin 
detection reported in literature were employed with binding buffers at neutral pH, but a 
slightly different ionic strengths and in the presence of K+ compared to the ones used in 
the SELEX processes. Nevertheless, it has been reported that the quadruplex structure 
of the TBA is thermodynamically stable even in the absence of KCl, at temperature 
lower than the TBA melting temperature, which depends upon the ionic strength [143]. 
The aptamer-thrombin interaction upon DNA folding has been observed even in pure 
water [152]. However, the quadruplex structure that was formed in the absence of K+ or 
other small ions had an intramolecular configuration different from that existing in the 
presence of cations [153], while the formation of a bimolecular, and not 
monomolecular, guanine quadruplex was observed  at very low ionic strength [154].   
 
In the case of CRP detection, the best analytical performances were found when 
employing 10 mM HEPES pH 6.5, a buffer slightly different in ionic strength, pH and 
salt content compared to the one used in the SELEX process for the aptamer selection 
(50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM KCl, 1 mM MgCl2, 0.1 % NaN3) [88]. 
Furthermore, it was observed that the addition of calcium ions to the binding buffer 
promoted the binding event with CRP, resulting in an increase in the aptamer-protein 
complex stability, with consequent increase in aptasensor sensitivity. In fact, it has been 
reported that in the absence of calcium, the pentameric CRP structure dissociated to 
monomers [94]. Under the optimised working conditions, the minimum detectable 
amount of analyte was 0.005 ppm CRP using the SPR device, in the CRP concentration 
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range 0 - 0.1 ppm, with good linearity (R2 = 0.982). As a comparison, a minimum 
detectable amount of analyte of 1 ppm was found with another label-free biosensor 
based on surface plasmon resonance for CRP detection in standard solution, using 
antibodies as recognition elements [108]. 
 
In the case of thrombin detection with the QCM device, a minimum detectable amount 
of analyte of 50 nM thrombin was recorded employing the optimised working 
conditions, in the thrombin concentration range 0 - 200 nM. An increase in the aptamer-
protein interaction time (from 20 min to 30 min) resulted in an improved binding 
efficiency in terms of linearity (R2 = 0.998), in accordance with other reports [143], 
where up to 90 minutes of incubation had been employed. Other label-free aptasensors 
for thrombin detection have been reported, based on the quartz crystal microbalance 
[73] and surface acoustic wave (SAW) devices [69; 155]. In the case of QCM [73], a 
detection limit for thrombin of 1 nM in buffer was reported, even if this datum was not 
supported by the study of other important analytical parameters such as specificity, 
reproducibility or matrix effect. For SAW devices [69; 155], the reported sensitivity 
was in the same order of magnitude (submicromolar) as the proposed approach, but the 
analysis was limited to standard solutions.  
 
Unlike proteins, which are irreversibly denatured in unfavourable conditions, 
oligonucleotides are capable of reversible denaturation. Consequently, aptamers can be 
subjected to repeated use, thereby realising a device where the analyte binding with the 
immobilised receptor is an almost completely reversible process. Target dissociation is 
generally realised by rinsing the surfaces with acid or basic solutions, as was observed 
in the case of CRP, where solutions of HCl or NaOH were employed for surface 
regeneration. In other cases, solutions having a high ionic strength were used to remove 
the target analyte from the surface, while the receptor layer was completely 
reconstituted simply by returning to the original buffer conditions. In fact, high 
concentrations of salt cause disruption of hydrogen bonds and electrostatic interactions 
responsible for most of the aptamer-target association. In agreement with the result 
reported by Baldrich et al. [143], the best regenerating solution for the TBA-thrombin 
complex was 2 M NaCl, probably because this solution induced a change in TBA or 
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thrombin folding, thus affecting their binding without damaging the oligomer structure. 
As a consequence, recovery of the quadruplex was facilitated as soon as the 
regeneration solution was replaced by the binding solution. Under the specific 
optimised working conditions, up to 22 cycles were realised on the same piezoelectric 
crystal for thrombin detection and up to 50 cycles were performed on the same SPR 
chip for CRP detection without decrease in sensitivity.  
 
The specificity of the biosensor was tested for TBA aptamer as well as for CRP aptamer 
by the use of high concentrations of HSA, under the same experimental conditions as 
the target proteins. Since HSA is the most abundant protein in serum and plasma, where 
it is present at high concentration (~ 50000 ppm, i.e. 770 µM), human serum albumin 
was chosen as negative control. In the case of the TBA aptamer, the specificity of the 
piezoelectric aptasensor was demonstrated by employing a concentration of HSA 
corresponding to a 1400-fold excess with respect to thrombin, i.e. a 1:10 dilution of 
HSA with respect to the physiological concentration. In the case of the aptamer for 
CRP, the negative control test with the SPR device was conducted employing HSA 
diluted 1:100 with respect to the physiological concentration and a non-specific 
response was observed, corresponding to the 10% of the specific signal given by CRP at 
the same dilution factor. This poorer specificity of CRP aptamer with respect to TBA 
reflected its lower affinity constant (KD = 125 nM for CRP aptamer [88] vs. KD = 26 nM 
for TBA [54]), even if it compares favourably with the affinity of anti-CRP antibodies, 
with reported values for different clones of 440 and 550 nM, respectively [111; 113]. 
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4.2. Aptamers as receptors for detection of proteins in complex 
matrices 
 
One of the greatest challenges of protein assays is the development of fast, easy-to-use 
devices for detection of protein in complex matrices, with potentially wide applicability 
in diagnostics. Biosensors represent an interesting approach for protein detection 
because of their intrinsic characteristics such as real-time detection, fast analysis time, 
low cost and label-free analysis. The major problem currently encountered in biosensor 
development, when working with complex matrices such as serum and plasma, is the 
non-specific binding of protein, which results in high signal backgrounds and 
consequent decrease of assay sensitivity. In this work, the capability of aptamers to 
specifically detect their targets in complex matrix samples was investigated, using the 
different biosensor formats.  
 
A few aptamer-based biosensors have been developed for detection of proteins of 
clinical interest (such as thrombin, platelet-derived growth factor (PDGF) and vascular 
endothelial growth factor (VEGF)) in real matrices by making use of labels to enhance 
the signal. In particular, Lai et al. [156] reported the fabrication and characterisation of 
an electrochemical aptamer-beacon sensor (E-AB) directed against the blood protein 
PDGF, using Methylene Blue (MB)-modified PDGF-binding aptamer attached to a gold 
electrode. The E-AB sensor was employed directly in complex, contaminant-ridden 
samples, such as serum diluted 1:1 and undiluted blood serum and yielded a detection 
limit of 50 pM and rapid sensor response (10 min – 1 h). After a regeneration step, the 
sensor was reusable up to 5 times before unacceptable degradation was observed. On 
the basis of the same principle, a MB-modified thrombin-binding aptamer was 
employed for electronic detection of the analyte in 50 % diluted human serum spiked 
with thrombin [75].  
 
Drolet et al. [157] used the anti-VEGF aptamer to quantify the analyte in serum via a 
sandwich type microtitre plate assay. An enzyme-linked oligonucleotide assay 
(ELONA) was realised using a monoclonal antibody directed against hVEGF as capture 
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reagent and a fluorescein-tagged version of the hVEGF-binding oligonucleotide as 
detection reagent. After a final incubation with alkaline phosphatase conjugated with 
antifluorescein Fab fragments, signal was generated using a chemiluminescent alkaline 
phosphatase detection system. The theoretical DL in rat serum was 25 ppt, with no 
significant cross-reactivity for other serum proteins, such as Placental growth factor 
(PlGF), PDGF, fibroblast growth factor (bFGF), thrombin and cytokines. 
 
A recent electrochemical sandwich approach based on the use of an enzyme as 
traditional amplifying label and aptamer-functionalised magnetic beads was developed 
and applied to the detection of spiked thrombin directly in human plasma [84].  
 
 
 
4.2.1. Detection of Thrombin in a complex matrix  
 
In this work, a direct approach to detection of human proteins in complex matrix was 
attempted using label-free aptamer-based biosensor formats. In the case of the TBA 
aptamer immobilised on the gold surface of a quartz crystal microbalance, the detection 
of thrombin spiked in complex media was successfully demonstrated. In particular, 
human serum diluted 1:100 and human plasma diluted 1:100, after the selective 
precipitation of fibrinogen to avoid sample clotting, were employed. The selective semi-
quantitative precipitation of fibrinogen by addition of a high ionic strength solution is a 
standardised procedure in clinical analysis [158; 159]. Different thrombin 
concentrations in the analytical range 0 - 200 nM could be detected in treated human 
plasma with good linearity (R2 = 0.990) despite a high background signal (-21 Hz) due 
to the complexity of the solution. Thus, the ability of the TBA to detect the analyte in 
complex matrices demonstrated the potential of aptamer-based sensing for medical 
investigations. However, due to the high dilution factor, the sensitivity achieved was not 
sufficient for a direct application of the aptasensor to the detection of thrombin in real 
samples. Compared to other reported aptamer-based protein detection biosensing 
methods which have been applied to complex matrices analysis [75; 84], the proposed 
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approach was able to directly detect the analyte in human biological fluids with 
negligible matrix effect. Conventional assays for the detection of thrombosis markers in 
blood include immunochemical assays for active pro-coagulants or activation peptides. 
The conventional assays of blood coagulation are usually indirect because the end point 
is represented by the clotting fibrinogen, which is dependant not only on thrombin 
levels but also on many other factors [59]. In addition, by using the available 
technologies for evaluating clinical hemorrhagic risk or thrombosis, i.e. the addiction of 
tissue factor, most of the generated thrombin is ignored since the formation of the fibrin 
clot occurs at 10-30 nM thrombin, which is the 3% of the total amount of thrombin 
produced during the reaction [160]. For these reasons, a direct label-free assay for the 
detection of the presence of thrombin in blood could have an important diagnostic value 
for the study of diseases associated with coagulation abnormalities [59]. 
 
 
 
4.2.2. Detection of C- Reactive Protein in a complex matrix 
 
In this work a direct detection of CRP in diluted human serum was also attempted, by 
the use of CRP aptamer immobilised on a SPR chip. Unfortunately, despite filtration, 
dilution and introduction of a sample pre-treatment, the measurement of spiked CRP in 
human serum was not achieved because of a large matrix effect. 
 
It has been generally recognised that matrix interference limited the success of SPR 
biosensor system in the study of binding events in complex biological samples, because 
of the inability to control non-specific adsorption [161]. Actually, SPR measures any 
change of refractive index at the probe surface, thus non-specific binding will produce a 
signal indistinguishable from specific binding, despite the use of carboxylated-dextran 
derived chips. In fact, dextran flexible chains which extend approximately 100 nm in 
aqueous solution, form a highly hydrophilic surface with little tendency for non-specific 
adsorption of proteins and other biomolecules, providing a barrier between 
biomolecules and the gold substrate [136]. Various strategies have been employed to 
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resolve the problem of non-specific binding in real-time biospecific interaction analysis, 
such as a method for measuring anti-myoglobin in bovine serum by SPR using chips 
where CM-dextran was replaced by other biocompatible polymers [162]. Recently, a 
method for minimising non-specific binding of bovine serum components to the surface 
of CM-dextran coated chips has been proposed [163]. Bovine leptine protein (in 
concentration > 10 ppm) was measured in bovine serum diluted 1:10 in an optimised 
buffer having high ionic strength and containing carboxymethylated dextran to reduce 
the non-specific adsorption on the surface. However, direct detection of proteins in a 
complex matrix by SPR measurements using Biacore CM5 chips has been successfully 
demonstrated [164], by immobilising an antibody specific for vitellogenin and adding a 
solution of target protein spiked in fish plasma diluted 1:500. Furthermore, SPR-based 
immunosensing was very recently applied to CRP detection in human serum [109], but 
the main limitation of this approach was the single use of a valuable chip, the 
functionalisation of which via amide-linked NHS-dextran was time-consuming. In fact 
the CRP, spiked in serum diluted 1:10, was directly immobilised on the chip and probed 
with anti-CRP antibody, the signal was further enhanced by using anti-IgG as a 
secondary antibody. Protein immobilisation on the sensor chip prevented any reuse of 
the surface, thus each measurement was conducted on a different chip. In contrast, the 
approach proposed in this work is based on the reuse of the sensing surface, facilitated 
by dissociation of the affinity complex.  
 
In the proposed approach, filtration and dilution 1:100 of human serum with binding 
buffer did not appear to have an effect on reducing unspecific adsorption on the surface 
modified with the CRP aptamer, since a clear matrix effect was observed, mostly caused 
by immunoglobulins, which represent the main class of proteins in serum. As with other 
proteins of interest as potential biomarkers for diseases, CRP is present in serum at ppm 
levels, making it difficult to detect among abundant proteins such as IgG and HSA, 
which constitute more than 85% of the bulk mass of the total proteins in plasma [165]. 
Further dilution of serum was avoided, since the minimum detectable amount of analyte 
of CRP in standard solution corresponded to a dilution of 1:200 with respect to its 
physiological concentration (1 ppm).  
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Since high abundance proteins tend to mask lower abundance ones in serum analysis, 
different commercial methods for specific depletion of IgG and HSA have been 
proposed at high removal rates (> 95%) [166]. Among these, magnetic beads and 
purification columns are used coupled to Protein G, which specifically binds the Fc 
region of IgG, realising a biological affinity separation. In another approach [167], a 
column packed with Immunoglobulins Y immobilised on microbeads was used to 
remove serum abundant proteins, but successful detection of CRP was realised only at 
very high concentrations (370 ppm), which was completely out of the significant range 
as a clinical biomarker (1-10 ppm). In fact, the major problem with separation methods 
is the potential loss of non-abundant proteins by inadvertent capture, which causes 
depletion of important biomarker candidates during the protein depletion process. A 
comparison among different commercial kits for removing high abundant proteins from 
serum samples has been recently reported, showing the importance of this up-to-date 
issue and confirming the lost of several clinically interested proteins upon elution, due 
to interaction with HSA or binding to column [168]. As a consequence, some proteins 
might be completely withdrawn from the analysis.  
 
In this work, different sample pre-treatments, such as magnetic beads, affinity columns 
and a commercial reducer of non-specific binding (NSB-Reducer) were introduced, 
with the aim of removing IgG or both IgG and HSA from the matrix, and reducing the 
non-specific adsorption on the surface. In particular, the contribution of HSA and IgG to 
the matrix effect was studied by using magnetic beads for the treatment of simulated 
serum solutions containing hIgG and HSA or hIgG, HSA and CRP corresponding to a 
dilution 1:100 with respect to physiological concentration. Since the recorded SPR 
signals were lower than those recorded for each single component, an interaction effect 
between the proteins occurred. In fact, albumin is a well known carrier and transport 
protein in serum [166].  
 
Based on the same principle, disposable affinity columns for depletion of both IgG and 
HSA were used to treat human serum and the treated solution was supplemented with a 
commercial non-specific binding reducer. Since NSB-Reducer contained 
carboxymethyl dextran, its structure was similar to the dextran matrix on the sensor 
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surface. Consequently, by adding NSB-Reducer to the complex matrix prior of 
injection, the non-specific binding of complex sample components to the surface was 
reduced via a competition effect. It has been reported that non-specific binding levels 
should be reduced in the range 69-98 % without affecting the measurements of specific 
binding interactions (www.biacore.com). In this work, a drastic reduction of interfering 
signal was achieved by combining purification columns with the commercial non-
specific binding reducer, but it was not possible to measure significant concentrations 
(0.2 – 0.3 ppm) of CRP spiked in these treated matrices. Probably, spiked CRP was 
captured by NSB-Reducer in solution and as a consequence only a weak interaction 
with the immobilised aptamer was observed upon injection.  
 
The low ability of the CRP immobilised aptamer to recognize its target in complex 
matrix could be also due to a lack of specificity and stability, since this is an RNA 
aptamer, which is subject to RNase degradation. For this reason the pyrimidine 
nucleotides of the CRP aptamer sequence were chemically modified with 2’ fluorine 
functional groups, with the aim of increasing the aptamer stability in biological fluids  
[169]. A lower sensitivity and reproducibility for the modified aptamer was found 
together with a higher minimum detectable amount of analyte compared to the 
unmodified aptamer (0.015 ppm vs 0.005 ppm). Probably the 2’-F modification affected 
the folding of the oligonucleotide sequence upon binding to the target protein. The main 
advantage that 2’-F modification offered was the possibility to facilitate the working 
conditions, operating in buffers prepared in MilliQ water and avoiding those special 
precautions necessary for working with RNA sequences, in the attempt to realise a 
“RNase free” environment. As a consequence, experimental time was reduced and ease 
of analysis was achieved. Despite the increase in aptamer stability, direct detection of 
spiked CRP in diluted serum was not yet achieved due to the matrix effect. For this 
reason the possibility to realise a sandwich assay with CRP aptamer as immobilised 
receptor as well as secondary affinity ligand was evaluated, with the aim of amplifying 
the specific signal or realising an indirect assay for CRP detection in complex matrices.  
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4.3. Selection of Thrombin-binding aptamers by a computational 
approach 
 
Combinatorial techniques are used to generate libraries of millions of oligonucleotides 
[170]. Huge libraries have been employed in selection techniques to discover new 
sequences capable of binding with high affinity and selectivity to a target molecule. The 
introduction of a computationally-assisted prediction could reduce the experimental 
work currently employed in SELEX or non-SELEX methods for aptamer selection. It 
might also avoid experimental issues currently encountered, such as reagent instability 
and inaccuracy as well as lack of sensitivity and selectivity of each of the employed 
techniques in a multi-step selection processes.  
 
Computational approaches are routinely applied to identify candidate compounds for 
new drugs using information obtained from the target structure, because of the necessity 
to use cost- and time- effective ways to find lead compounds [171]. Docking methods 
are used to identify the pose of a ligand in the protein binding site and to predict the 
affinity between a protein and a ligand, by screening a library of potential candidates as 
ligands. Information required for the docking approach are the three-dimensional 
structures of protein and ligand at atomic resolution. A huge number of protein and 
ligands complexes have been resolved by X-Ray crystallography, NMR, mass 
spectrometry and other spectroscopic techniques and their structures have been 
deposited into public repositories such as Protein Data Bank. 
 
In this work, a computational method developed to screen databases of drug-like 
molecules was adapted to screen a database of oligonucleotides, with the aim of 
introducing a novel technique able to find new aptamers. The DNA aptamer that binds 
to thrombin (TBA) was chosen as a model, because it is one of the most well 
characterised. Its structure has been determined [56], as well as its binding site [66; 67] 
and its stability in vivo and in vitro [172]. The 15-mer TBA sequence was identified by 
SELEX as the minimal consensus sequence (5’-GGTTGGTGTGGTTGG-3’) from a 
pool of ~1013 96-mer oligonucleotides containing a randomised 60-mer sequence [54]. 
Discussion 
 
132 
 
Actually, the TBA sequence was one of a family of DNA oligonucleotides containing 
the consensus sequence d(GGNTGGN2-5GGNTGG), where G and T were invariant 
nucleotides and N was variable, but with a bias for a particular nucleotide. Starting from 
the TBA sequence, an in silico post-SELEX procedure was introduced by performing 
mutations in one or two positions of the 15-mer and calculating the affinity of each 
ligand for thrombin on the basis of a binding score. For this purpose, the three-
dimensional NMR structure of the thrombin-aptamer complex was used to study the 
interaction between thrombin and different nucleotide sequences, in order to investigate 
the influence of different mutations in different positions of the sequence on the binding 
affinity towards thrombin.  
 
The three-dimensional structures of TBA and 990 mutated sequences were virtually 
created in Hyperchem 7.5 in helix conformation. Using the open-source Openeye 
Scientific Software Inc., this library of oligonucleotides was screened for the ability of 
each compound to bind thrombin, after energy minimisation and conformational search 
steps. The theoretical number of mutated sequence to be created was astronomical, but 
had to be reduced to 990 by restricting to 2 the maximum number of mutations 
performed in each sequence, in order to reduce the calculation time. Since the TBA 
sequence was formed only by guanines and thymines, and a maximum of two mutations 
were introduced, a library of G-rich oligonucleotides was generated. 
 
The ability of G-rich oligonucleotides to bind a specific protein is not related to the 
nucleic acid primary sequence, but rather binding specificity depends upon the three-
dimensional structure [173]. A typical characteristic of G-rich nucleic acids sequences 
is the formation of G-quartets. Many kinds of guanine quadruplexes have been 
observed, depending upon the number of molecules in the quadruplex (intramolecular, 
bimolecular, tetramolecular and octamolecular), mutual orientations of strands (parallel, 
antiparallel), position of the loops in the quadruplex, and syn-anti glycosidic 
orientations of guanine residues [154]. Therefore, G-rich nucleic acids can form a 
variety of possible quadruplex structures depending on both thermodynamic and kinetic 
considerations [174]. In the case of TBA, the aptamer folded structure, referred to as the 
“chair conformation”, presents four guanines forming two G-quartets through base-
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pairing, aligning in a planar arrangement [64] and connected by two TT loops and a 
TGT loop [56]. However, the aptamer binding conformation depends upon the binding 
conditions. NMR studies have shown that the quadruplex structure formed in the 
absence of K+ or other small ions had an intramolecular configuration different from 
that existing in the presence of cations [153]. In addition, circular dichroism studies 
showed that TBA generated a bimolecular, and not monomolecular, guanine quadruplex 
at very low ionic strength, i.e. in 1 mM sodium phosphate, at pH 7 [154].  
 
In this work a database of G-rich oligonucleotides was screened for their binding 
affinity towards thrombin by means of in silico docking experiments. Current research 
is focused on solving several issues of computational docking, such as ligand flexibility, 
molecular size, tautomeric equilibrium, protonation state of ligands and aminoacids in 
the binding pocket [175]. Because of the high computational cost that flexibility 
implicates, most docking programs assume the protein to be rigid and the ligand to be 
flexible. In the case of Openeye Scientific Software, the docking program FRED 
applied a Gaussian shape fitting function to optimise the contact surface between the 
ligand and the protein, thereby allowing an extremely fast rigid-docking procedure. The 
flexibility of the ligand was represented by a set of conformers for each ligand, 
generated by the tool Omega, thus improving the rigid-body docking accuracy. In this 
work, an average of 53 conformers was generated for each sequence and this average 
number was consistent with other work making use of Omega [176; 177].  
 
Docking of a virtual database of ligands against a specific target aims to distinguish 
binders from non binders and even high affinity binders from low affinity binders on the 
basis of a binding score. Each docked pose is scored and ranked according to the 
protein-ligand binding affinity, represented by the binding score, which allows a direct 
comparison between different ligands. Different scoring functions have been developed 
[178], but the choice of the proper scoring function for a particular protein-ligand 
system still remains a challenge in molecular modelling. In fact none of the scoring 
functions can be generally applied to different targets and databases, since systematic 
docking errors occur in all programs [175]. In particular, in this work FRED was 
applied to dock ligands having a 3-fold higher molecular weight than the maximum one 
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(1500 g/mol) for which FRED was designed to work. When ligands having high 
molecular weight are docked, the binding scores are overestimated because of the large 
molecular surface area, resulting in a larger number of unspecific interactions with the 
protein [46; 175]. Among the scoring functions that FRED supports, Shapegauss was 
the only one that could be fit to work with large ligands, because it only finds shape 
complementarity instead of chemical complementarity and uses less computational 
memory (Warren, G., Openeye Scientific Sofware, Inc., personal communication). 
Together with physical-chemical features, shape complementarity is essential in 
determining protein-ligand binding affinities. As an example, Shapegauss and other 
open-source methods have been developed for performing shape-complementarity 
search as a first step to rapidly reduce the size of a large compound database, prior to 
use more accurate but slow docking/scoring computations [177].  
 
The FRED strategy is to exhaustively dock and score all possible positions of each 
ligand by performing rigid rotations and translations of each conformer within a binding 
box created by the user. Poses that clashes with the protein or that do not have enough 
contacts with the receptor are rejected. In this work the aptamer-thrombin docking area 
was defined as a box of 25803 Å3 for the fibrinogen binding site and of 28427 Å3 for 
the heparin binding site, in order to contain the whole aptamer structure. The chair-
shaped aptamer was docked as a reference and the top-ranked pose received a binding 
score of –1762 and -1373, in the fibrinogen and heparin exosite respectively. These 
reference binding scores were significant lower than the ones obtained from docking of 
TBA structure drawn in helix conformation and minimised (binding score -1422 and -
982, respectively in the fibrinogen and heparin binding site). However, these reference 
binding scores were very similar to those obtained from docking of the candidate 
mutated sequence subjected to the same procedure of TBA (drawing in Hyperchem, 
energy minimisation and conformer search) and named “Best” because of the top-
ranked hit-list positions (binding score -1748 and -1364, respectively).   
 
Thrombin displays two positively charged exosites where DNA sequences are expected 
to bind and both these binding sites were taken into account for the simulations. In fact, 
the two basic sites which are able to interact with acidic regions of thrombin-binding 
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molecules (fibrinogen, heparin, hirudin, thrombomodulin), are likely targets for 
oligonucleotides, because of the polyanionic nature of the nucleic acid phosphodiester 
backbone [64; 179]. X-Ray and NMR studies showed that TBA interacted in the 
fibrinogen binding site of thrombin as well as in the heparin binding site of a symmetry-
related molecule [66; 67]. From the analysis of the binding scores it appeared that TBA 
and the most of the mutated sequences preferably bound to the fibrinogen than to the 
heparin binding site. However, in this study only 15-mer nucleotides were considered 
starting from the TBA sequence isolated by Bock et al. [54]. The 29-mer thrombin 
aptamer isolated by Tasset et al. [55] and reported to interact in the heparin binding site, 
forming a more stable complex with thrombin than TBA, was not taken into account 
because of the dimensions and the molecular weight of this structure, with consequent 
problems in docking accuracy and computational time and memory.   
 
 
Results extrapolated from computational procedure were verified by correlating the 
binding scores with the analytical performance of biosensors developed by 
immobilising TBA and other mutated oligonucleotides, selected on the basis of their 
binding score, onto optical chips. Other comparative studies between binding scores 
obtained from a database of candidates and experimental results obtained by testing the 
ability of ligands to bind a target were reported, but only oligopeptides [180; 7; 181; 
176] or small organic compounds [182; 183; 184; 185] were employed as potential  
ligands. Few of these reports [176; 184; 185] used Openeye Scientific Software to 
perform docking simulations. In particular, a computational study making use of 
Hyperchem for library creation and of the Openeye algorithm FRED for database 
screening was applied to select oligopeptides binding to protein internalin, and an 
experimental verification was carried out by colorimetric competition assays [176]. 
Other studies employed different docking programs such as Leapfrog® [180] or Gold 
[7] to select rational designed oligopeptides to be experimentally tested using a QCM in 
a biosensor format. 
 
For the aim of this work, three mutated sequences were experimentally tested by SPR 
measurements. In particular, a sequence mutated in position 5 with a thymine and in 
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position 14 with an adenine was selected because of strong binding to thrombin, both in 
the fibrinogen and heparin binding site. A sequence mutated in position 4 with an 
adenine and in position 15 with a cytosine was selected by virtue of being the worst 
candidate for binding thrombin in both the exosites. Finally, a sequence mutated in 
position 3 with a cytosine and in position 11 with an adenine was selected because it 
was docked with similar binding scores in the two exosites. Despite successful 
immobilisation of all the tested sequences, preliminary results showed that, in contrast 
to the TBA, the immobilised mutated sequences were not able to recognise the target 
under the previously optimised binding conditions. On the contrary, a binding 
interaction for all the probed sequences was observed upon a harsh reduction in ionic 
strength of the binding buffer. Therefore, it appeared that the mutated sequences 
identified by computational approach were able to recognise the target only when the 
experimental conditions were close to the conditions employed in the simulations. In 
fact, affects associated with solvent such as ionic strength and presence of particular 
ions were not taken into account in the computations. For this reason, in the SPR 
measurements the binding buffer routinely employed in thrombin-aptamer recognition 
assays was diluted, in order to find the minimum ionic strength able to assure the 
formation of a stable complex between thrombin and the mutated sequence. Even at 
extremely low ionic strength an interaction between aptamer and thrombin was 
observed. In fact it has been shown that the TBA-thrombin recognition event upon 
aptamer folding in the quadruplex structure, occurred at very low ionic strength [154] 
and also in pure water solution [152]. Only the binding buffer ionic strength was 
changed, while its pH was maintained at 7.4, which was the optimum pH found in this 
study and in reports by other workers [147], because it avoided the protein becoming 
charged during the binding event. In fact, thrombin is known to have a pI of 7.0-7.3-7.6 
in three isoionic forms [186] and thus is expected to remain almost neutral when the 
binding buffer pH is equal to its pI, and to readily adhere to both apolar and negatively 
charged surfaces [187; 188]. 
 
Experimental results obtained using binding buffer diluted 1:50 confirmed the 
computational results, since slightly improved analytical performances in terms of 
sensitivity and reproducibility were obtained for the sequence named “Best” compared 
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to TBA or “Medium”, while significantly poorer results were obtained for the sequence 
named “Worst”. These results appeared to prove the ability of FRED to discriminate 
between high binding and low binding sequences through the in silico procedure 
adopted in this work. This finding was surprising given the numerous limitations of 
computational experiments mentioned above, but also because top-ranked docked 
molecules are often unable to bind the target at reasonable concentrations [44]. Indeed, 
in this work four calibration curves were obtained in the same thrombin concentration 
range (0-50 nM), with the same experimental detection limit (5 nM), but differing in 
sensitivity and reproducibility of measurements. High error bars observed were 
probably due to the sub-optimal working conditions, but also to thrombin degradation 
once the stock solution was unfrozen and diluted.  
 
The findings of other workers [54; 55; 189; 190] were consistent with these 
computational results. In fact, several mutated sequences are reported in literature for 
their lower ability to inhibit thrombin in comparison with TBA. The capability of these 
sequences to inhibit thrombin-catalysed conversion of fibrinogen to fibrin was 
determined by measuring the clotting time. Unfortunately, clotting times determined for 
the same sequence by different groups were not directly comparable because they were 
calculated for different experimental conditions, in terms of dilution buffer, thrombin 
concentration, oligonucleotide concentration and matrix (purified fibrinogen or human 
plasma). 
 
Three 15-mer sequences (named “a” [54], “b” and “c” [55]) known for their low 
capability to inhibit thrombin were drawn in Hyperchem and added to the library of 
mutated oligonucleotides to perform docking experiments. Two of these sequences were 
bottom-ranked in the binding score lists referred to both the thrombin exosites, while 
the docking of sequence “c” failed in both the binding sites. Bock et al. [54] carried out 
inhibition tests by incubating TBA or “a” sequence (in concentration 100 nM) in a 
solution of 2 mg/ml of purified fibrinogen (in selection buffer) for 1 min at 37 °C and 
measuring the clotting time after the addition of thrombin (13 nM). Fibrin formation 
was observed after 169 seconds in presence of TBA, compared with 26 seconds in 
presence of the scrambled sequence “a” and with 25 seconds in the absence of DNA. 
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The inhibition test was carried out also in human plasma, where the TBA aptamer 
showed a less potent anti-clotting activity (43 sec) compared to the solution of purified 
fibrinogen. 
 
Tasset et al. [55] identified the low-binding mutated sequences “b” and “c” by 
measuring dissociation constants for the thrombin-aptamer complexes: KD > 1000 nM 
were determined for both “b” and “c” sequences, in comparison with KD = 26 nM for 
TBA [54] and KD = 0.5 nM for the 29-mer thrombin aptamer interacting with the 
heparin-binding exosite [55]. Furthermore, inhibition tests were carried out in 2 mg/ml 
of purified fibrinogen, after the addition of 200 nM DNA sequence and thrombin. The 
clotting time was 156 sec for TBA, compared with 17 sec for sequence “b” and 34 sec 
for the 29-mer aptamer. 
Making use of the SELEX process Macaya et al. [189] identified a group of DNA 
structures able to bind thrombin more strongly than TBA. These sequences contained a 
quadruplex/duplex motif  consisting of a central 15-mer that could be mutated in the 
TGT or TT loops with respect to the 15-mer TBA, flanked by additional 4-7 
complementary base pairs. Since these selected oligonucleotides were longer (24 - 48 
mer) than the 15-mer, a direct comparison with the computational results could not be 
performed. However, a 15-mer sequence mutated in position 9 with an adenine (Code 
T9A) was identified for binding to thrombin and its inhibition activity was evaluated by 
measuring the clotting time following the procedure described by Bock et al. [54]. 
Computational result was consistent with that reported by Macaya et al. [189], since a 
decrease in binding score % corresponded to a worse inhibition activity. 
 
A correlation between binding scores and inhibition ability of sequences identified by 
Bock et al. [54], Tasset et al. [55], and Macaya et al. [189] is reported in Table 16, with 
regards to the binding scores obtained for the Fibrinogen-binding site, where the 15-mer 
sequences are expected to bind, inhibiting the fibrinogen conversion to fibrin. 
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Code 
Binding score % 
(Fibrinogen binding site) 
DNA concentration for 
inhibition test (nM) 
Clotting Time 
(sec) 
Ref 
TBA 81.3 
100 
200 
100 
169 
156 
172 
[54] 
[55]  
[189] 
a 51.9 100 26 [54] 
b 58.5 200 17 [55] 
T9A 77.5 100 123 [189] 
Table 16. Correlation between binding score and clotting time for different 15-mer DA sequences 
having a lower capability to inhibit thrombin compared to TBA. Mutated sequences “a”, “b” and 
T9A were identified and tested by Bock et al. [54], Tasset et al. [55] and Macaya et al. [189], 
respectively.  
 
 
In addition, the findings reported by Ikebukuro et al. [190] were correlated with the 
computational results. Ikebukuro et al. described an evolution-mimicking algorithm (i.e. 
a genetic algorithm which mimics Darwinian evolution) for searching aptamers 
showing an inhibitory activity towards thrombin, in order to restrict the number of 
aptamers to be assayed. In fact, since binding sequences identified by SELEX might 
bind to the target protein without affecting its activity, inhibition assays of different 
nucleotide sequences are usually carried out one by one. Making use of the described 
evolution-mimicking algorithm, 16384 sequences were virtually generated by 
introducing mutations. Ten of these sequences were synthesized and clot-inhibition 
assays were carried out by measuring the clotting time. A decrease in the inhibitory 
effect was observed if the TGT loop or the T12T13 loop was mutated, because of the 
alteration of the binding structure. Five of the analyzed sequences presented only one or 
two mutations with respect to the TBA, therefore the results for these oligonucleotides 
were correlated with the results achieved in this study, taking into account the binding 
scores obtained for the Fibrinogen-binding site (Table 17), where the 15-mer sequences 
are expected to bind inhibiting the fibrinogen conversion to fibrin. This comparison 
study showed a good correlation between the inhibition activity reported by Ikebukuro 
et al. [190] and the evaluation of the thrombin-aptamer interaction resulting from the 
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computational method. In fact, a decrease in inhibition activity corresponded to a lower 
binding score compared to TBA.  
 
Code 
Binding Score % 
(Fibrinogen binding site) 
Clotting time (sec) 
Ref. [190] 
TBA 81.3 63 
G8T,T9G 73.4 30 
T7G,G8C 71.1 19 
T7A 69.8 20 
T7G 66.6 31 
G8C 63.0 18 
Table 17. Correlation between binding score and clotting time for different 15-mer DA sequences 
having a lower capability to inhibit thrombin compared to TBA. Mutated sequences were identified 
and tested by Ikebukuro et al [190]. 
 
 
To sum up, a good correlation was found between binding score and preliminary SPR 
experimental results conducted with TBA and the three mutated sequences “Best”, 
“Medium” and “Worst”. In addition, computational results corroborated with 
experimental results carried out by other groups, which performed inhibition tests in 
order to verify the lower potential inhibiting activity of mutated sequences compared to 
TBA. Sequences mutated in the 15-mer motif and binding to thrombin with higher 
affinity than TBA were identified [189], but unfortunately it was not possible to 
correlate their clotting times with the binding score because these oligonucleotides were 
longer than 15-mer, having additional motifs attached to the 15-mer.  
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CONCLUSIONS AND FUTURE WORK 
 
 
 
 
Artificial receptors such as aptamers represent an attractive alternative to antibodies for 
analytical assays and devices. Aptamers are generated through selection methods 
carried out in vitro, which allow chemical production of DNA or RNA affinity 
molecules showing high specificity and selectivity comparable to antibodies. So far, 
aptamers have found different applications in analytical chemistry, ranging from 
separation techniques to biosensors.  
 
In this work, aptamers have been employed as new receptors for the development of 
biosensors. The DNA aptamer specific for thrombin (TBA) was chosen as a model for 
biosensor development, being one of the most well known and characterised. In fact, 
TBA was the first aptamer to be selected by the SELEX procedure [54] for a protein 
with no known physiological binding to nucleic acids. This highly specific aptamer was 
coupled with a piezoelectric transducer with the aim of realising detection of a protein 
target in heterogeneous assays. Different parameters influencing the analytical 
performance (linearity, reproducibility, stability, selectivity) of this label-free and 
reusable sensor were considered, such as immobilisation procedure, presence of a 
spacer in the nucleotide sequence, thermal treatment of the aptamer, concentration of 
the aptamer, type of binding buffer, interaction time with thrombin and specificity 
against HSA. This work demonstrated how small variations in simple steps in the assay 
development could lead to much improved analytical performance. Therefore, the 
proposed study can be considered as a reference approach in aptasensor development.  
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In this work, the ability of label-free aptasensing to operate in complex matrixes was 
also studied. Even though the TBA aptamer has been used in several studies already, in 
only few cases has the possibility of detecting this protein in biological fluids been 
investigated, mainly making use of methods for signal enhancement. Indeed, in this 
work the direct detection of spiked thrombin in diluted serum and plasma was 
demonstrated, yielding the same minimum detectable amount as recorded in standard 
solution (50 nM), despite a relatively high background signal due to matrix effects. This 
result is of paramount importance for practical application of aptasensors as new, 
interesting and attractive devices for clinical diagnostics, and also for environmental 
and food analysis. In addition, in future, efforts could include the development of 
microarrays, which represent an interesting tool in aptamer-based methods, since a 
current challenge in diagnostics is the simultaneous detection of different proteins, with 
consequent reduction of analysis costs.  
 
Because of the successful application of TBA as a receptor molecule for thrombin 
detection, another aptamer, i.e. the recently selected RNA aptamer targeted towards C-
Reactive Protein [88], was used as recognition element in the development of an optical 
biosensor based on a Surface Plasmon Resonance transducer. So far, no application of 
this aptamer, studies on its employment, its structure nor the location of its binding on 
CRP have been described. Therefore, this work represents the first study of the 
interaction between the immobilised RNA aptamer and its target analyte, starting from 
the basic information available, i.e. the aptamer sequence. 
 
Since each aptamer is unique in the three-dimensional binding configuration adopted 
upon binding to its specific target, extensive studies of assay parameters were necessary 
to obtain the optimal analytical system. For this reason, also in the case of CRP, 
different critical parameters potentially affecting the analytical performances of the 
aptasensor were evaluated. In particular the importance of a non-nucleotide spacer for 
an aptamer containing all the four nucleotides and the influence of calcium ions on 
aptamer-CRP complex stability was clearly demonstrated, together with studies on 
aptamer concentration, type of binding buffer and specificity towards HSA. Under the 
optimised working conditions a minimum detectable amount of 0.005 ppm CRP in 
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standard solution was achieved, which was a significant improvement on a previously 
described SPR antibody-based biosensor [108].  
 
Since the experimental detection limit and the linear range were such as to allow 
quantification of CRP in physiological concentration, the detection of CRP spiked in 
real matrix was attempted.  Experiments performed in 1:100 diluted serum suggested 
the need for a sample pretreatment to apply this aptasensor in complex solutions. 
Studies to reduce the interfering effect, mainly caused by IgG, were conducted by 
sample treatment with magnetic beads or affinity columns coupled with protein G, 
together with the introduction of a commercial non-specific binding reducer. 
Unfortunately, the low concentration of CRP in serum as well as its interaction with 
other proteins, or with the different methods employed to reduce the matrix effect, 
prevented the detection of spiked CRP in real samples. Also the use of the CRP aptamer 
modified with 2’-fluoropyrimidines, in order to increase its stability, did not result in a 
successful detection of physiological concentrations of CRP in serum. However, the 
possibility to realise a sandwich assay by interaction of the CRP aptamer with the CRP-
aptamer complex can open a new route for detection of CRP in real matrix by signal 
enhancing or competitive assay. In addition, further efforts to minimise the matrix effect 
could be performed by diluting serum 1:500, thanks to the high sensitivity of the assay 
in standard solution. Finally, this study represents the starting point for future 
applications of the CRP aptamer with different transducers. 
 
In the third part of this work, the possibility of introducing a computational method for 
aptamer selection was evaluated. Docking methods are routinely applied for drug 
discovery, but have also been successfully employed for selection of bio-mimetic 
peptides as well as for MIP design.  The introduction of an in silico approach to aptamer 
selection could reduce the drawbacks and limitations currently faced by SELEX and 
other experimental procedures. For this reason, a computational method formerly 
developed for docking of small molecules to a protein active site has been adapted to 
docking of nucleotide sequences to the thrombin-binding exosites, with the aim of 
studying the interaction between protein and mutated oligonucleotides with respect to 
the thrombin-binding aptamer. The affinity of each mutated sequence towards thrombin 
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was described by a binding score, compared with the one obtained with the TBA. 
Therefore, a retrospective docking study was developed, also making use in this case of 
TBA as a model, since it is the most studied aptamer.  
 
On the basis of their binding scores, three mutated sequences were chosen to be further 
employed in experimental tests performed with the SPR device, in order to test the 
reliability of computational results. In particular, the sequences showing the best, 
medium and worst binding score among the docked oligonucleotides were employed for 
the development of optical biosensors, the analytical characteristics of which were 
compared with those obtained for TBA. A good correlation between in silico selection 
and experimental results was found, although different working conditions (in terms of 
ionic strength) with respect to those previously optimised in this work were employed, 
in order to reproduce an experimental environment close to that computationally 
simulated. In addition, in silico results corroborated other experimental results reported 
in literature [54; 55; 189; 190]. In fact, eight mutated sequences tested for their lower 
capability of inhibit thrombin with respect to TBA received a worse binding score than 
TBA. Despite TBA the binding score corresponding to only 81.3% of the best 
candidate, the computational approach partially confirmed results observed in SELEX, 
identifying high affinity binding sequences (TBA) from low affinity binding sequences 
reported in literature. Further studies should be carried out in order to validate the 
proposed computational approach to aptamer selection. In particular, inhibition tests of 
the three experimentally probed mutated sequences should be performed and other 
mutated aptamers should be experimentally tested. In addition, consideration should be 
given to the mutated aptamers’ binding mode to thrombin. This work could have a 
significant impact on future aptamer selection for sensors and diagnostics. In addition, 
this new research approach may encourage significant collaborative research in this 
field, with the objective of facilitating the development of new and improved 
algorithms.
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Appendix  
 
For piezoelectric aptamer-based biosensor development for thrombin detection, the 
biotinylated 15-mer aptamer with polyT tail was immobilised on piezoelectric crystals 
and different parameters influencing the aptasensor analytical performance were 
evaluated. In particular, the influence of simple key steps (such as aptamer thermal 
treatment, aptamer concentration and binding time with the analyte) on aptasensor 
linearity, sensitivity and reproducibility was studied. Thrombin calibration curves 
obtained by varying these parameters are reported in Figure A1, A2, A3 and A4. 
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Figure A1. Calibration curve for thrombin in the range 0-200 nM in binding buffer. Experimental 
parameters: concentration of 15-mer biotinylated aptamer with PolyT tail 1 µM; no aptamer 
thermal treatment; binding time 20 min. Each error bar represents standard deviation of three 
replicates (n = 3). 
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Figure A2. Calibration curve for thrombin in the range 0-200 nM in binding buffer. Experimental 
parameters: concentration of 15-mer biotinylated aptamer with PolyT tail 1 µM; aptamer thermal 
treatment 95 °C 1 min, 0 °C 10 min; binding time 20 min. Each error bar represents standard 
deviation of three replicates (n = 3). 
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Figure A3. Calibration curve for thrombin in the range 0-200 nM in binding buffer. Experimental 
parameters: concentration of 15-mer biotinylated aptamer with PolyT tail 0.5 µM; aptamer 
thermal treatment 95 °C 1 min, 0 °C 10 min; binding time 20 min. Each error bar represents 
standard deviation of three replicates (n = 3). 
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Figure A4. Calibration curve for thrombin in the range 0-200 nM in binding buffer. Experimental 
parameters: concentration of 15-mer biotinylated aptamer with PolyT tail 0.5 µM; aptamer 
thermal treatment 95 °C 1 min, 0 °C 10 min; binding time 30 min. Each error bar represents 
standard deviation of three replicates (n = 3). 
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Abstract The development of a RNA-aptamer-based optical
biosensor (aptasensor) for C-reactive protein (CRP) is reported.
CRP is an important clinical biomarker; it was the first acute-
phase protein to be discovered (1930) and is a sensitive sys-
temic marker of inflammation and tissue damage. It has also
a prognostic value for patients with acute coronary syndrome.
The average concentration of CRP in serum is 0.8 ppm and it
increases in response to a variety of inflammatory stimuli,
such as trauma, tissue necrosis, infection and myocardial
infarction. The interaction between the 44-base RNA aptamer
and the target analyte CRP is studied. In particular, the
influence of the aptamer immobilization procedure (chemis-
try, length, concentration), as well as the binding conditions,
i.e., the influence on the binding of different buffers, the
presence of Ca2+ ion and the specificity (against human
serum albumin) have been evaluated. Using the best working
conditions, we achieved a detection limit of 0.005 ppm, with
good selectivity towards human serum albumin. Some pre-
liminary experiments in serum are reported.
Keywords Aptamer . C-reactive protein .
Surface plasmon resonance
Introduction
The detection and quantification of proteins play an essential
role in fundamental research as well as in clinical practice. To
date, the antibody-based assays are the most commonly used
diagnostic methods; however, a new class of receptors called
aptamers has appeared in the literature [1]. Aptamers are
DNA or RNA molecules isolated from a library of random
sequences by an “in vitro” selection and amplification pro-
cess, called Systematic Evolution of Ligands by EXponential
enrichment (SELEX) [2, 3]. They have been shown to be
useful for the detection of proteins and can rival antibodies
in diagnostic applications. In this regard, numerous aptamers
have been selected for a broad range of proteins. Aptamers
bind the relative target with affinity and specificity compa-
rable to those of monoclonal antibodies. They offer several
advantages over antibodies, making them very promising in
analytical and diagnostic applications. Avoiding the use of
animals, the in vitro selection and chemical synthesis of
aptamers allow reduction of the batch-to-batch variation
encountered with antibody production. Moreover, they can
be easily chemically modified and are more resistant to
degradation and denaturation if working in harsh conditions
[4, 5].
Different aptamer-based bioanalytical assays have been
developed and reviewed [6–12]. Among these, biosensors
represent an interesting approach because of their intrinsic
characteristics such as real-time detection, fast analysis time,
low cost and label-free analysis. Many aptamer-based bio-
sensors (aptasensors) have been developed for protein detec-
tion using different assay formats. Very recently, aptasensors
for proteins with innovative approaches, i.e., immunoglob-
ulin E using carbon nanotube field-effect transistors [13] and
vascular endothelial growth factor using new surface
plasmon resonance (SPR) imaging instrumentation [14],
have been reported.
Few papers concern the detection of proteins of clinical
interest (for example, thrombin and platelet-derived growth
factor) in real matrices such as plasma and serum [15–19].
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C-reactive protein (CRP) represents an important analyte
in clinical analysis. This protein has been selected as a
relevant analyte in the Integrated Project founded by the
European Community, entitled “Healthcare by biosensor
measurements and networking (Care-Man),” for developing
innovative analytical devices for fast molecular diagnostic.
CRP is one of the cytokine-induced “acute-phase” proteins
whose blood levels rise during a general, unspecific response
to infections and noninfectious inflammatory processes.
Moreover, CRP is an acute-phase reactant and a factor in
the development of atherosclerosis plaques. Although CRP
was initially believed to be only a marker of vascular inflam-
mation, a recent research indicates that it also plays an active
role in atherogenesis [20]. CRP is normally present in serum
at concentrations below 10 ppm; in adults the average con-
centration is 0.8 ppm. CRP serum levels increase in response
to a variety of inflammatory stimuli, such as trauma, tissue
necrosis, infection and myocardial infarction. Following an
acute-phase stimulus, the levels may increase to more than
500 ppm, resulting in the release of elevated quantities into
the circulation.
Commercially available immunochemical methods for CRP
detection include qualitative, semiquantitative and quantita-
tive assays. Enzyme-linked immunosorbent assay (ELISA)
is applied in highly sensitive detection of CRP with a detec-
tion limit of 100 ppb [21].
Other immunochemical approaches for CRP detection
have been reported. Among these, a competitive liposome-
based immunosorbent assay to detect human CRP in standard
solutions (detection limit 0.1 ppm) by an electrogenerated
chemiluminescence technique has been described [22]. More
recently alternative new approaches for CRP detection in
complex matrices such as whole blood, serum and plasma
have also been studied. In particular, Kartalov et al. [23]
developed a multianalyte ELISA test for simultaneous CRP,
prostate-specific antigen, ferritin and vascular endothelial
growth factor detection in blood by fluorescence. A mag-
netic permeability detection in whole blood [24] and a
magnetic assay in serum, saliva and urine [25], both using
magnetic beads, have been also reported.
Finally, immunosensors for CRP analysis have been
described. Some optical biosensors, with the antibody immo-
bilized on the sensing surface and the sample analyte added
directly, have been reported only for CRP detection in buffer
solutions [26–28]. CRP detection in human serum has been
achieved by SPR-based immunosensing [29], in which the
analyte, instead of being added in solution for receptor
binding, was directly immobilized on dextran-modified chips
by adding serum drops (diluted 1:10).
Although immunosensors showed very interesting per-
formances, the availability of a CRP RNA-aptamer [30]
encouraged the development of the relative RNA-based
aptasensor. The affinity constant of the aptamer for CRP,
expressed as KD, is 125 nM. This affinity competes with
antibody affinities, whose reported values for different clones
are, respectively, 440 and 550 nM [28] and 720 nM [27].
In this work the RNA aptamer specific for CRP was
immobilized on the chip surface and the interaction was
monitored by SPR.
To our knowledge, this is the first paper regarding the
interaction between the RNA aptamer and its target analyte.
On the basis of this, the main goal of this work was to find the
conditions for the binding in the heterogeneous phase and
then to improve the analytical performances of the aptasensor
by optimization of some simple but critical parameters.
Such parameters that could affect the analytical perfor-
mance of the aptasensor [16] in terms of selectivity, linear-
ity (R2), reproducibility (coefficient of variation) and stability
(cycles) have been studied. In particular, the influence of the
aptamer immobilization procedure (chemistry, length, con-
centration), as well as the binding conditions, i.e., the
influence of different buffers on the binding, the presence
of Ca2+ ion and the specificity (against human serum
albumin, HSA) were evaluated. Preliminary assays in human
serum were performed.
Materials
Reagents
1-Ethyl-3-(dimethylaminopropyl) carbodiimide (EDAC),
diethyl pyrocarbonate (DEPC), RnaseZAP™, polyoxyethye-
lene-sorbitan monolaurate (Tween 20), 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES), 2-(N-morpholino)
ethanesulfonic acid (MES), tris(hydroxymethyl)aminomethane
(Tris) and all the other reagents for the buffers were pur-
chased from Sigma (Milan, Italy). EDTA and calcium chlo-
ride were purchased from Merck (Milan, Italy).
All the solutions used in the experiments were prepared
in DEPC-treated water, filtered with 0.22-μm-pore size
filters (Nalgene, Milan, Italy) and degassed daily prior to
use. DEPC-treated water was prepared adding 1 ml DEPC
to 1 l Milli-Q water and the mixture was stirred overnight.
The solution was then autoclaved at 1 atm for 20 min.
The sequence of the CRP 44-mer RNA aptamer is as
follows: 5′-GCCUGUAAGGUGGUCGGUGUGGCGAGU
GUGUUAGGAGAGAUUGC-3′.
This aptamer was selected through ten SELEX rounds
[30]. Two of the possible secondary structures that the CRP
aptamer can adopt were calculated using freely available
software (RNA mfold version 2.3 server, available from
http://www.bioinfo.rpi.edu/applications/mfold/, by M. Zuker
and D.H. Turner) and are reported in Fig. 1.
The RNA aptamer biotinylated at the 5′ end was pur-
chased by IBA (Germany) with two different spacers, a
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polyT and a triethylene glycol (TEG) tail. The polyT tail is
formed by 20 thymines, while the TEG tail (C6H14O4) is a
spacer arm based on a triethylene glycol, containing four
oxygen atoms. The functionalization of the aptamer with a
spacer confers a certain flexibility to the molecule without
interfering with the binding to streptavidin. The sequence of
the aptamer with the two modifications is reported below:
– 5′-biotin-TT TTT TTT TTT TTT TTT TTT-GCCUGU
AAGGUGGUCGGUGUGGCGAGUGUGUUAGGAG
AGAUUGC-3′,
– 5′-biotin-TEG-GCCUGUAAGGUGGUCGGUGUGG
CGAGUGUGUUAGGAGAGAUUGC-3′.
Purified human CRP (molecular mass 115.135 g/mol) was
purchased from Biodesign (Milan, Italy) with a concentration
of 2,000 ppm in 0.1 M Tris, 0.2 M NaCl, 2 mM CaCl2, pH
7.5 buffer containing 0.1% NaN3 as a preservative and it
was stored at 4 °C. Further dilutions were performed and the
solutions were kept in ice during the experiments to prevent
denaturation.
Biotin, HSA, human immuoglobulin G (IgG) and human
serum were obtained from Sigma (Milan, Italy). HSA and
human IgG were used as negative controls.
Magnetic beads coupled with protein G with a diameter
of 2.8±0.2 μm were obtained from Dynal Biotech (Milan,
Italy).
The buffers tested in this study were as follows: 10 mM
MES pH 6.0, 10 mM HEPES pH 6.0, 10 mM Tris/HCl pH
6.0, 10 mM MES pH 6.5, 10 mM HEPES pH 6.5, 10 mM
Tris/HCl pH 6.5, 10 mM HEPES pH 7.0, 10 mM Tris/HCl
pH 7.0, 10 mM HEPES pH 7.5, and 10 mM Tris/HCl pH
7.5. The immobilization buffer was 300 mM NaCl, 20 mM
Na2HPO4, 0.1 mM EDTA pH 7.4.
Instrumentation
SPR measurements were performed using the BIACORE
X™ instrument (Biacore, Uppsala, Sweden) and carboxylated
dextran-coated chips (CM5 chip, Biacore, Uppsala, Sweden).
The SPR signal is expressed in resonance units (RU).
Methods
Aptamer immobilization
To prevent the RNA sequence from undergoing RNase
degradation, a “nuclease-free” environment was necessary.
For this reason careful cleaning of the glassware, vials and
instrumentation was necessary. Before use, the instrumen-
tation (the fluid cartridge and the tubing) was treated with
cleaning solutions by running specific Biacore cleaning
procedures (BIAcore Desorb and Sanitaze methods). More-
over, all the external instrumental components (the needle
and the tubing) were treated with specific RNase inhibitors.
Finally, before chip docking, an RNase-inhibiting solution
(20 μl RNaseZap™ solution at 20 μl/min) was injected
Fig. 1 Two of the possible
secondary structures of the
C-reactive protein (CRP) RNA
aptamer, calculated using RNA
mfold version 2.3 server. These
structures have a comparable
energy (ΔG)
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followed by ten subsequent injections of DEPC-treated
water [31].
The immobilization procedure was performed at a con-
stant flow rate of 5 μl/min at 25.0 °C. For the immobilization
of the CRP aptamer, the dextran surface of the chip was
further modified with streptavidin (35 μl, 200 μg/ml in
10 mM acetate buffer, pH 5.0) after an activation step (35 μl)
with 50 mM N-hydroxysuccinimide and 200 mM EDAC
[32]. The remaining carboxylated sites on dextran were
blocked with ethanolamine (1 M pH 8.6, 35 μl), then the
biotinylated aptamer in immobilization buffer was injected
(100 μl) after the thermal treatment (95 °C for 1 min, 0 °C
for 10 min) [33, 34]. Finally, the surface was blocked with
biotin (500 ppm in immobilization buffer, 100 μl) to saturate
the remaining free streptavidin sites.
Binding measurement procedure
After the immobilization of the CRP aptamer on the chip,
the binding between the immobilized receptor and CRP, in
different concentrations, was monitored with an interaction
time of 15 min followed by washing with running buffer.
Binding interactions were monitored at a constant flow rate
of 2 μl/min at 25 °C.
The measurement cycle consisted of recording the base-
line, followed by sample injection, washing with buffer,
signal recording and surface regeneration.
A schematic representation of the assay is reported in
Fig. 2.
Surface regeneration
The aptamer-CRP binding was dissociated with 1-min
injection of HCl at different concentrations (1, 10 or
25 mM), depending upon the entity of the binding shift to
be regenerated. With this treatment the sensor-bound
analyte is released from the aptamer.
Sample pretreatment with magnetic beads
Standard solutions of CRP (0.01 ppm), HSA (500 ppm),
IgG (240 ppm) or a mixture of them with and without
addition of CRP were incubated with 200 μl of magnetic
beads coupled with a protein G suspension for 20 min; then
the magnetic separation between the beads and the solution
was performed with the use of a magnetic bar. The solutions
were further diluted (1:2) in order to reach the relative con-
centrations corresponding to a 1:100 serum dilution, then
these were tested with the aptasensor.
Results and discussion
In aptasensor development it is important to select a proper
immobilization protocol to ensure good analytical perform-
ances. Improved sensor performances can be obtained by
the addition of tails to the aptamer sequence [16]. Thus, it is
necessary to identify the most suitable tail to be used as a
spacer when immobilizing the aptamer of interest on a solid
surface.
First we investigated the effect of two different tails
consisting of a 20-mer polyT and a TEG tail. In both cases
the aptamer carried a biotin at the 5′ end to ensure its
anchoring to streptavidin-modified surfaces.
In Fig. 3 the immobilization of the aptamer with the TEG
tail on the dextran-streptavidin-modified chip is reported
versus the SPR signal. Before immobilization, 1 μM aptamer
solution was subjected to a thermal treatment (95 °C for
1 min, 0 °C for 10 min), which unfolded the aptamer, making
the biotin label at the 5′ end available for interaction with
streptavidin on the surface [35]. Finally, the surface was
saturated with biotin. The signal recorded for the aptamer
binding was 1,988 RU.
When developing an aptasensor, the first step is to optimize
the buffer to be employed in the assay. In fact it has been
Fig. 2 A schematic representa-
tion of the assay on the
CM5 chip
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reported [16] that this parameter differs from one interaction
to another, thus it is difficult to directly transfer the working
conditions from an optimized system to a new one.
Binding buffer optimization
After the immobilization of the aptamer with the polyT tail,
the interaction between the immobilized receptor and 1 ppm
CRP was monitored with an association time of 15 min
followed by washing with running buffer. The experiments
were conducted at 25.0 °C. The analyte CRP was dissolved
in several buffers differing in salt composition and pH. The
effect of the pH in the range 6–7.5 was studied. During the
experiments the same buffer was used as a solvent to
dissolve the analyte (binding buffer) and as a running buffer,
flowing on the chip surface before and after CRP injection.
The following buffers were tested: 10 mM MES pH 6.0,
10 mM HEPES pH 6.0, 10 mM Tris/HCl pH 6.0, 10 mM
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Fig. 3 Immobilization of the CRP aptamer with the polyT tail on the
CM5 chip modified with streptavidin. After the activation with N-
hydroxysuccinimide (NHS)/1-ethyl-3-(dimethylaminopropyl)carbodii-
mide (EDAC), streptavidin (200 ppm) was covalently bound to the
carboxylic groups present on the dextran, finally saturated with
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thermally treated, was anchored to the surface via biotin-streptavidin
binding, with a resulting shift in the resonance signal of 1,988 RU.
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Fig. 4 Binding buffer optimiza-
tion using 1 ppm CRP and
100-fold excess concentration of
human serum albumin (HSA;
100 ppm), as a negative control.
The same buffer used in the
binding assay was also
employed as the running buffer.
MES 2-(N-morpholino)ethane-
sulfonic acid, HEPES 4-(2-
hydroxyethyl)piperazine-
1-ethanesulfonic acid, Tris tris
(hydroxymethyl)aminomethane
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MES pH 6.5, 10 mM HEPES pH 6.5, 10 mM Tris/HCl pH
6.5, 10 mMHEPES pH 7.0, 10 mM Tris/HCl pH 7.0, 10 mM
HEPES pH 7.5, and 10 mM Tris/HCl pH 7.5.
Tris/HCl buffer was tested since a similar buffer was used
for the aptamer selection in the SELEX process. The results
are shown in Fig. 4, where the frequency shifts recorded for
the interaction of the immobilized aptamer with 1 ppm CRP
as well as with 100 ppm HSA are reported. HSAwas chosen
as a negative control since it is the most abundant protein
in serum.
HEPES (10 mM at pH 6.5) was chosen as the binding
and running buffer, since in this buffer the best ratio between
the specific signal (in the presence of CRP) and the un-
specific signal (in the presence of HSA) was found.
The surfaces carrying the aptamers modified with the
two different tails were tested for their ability to bind the
target analyte, in the presence and absence of calcium ion.
It should also be noted that the selection process for
generating the CRP aptamer was performed in the absence
of calcium ions, but on the other hand, calcium ions play an
important role in the maintenance of the CRP pentameric
structure.
CRP is a soluble Ca2+-dependent ligand-binding serum
protein (115 kDa) and it has been reported that Ca2+
influences the stability of the protein in its pentameric form.
In particular, CRP is composed of five identical non-
glycosylated polypeptide subunits (206 amino acids, molec-
ular mass 23 kDa), held together by noncovalent interactions
to form a circular structure (pentraxin). The ligand-binding
site of each protomer is composed of loops with two calcium
ions [36]. Human CRP circulates in blood as a stable pentamer
(pCRP) in soluble form, but another structural form of CRP
exists, known as monomeric CRP (mCRP) [37]. In serum
as well as in the purified state CRP has a variable molecular
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Fig. 5 CRP binding curve in
the absence of calcium ions.
CRP aptamer with the polyT
tail, CRP concentration 0.5 ppm,
binding time 15 min. Binding
and running buffer 10 mM
HEPES pH 6.5, flow rate 2 μl/
min, 25 °C. Binding shift
recorded 15 min after the end of
the injection 784 RU. Regener-
ation with 1 mM HCl (three
injections)
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Fig. 6 Calibration curves
obtained by immobilizing CRP
aptamer with the triethylene
glycol (TEG) tail at two differ-
ent concentrations (1 and
0.1 μM) in 10 mM HEPES pH
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CM5 Biacore chip. Flow rate
2 μl/min, 25 °C. Binding shifts
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end of injection
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mass ranging from 110 to 144 kDa [38]. It is reported that
in the absence of calcium, CRP in a neutral and mildly acid
environment self-dissociates, slowly but persistently [39].
Therefore, pCRP is stored in buffer containing CaCl2 to
prevent spontaneous formation of mCRP [40]. The purified
CRP used in this study was stored in a buffer containing
2 mM CaCl2.
For this reason, the influence of the calcium ions on the
binding was first investigated in the case of both polyT- and
TEG-modified aptamers immobilized on the chip.
In Fig. 5 a CRP (0.5 ppm) binding curve for binding on
the polyT tail aptamer, in the absence of calcium ions, is
shown. The aptamer-CRP interaction time was set at 15 min.
It was observed that as soon as the injection ended, CRP
slowly dissociated. For this reason the binding shift was
recorded every time 15 min after the end of the injection. The
aptamer-CRP binding was dissociated by using HCl solu-
tions. Up to 45 cycles of binding/regeneration cycles were
performed on the same chip without losing sensitivity (data
not shown). The slight baseline drift was removed by adding
0.005% Tween 20 both to the running buffer and to the
binding buffer, as reported in the BiacoreX™manual. So the
final solution used as the running and binding buffer was
10 mM HEPES pH 6.5, 0.005% Tween 20 with or without
the addition of calcium ions.
Influence of calcium ions on the aptasensor
Calibration of CRP in the absence of calcium ions using
the CRP aptamer modified with the TEG tail
The aptamer concentration is one of the critical parameters
that influence the analytical performances of the assay; for
this reason it was decreased from 1 to 0.1 μM in order to
reduce the steric hindrance on the surface.
The analytical performances of the CRP aptamer with
the TEG tail was studied in the absence of calcium ions.
Calibration curves obtained using the CRP aptamer with the
TEG tail immobilized at two different concentrations (1 and
0.1 μM) are compared in Fig. 6. The reported measurements
are referred to three repetitions (n=3) of each protein concen-
tration. A sensitivity increase (10 times) was found when
0.1 μM aptamer was used for the immobilization. This could
be due to the decreased steric hindrance on the surface, in
agreement with what was previously reported [16].
Calibration without calcium ions: CRP aptamer modified
with a 20-mer polyT tail
Since the best analytical results were obtained using a
0.1 μM solution of the TEG aptamer, the same concentra-
tion was also tested for the immobilization of the CRP
aptamer by the polyT tail.
Table 1 Analytical characteristics of the assay using the aptamer with
the triethylene glycol (TEG) and the polyT tails immobilized on the
chip (solution used for the immobilization 0.1 μM)
Aptamer modification TEG PolyT
Aptamer concentration (μM) 0.1 0.1
Linear range (ppm) 0–0.5 0–0.5
Experimental DL (ppm) 0.015 0.05
R2 0.999 0.977
Average CV (%) 8 8
Binding buffer 10 mM HEPES pH 6.5,
0.005% Tween 20
DL detection limit, CV coefficient of variation, HEPES 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid
Data recorded in the absence of calcium ions
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Fig. 7 CRP binding curve in
the presence of calcium ions.
CRP aptamer with the TEG tail,
CRP concentration 0.025 ppm,
binding and running buffer
10 mM HEPES pH 6.5, 0.005%,
Tween 20, CaCl2 2 mM. Bind-
ing shift at the end of the
injection 115 RU. Regeneration
injections in order to return to
the baseline 1 mM HCl,
1 mM NaOH
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Also in this case the CRP-aptamer binding was monitored
using 10 mM HEPES pH 6.5 with 0.005% Tween 20 as the
running and binding buffer and HCl as the regeneration
solution. The analytical characteristics of the assay using the
aptamer modified with the polyT and TEG tails, respectively,
are reported in Table 1. From the comparison, a slightly
superior analytical behavior for the TEG tail aptamer was
found.
Calibration in the presence of calcium ions
The influence of calcium ions on the analytical performances
of the assay was studied. The physiological concentration of
calcium is 2 mM as total calcium and 1.3 mM as Ca2+ free
ion. To mimic the physiological conditions, 2 mM Ca2+
was added to the binding and running buffer. The sensor-
gram recorded during the binding of CRP to the immobi-
lized TEG aptamer is shown in Fig. 7.
The aptamer-CRP complex did not dissociate at the end
of the injection, indicating a higher stability of the complex
in the presence of Ca2+. Consequently, higher RU signals
were recorded after 15 min of interaction, with an increase
of sensitivity (the experimental detection limit was reduced
to 0.005 ppm), using chips modified with either the TEG
aptamer or the polyT aptamer. The binding constant, using
the BIAevaluation 3.1 program, was estimated to be 0.5 nM
(expressed as KD). This value, calculated with the TEG-
modified aptamer, is lower than the one reported in the
literature (125 nM) [30], calculated in solution but in the
absence of calcium.
In Fig. 8 the relative calibration curves are reported. The
sensor carrying the aptamer with the TEG tail shows a
higher sensitivity, expressed as the slope of the regression
line, and the reproducibilities obtained using the aptamer
modified by both tails were similar (Table 2). Using the
TEG aptamer, we also tested the sensor by decreasing the
calcium concentration to 1 mM. Similar results to those
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Fig. 8 Calibration curves
obtained by immobilizing
0.1 μM CRP aptamer with the
polyT tail or the TEG tail. Flow
rate 2 μl/min, 25 °C. Binding
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of the injection
Table 2 Analytical characteristics of the assay using chips modified
with the polyT-tail or the TEG-tail aptamer (concentration 0.1 μM), in
presence of calcium ions in the binding buffer
Aptamer modification PolyT TEG
Binding buffer 10 mM HEPES pH 6.5, 0.005%
Tween 20, 2 mM CaCl2
Linear range (ppm) 0–0.1 0 – 0.1
Experimental DL (ppm) 0.005 0.005
R2 0.975 0.982
Linear regression y=2827.3x−12.3 y=6297.9x−27.7
Average CV (%) 9 11
Cycles 50 50
Table 3 Summary of the standard solutions, that were pretreated by
magnetic beads coupled to protein G and then tested with the aptasensor
Solution Recovery of proteins
after treatment (%)
Shift
(RU)
0.01 ppm CRP 99 38
120 ppm IgG 16 158
500 ppm HSA 100 22
500 ppm HSA + 120 ppm IgG 58 70
500 ppm HSA + 120 ppm IgG
+ 0.01 ppm CRP
51 83
CRP C–reactive protein, IgG immunoglobulin G, HSA human serum
albumin, RU resonance units
The recovery of the proteins after this pretreatment was estimated by
spectrophotometric measurements
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obtained for 2 mM Ca2+ were obtained. In particular, when
a low (0.025 ppm) CRP concentration was tested, 358 and
327 RU were recorded, respectively, in the presence of 1
and 2 mM Ca2+. Similar findings were obtained at 0.1 ppm
CRP. In particular 78 and 95 RU were found, respectively,
for 1 and 2 mM Ca2+.
To test the specificity of the aptasensor, 500 ppm HSA
was used and the recorded response was 10% of the CRP
signal at the same dilution factor (10±4 compared with 58±
5 RU).
Matrix effect evaluation and sample pretreatment
The final goal of this new aptasensor would be the detection
of CRP directly in complex matrices like serum samples.
SPR-based immunosensing has very recently been applied to
CRP detection in human serum [30], but the main limitation
of this approach is the single use of a valuable chip, whose
functionalization is time-consuming. In fact the CRP, present
in serum diluted 1:10, was immobilized directly on the chip,
preventing any reuse of the surface. In contrast, our approach
is based on the reuse of the sensing surface, allowed by
affinity complex dissociation.
For this reason the aptamer was immobilized on the SPR
chip and directly exposed to the analyte in solution. Thus,
some preliminary experiments in a diluted serum sample
were performed to estimate the applicability of the CRP
aptasensor to complex matrices.
The sensor, modified by immobilization of the aptamer
with the TEG tail, was exposed to serum solutions, diluted
1:100 and filtered (0.2-μm filter) and the response was
recorded. Unfortunately, a clear matrix effect was found since
a very high RU signal was measured. Since one important
protein class in serum is represented by immunoglobulins
(IgG), the aptasensor was exposed to an IgG solution. The
concentration of IgG injected on the chip was 120 ppm
because this is the concentration present in a 1:100 diluted
serum. The relative results indicated a very important RU
shift induced by IgG, demonstrating a clear interfering effect
in the assay.
From this preliminary study, it is evident that a sample
clean-up should be conducted to minimize such a matrix
effect. For this reason an additional sample pretreatment
was applied, in order to remove IgG from serum by using
magnetic beads coupled with protein G, able to bind the Fc
portion of IgG. Different standard solutions containing CRP
or HSA or IgG or a mixture of them, with and without
addition of CRP, were tested at a concentration corresponding
to a 1:100 serum dilution. The recovery of the proteins after
such sample pretreatment was evaluated by spectrophotomet-
ric measurements at 280 nm. The results are shown in Table 3.
The recovery data and the RU signals indicated that CRP
and HSA were not retained by the beads, whereas IgG was
partially removed from the sample and a recovery of 16%
was observed, resulting in a significant RU shift. In the case
of the mixtures containing HSA and IgG or HSA, IgG and
CRP, the recorded RU signals are always lower than those
related to each single component. This could be due to an
interaction effect between IgG and the other proteins. In
conclusion, the interesting analytical performances obtained
with the aptasensor represent the prerequisite for the
possible application of the device to real matrices. However,
further work is required on sample pretreatment in order to
reduce the interferences that have not yet been completely
identified.
Conclusions
Different parameters potentially affecting the analytical per-
formances [selectivity, linearity (R2), reproducibility and
stability] of the aptasensor were evaluated. In particular, the
influence of the aptamer immobilization procedure (chemis-
try, length, concentration), as well as the binding conditions,
i.e., the influence of different buffers on the binding, the
presence of Ca2+ ions and the specificity (against HSA),
were evaluated. Regarding the immobilization step, it has
been demonstrated that the TEG tail was more suitable for
aptamer immobilization than the polyT tail. Then it was
found that HEPES at pH 6.5 with 0.005% Tween 20 was
the best buffer to use in the binding step, giving the highest
specific CRP response. The influence of calcium ions on
the sensor performances was clearly demonstrated. In the
presence of 2 mM Ca2+, the aptamer-CRP complex was
stabilized and higher signals were recorded. The reproduc-
ibility of the system, expressed as the coefficient of variation
was estimated to be 11% and the experimental detection limit
(0.005 ppm) was very good and compatible with clinical
applications. Experiments performed in serum suggest the
need for a sample pretreatment to apply this aptasensor in
complex solutions. Preliminary studies to reduce the inter-
fering effect caused by IgG were conducted by a sample
treatment with magnetic beads coupled with protein G.
Further efforts will be made to minimize the matrix effect by
diluting serum 1:500, thanks to the high sensitivity of the
assay.
This study is important for future analytical applications
of the sensor, eventually using different transduction
principles. To our knowledge, the interaction between the
RNA aptamer, immobilized on the sensing surface, and its
target analyte had not been studied before. On the basis of
this, the main goal of this work was to find the conditions
for the binding in the heterogeneous phase and then to
improve the analytical performances of the aptasensor by
optimization of some simple but critical parameters.
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Aptamer-based assays represent a modern and attractive
approach in bioanalytical chemistry. The DNA thrombin
aptamer has been extensively investigated, and the cou-
pling of this aptamer to different transduction principles
has demonstrated the wide applicability of aptamers as
bioreceptors in bioanalytical assays. The goal of this work
was to critically evaluate all the parameters that can
influence the sensor performances by using the thrombin
aptamer immobilized onto piezoelectric quartz crystals.
The optimization of the immobilization and the binding
protocol was of paramount importance, and improve-
ments in analytical performances could be obtained by
optimizing simple steps in immobilization and assay
conditions. Moreover, the work demonstrated the pos-
sibility of using aptamer-based sensors in complex ma-
trixes, opening the possibility of a real application to
diagnostics or medical investigation.
Bioanalytical approaches based on aptamers as affinity ligands
represent an interesting tool for protein detection,1,2 and homo-
geneous or heterogeneous assays have been proposed for the
analysis of the relative target.3,4 A very interesting application is
the exploitation of aptamers as biorecognition elements in
biosensors,5-7 where most of the work refers to the thrombin-
binding aptamer, with or without labels.8-18 However, even if
aptamer-based sensing represents a modern and attractive ap-
proach, a critical evaluation of the key steps (immobilization,
binding assay format, and conditions) in developing such devices
is still needed.19 Moreover, most of the reported work deals with
standard solutions of the analyte, but very important applications
of aptasensing would interest real matrixes, which have been
considered only in very few cases.6,20,21
In this paper, a study conducted with the aptamer specific for
thrombin coupled to label-free piezoelectric transduction is
reported. We aimed at critically evaluating the importance of
simple key steps in aptasensor development, which have signifi-
cant implications on its analytical performances in terms of
selectivity, linearity (R2), reproducibility (coefficient of variation
CV %), and stability (cycles). In particular, the influence of the
aptamer immobilization procedure (chemistry, length, concentra-
tion, and pretreatment of the aptamer) as well as the binding
conditions employed in the assay was studied.
The sensor is finally applied to the analysis of complex matrixes
such as human serum and plasma to exploit its ability to also bind
the target analyte in these complex samples.
The elucidation of critical parameters for optimal aptamer
performance is of general applicability in aptasensing development,
and also when other transduction principles and aptamers are
employed. The final aim and the novelty of the paper is to
demonstrate that simple, sometime neglected, steps are strategic
for the true analytical applicability of the label-free device, having
however in mind that each aptamer possess individual character-
istics.
EXPERIMENTAL SECTION
Apparatus. The 9.5-MHz AT-cut quartz crystals (14 mm) with
gold evaporated (42.6-mm2 area) on both sides were purchased
from International Crystal Manufacturing. The measurements
were conducted in a methacrylate cell where only one side of the
crystal was in contact with the solution. Experiments were carried
out using the quartz crystal analyzer Liquid Oscillator Unit with
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the software QCMagic 0.3.1× by Elbatech (Marciana, Livorno,
Italy). The resonance frequency was displayed in real time and
recorded. All the measurements have been performed at room
temperature (T ≈ 25 °C).
Reagents and Aptamers. The DNA thrombin-binding aptam-
er was purchased from MWG Biotech (Milan, Italy) with two
different modifications: (a) 5′-biotin-TT TTT TTT TTT TTT TTT
TTT GGT TGG TGT GGT TGG - 3′; (b) 5′-biotin-GGT TGG TGT
GGT TGG - 3′; (c) 5′-SH-(CH2)6-GGTTGGTGTGGT TGG-3′.
The composition of the buffers used for the experiments is
reported below: (a) immobilization buffer, 300 mM NaCl, 20 mM
Na2HPO4, 0.1 mM EDTA pH 7.4; (b) binding buffer, 50 mM Tris-
HCl, pH 7.4, 140 mM NaCl, 1 mM MgCl2.
Human serum albumin (HSA) and all the reagents used for
the buffer preparation were purchased from Sigma (Milan, Italy).
Modification of the Sensor Surface and Biotinylated
Aptamer Immobilization. The gold surface of the quartz crystal
was modified by immobilizing the thrombin-binding aptamer. The
crystal was washed with a 1:1:5 solution of H2O2 (30%), NH3 (30%),
and MilliQ water for 10 min and then rinsed with MilliQ water.
The biotinylated aptamer was immobilized via biotin-streptavidin
interaction on the gold sensor surface previously modified with
a layer of thiol/dextran/streptavidin as reported by Tombelli et
al.22
Thiolated Aptamer Immobilization. The thiolated aptamer
is anchored to the sensor surface by chemisorption based on
the formation of gold-thiol bonds. Several crystals were modified
with thiolated aptamer following the procedure previously re-
ported.23
Binding Measurements. Once the receptor was immobilized
on the gold surface, the binding step with thrombin in binding
buffer was realized by adding 100 µL of the protein solution at
different concentrations in the range 50-200 nM. The reaction
was monitored for 20 min, the solution was then removed, and
the surface was washed with the same binding buffer to eliminate
the unbound protein. The analytical signal, reported as a frequency
shift (Hz), was given by the difference between the value recorded
before the binding and after the washing (baseline), once the
binding has occurred; both values are taken when the crystal is
in contact with the same solution (binding buffer).
After each cycle of binding, the crystal surface was regenerated
by a 1-min treatment with 2 M NaCl.19 With this treatment, the
sensor-bound analyte is released at increased ionic strength, which
unfolds the three-dimensional structure of the aptamer without
damaging the oligomer structure, and the baseline is reached
again, allowing the multiuse of the sensor.
Spiked Samples. Standard solutions of thrombin were added
to serum or plasma to test the performance of the sensor in
complex matrixes. Since serum does not contain coagulation
factors, the addition of thrombin does not affect the samples. On
the contrary, the addition of thrombin to plasma, which contains
all the proteins involved in the coagulation cascade including
fibrinogen, leads to the formation of fibrin and to rapid sample
clotting. To avoid this phenomenon, fibrinogen was precipitated
from plasma before the addition of thrombin in the preparation
of spiked samples.
Such selective precipitation is based on the use of ammonium
sulfate as precipitant: 250 µL of plasma was treated with 1250 µL
of 2 M ammonium sulfate and 1000 µL of 0.1 M sodium chloride.
The solution was mixed for 3-4 min, then centrifuged, and the
supernatant was eluted in a NAP column for rapid desalting and
buffer exchange. The protein amount of the raw plasma and of
the eluted solution was evaluated by spectrophotometric measure-
ments at λ ) 280 nm, and a loss of protein content (∼40%) was
detected after precipitation of fibrinogen.
RESULTS AND DISCUSSION
The developed aptasensor consists of the 15-mer thrombin
aptamer (5′-GGTTGGTGTGGTTGG-3′) immobilized on the gold
surface of 9.5-MHz piezoelectric crystals and the analyte (throm-
bin) added in solution. The signal is recorded in real time without
the use of any label.
The binding buffer for the dilution of thrombin has been
previously24 optimized by using optical sensing with the Biacore
X device and then transferred to the piezoelectric system. The
best performances in terms of sensitivity and reproducibility were
obtained with thrombin diluted in 50 mM Tris-HCl, pH 7.4, 140
mM NaCl, 1 mM MgCl2, buffer very similar to the one used for
aptamer selection.25
The second step was the investigation of the influence of the
aptamer immobilization method on its binding with thrombin. The
aptamer has been immobilized on gold when modified with a thiol
group or on streptavidin when functionalized with biotin at its 5′-
end with the insertion of a polyT (20-mer) tail. After the
immobilization, the binding between the immobilized aptamer and
100 and 200 nM thrombin was studied with an interaction time of
20 min. The immobilization results for the biotinylated and the
thiolated aptamer are reported in Table 1. From the shifts resulting
from the immobilization of the two different aptamers, a similar
density of immobilized molecules can be estimated considering
1 Hz ) 2 ng/cm2. The tested aptamers were compared in terms
of signal amplitude, reproducibility, and selectivity. The results
indicated that the best performances were obtained with the 15-
mer biotinylated aptamer carrying the polyT(20) tail.
This aptamer showed a good reproducibility (average CV for
the two concentrations, 13%) and a very good selectivity as
demonstrated by the low signal (∆F < 3 Hz) obtained with a high
concentration of HSA (77 µM), used as negative control. The
higher sensitivity obtained with this aptamer is probably due to
the presence of the spacer, which maintains the aptamer far from
(22) Tombelli, S.; Mascini, M.; Turner, A. P. F. Biosens. Bioelectron. 2002, 17,
929-936.
(23) Tombelli, S.; Minunni, M.; Mascini, M. Methods 2005, 37, 48-56.
(24) Centi, S.; Tombelli, S.; Minunni, M.; Mascini, M. Anal. Chem. 2007, 79,
1466-1473.
(25) Bock, L. C.; Griffin, L. C.; Latham, J. A.; Vermaas, E. H.; Toole, J. J. Nature
1992, 355, 564-566.
Table 1. Comparison between the Results Obtained
with the Sensor When Immobilizing the Biotinylated or
the Thiolated Aptamer
immobilized aptamer
immobilization
shift (Hz) and
density (molecules/cm2)
thrombin
100 nM
(Hz)
thrombin
200 nM
(Hz)
biotinylated aptamer
(with tail)
-225 ( 36;
2.4 × 1013
-16 ( 9 -48 ( 10
thiolated aptamer -138 ( 30;
3.4 × 1013
-12 ( 13 -23 ( 13
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the sensor surface, allowing the proper conformation for molecular
recognition. When the biotinylated aptamer (without polyT tail)
was also immobilized, very low sensitivity (∆F for 200 nM
thrombin, <20 Hz) was found, even if comparable surface density
occurred.
Further investigation has been conducted with the biotinylated
aptamer with the polyT tail by studying the different parameters
influencing the aptamer immobilization and consequently its
binding to the protein. In particular, the influences of a thermal
treatment of the aptamer (heating at 95 °C for 1 min and then
cooling in ice for 10 min) and its concentration (varied from 0.1
to 1 µM) have been investigated. Moreover, in the binding
conditions optimization, the interaction time has been increased
from 20 to 30 min. The results are reported in Table 2, which
shows the improvements in terms of sensitivity, linearity, repro-
ducibility, and reusability, by varying these parameters.
The thermal treatment unfolds the aptamer making the biotin
label at the 5′-end available for interaction with streptavidin on
the crystal surface.26 Even if the thermal treatment has no effect
on the aptamer surface density (2.5 × 1013 molecules/cm2), the
linearity in the thrombin range 0-200 nM (R2 ) 0.977), and the
reproducibility of the binding step (CV ) 21%) significantly
improved. This result confirms that the thermal treatment ensures
correct intramolecular folding. Moreover, the results indicate that
the surface capacity was not affected by the dilution from 1 to 0.5
µM of the aptamer. On the contrary, a further dilution to 0.1 µM
dramatically reduced the sensor sensitivity (data not shown).
Finally, the increase in the interaction time from 20 to 30 min
resulted in improved linearity and reproducibility. The sensorgram
showing a typical binding curve of the aptamer and 50 nM
thrombin, obtained with the optimized conditions, is displayed in
Figure 1.
To check the specificity of the sensor, HSA at a concentration
of 77 µM, in a 1400-fold excess with respect to thrombin, was
used. The interaction did not result in a measurable frequency
decrease (∆F < 3 Hz), demonstrating the high specificity of the
sensor.
Finally, the ability of the aptasensor to detect the analyte in
complex matrixes was tested. Thrombin is the last enzyme
protease involved in the coagulation cascade and it converts
fibrinogen to insoluble fibrin that forms the fibrin gel.27 Since the
detection of thrombin in plasma or blood is clinically relevant, an
aptamer-based sensor as alternative diagnostic tool for thrombin
analysis or blood coagulation investigation could gain a great
interest in the clinical and diagnostic area. Standard solutions of
thrombin were added to serum and plasma to test the perfor-
mances of the aptasensor in these complex matrixes. Since serum
does not contain coagulation factors, the addition of thrombin does
not affect the samples. On the contrary, the addition of thrombin
to plasma, which contains all the proteins involved in the
coagulation cascade including fibrinogen, leads to the formation
of fibrin and to rapid sample clotting. To avoid this phenomenon,
fibrinogen was precipitated from plasma before the addition of
thrombin in the preparation of spiked samples. Thrombin was
detected in serum diluted 1:100 spiked with thrombin in a
concentration range 0-200 nM, with a blank value of -32 Hz (data
not shown). The recorded signals increased with the concentration
of added thrombin, demonstrating that the aptasensor was able
to operate in this complex matrix. However, since serum does
not contain the proteins involved in coagulation, further experi-
ments have been carried out with plasma, which is the matrix
where thrombin is normally detected. Figure 2 shows the signals
obtained in spiked plasma without fibrinogen (final dilution 1:100).
Reproducibility is good (CV ) 13%), and the response is linear in
the tested concentration range, 0-200 nM, (R2 ) 0.990). In this
(26) Tombelli, S.; Minunni, M.; Luzi, E.; Mascini, M. Bioelectrochemistry 2005,
67, 135-141.
(27) Holland, C. A.; Henry, A. T.; Whinna, H. C.; Church, F. C. FEBS Lett. 2000,
484, 87-91.
Table 2. Comparison between the Analytical
Characteristics of the Sensor Obtained When
Immobilizing the Biotinylated Aptamer with a PolyT
Tail
immobilized
aptamer concn
binding
time (min)
linear
regression R2
CV
(%) cyclesa
1 µM 20 y ) -0.22x + 1.94 0.933 35 14
1 µM thermal
treatment
20 y ) -0.23x + 0.42 0.977 21 18
0.5 µM thermal
treatment
20 y ) -0.23x + 0.68 0.988 14 18
0.5 µM thermal
treatment
30 y ) -0.22x 0.998 10 22
a Binding cycles performed without loosing in sensitivity
Figure 1. Typical binding curve (30 min) obtained with 50 nM
thrombin interacting with the immobilized biotinylated aptamer.
Figure 2. Calibration plot obtained with different concentrations of
thrombin in buffer and plasma.
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range, no saturation of the surface was observed. The matrix effect
with a blank signal of -21 Hz is present but, despite the high
complexity of the matrix, the increase in thrombin concentration
could be detected. Due to the high dilution factor, the reached
sensitivity is not sufficient for a direct application of the aptasensor
to the detection of thrombin in real samples. This could be
successfully performed by the use of amplification methods such
as the use of a secondary affinity interaction or of enzymatic
reactions.24,28 The goal of this work was to critically evaluate all
the parameters that can influence the sensor performances by
using thrombin as the model target, and the ability to detect the
analyte in complex matrixes demonstrates the potentialities of
aptamer-based sensing for potential medical investigations.
Moreover, a simple 2 M NaCl treatment was applied as a
sensor regeneration step (1 min), allowing its reuse up to 20 times
without losing in sensitivity.
Other label-free reported aptasensors are based on the quartz
crystal microbalance (QCM),15,16 surface acoustic waves (SAW),29,30
or electrochemical transduction such as impedance14 or field-effect
transistors.18 In the case of QCM,16 a detection limit for thrombin
of 1 nM in buffer is reported, even if this datum is not supported
by the study of other important analytical parameters such as
specificity, reproducibility, or matrix effect. For SAW29,30 devices,
the reported sensitivity is in the same order of magnitude
(submicromolar) of the proposed approach, but also in this case,
the analysis is limited to standard solutions. By using impedance,14
significant improvement in the sensitivity, at least in buffer, was
achieved, but no evaluation of real samples is given. To date,
however, a rational evaluation of the different important key steps
in aptasensor development has been reported only for an ELONA
assay.19 The appealing aspect of this paper is represented exactly
by the consideration of the different parameters influencing the
analytical performances of this label-free, portable, and reusable
sensor. Microarrays could represent an interesting tool in aptamer-
based methods, improving the number of interactions that can
be detected simultaneously and decreasing the amount of capture
molecules immobilized on the chip with a reduction of the cost
of analysis.
CONCLUSIONS
The proposed study can be considered as reference approach
in aptasensing development. In particular, it should be stressed
how little variations in simple steps in the assay development could
lead to much improved analytical performances. In addition, the
proposed study demonstrates the ability of label-free aptasensing
to operate in complex matrixes. This is of paramount importance
for a real applicability of these new, interesting, and attractive
devices to clinical diagnostic, environmental, and food analysis.
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